<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Risperidone (depot) for schizophrenia - Sampson, S - 2016 | Cochrane Library</title> <meta content="Risperidone (depot) for schizophrenia - Sampson, S - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004161.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Risperidone (depot) for schizophrenia - Sampson, S - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004161.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004161.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Risperidone (depot) for schizophrenia" name="citation_title"/> <meta content="Stephanie Sampson" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="stephanie.sampson@nottingham.ac.uk" name="citation_author_email"/> <meta content="Prakash Hosalli" name="citation_author"/> <meta content="Seacroft Hospital" name="citation_author_institution"/> <meta content="Vivek A Furtado" name="citation_author"/> <meta content="University of Warwick" name="citation_author_institution"/> <meta content="John M Davis" name="citation_author"/> <meta content="University of Illinois at Chicago" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD004161.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/04/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004161.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004161.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004161.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Antipsychotic Agents [*therapeutic use]; Aripiprazole [therapeutic use]; Benzodiazepines [therapeutic use]; Delayed‐Action Preparations [therapeutic use]; Olanzapine; Patient Dropouts [statistics &amp; numerical data]; Quetiapine Fumarate [therapeutic use]; Randomized Controlled Trials as Topic; Risperidone [*therapeutic use]; Schizophrenia [*drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004161.pub2&amp;doi=10.1002/14651858.CD004161.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004161.pub2&amp;doi=10.1002/14651858.CD004161.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004161.pub2&amp;doi=10.1002/14651858.CD004161.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004161.pub2&amp;doi=10.1002/14651858.CD004161.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004161.pub2&amp;doi=10.1002/14651858.CD004161.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004161.pub2&amp;doi=10.1002/14651858.CD004161.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004161.pub2&amp;doi=10.1002/14651858.CD004161.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004161.pub2&amp;doi=10.1002/14651858.CD004161.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004161.pub2&amp;doi=10.1002/14651858.CD004161.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004161.pub2&amp;doi=10.1002/14651858.CD004161.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004161.pub2&amp;doi=10.1002/14651858.CD004161.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004161.pub2&amp;doi=10.1002/14651858.CD004161.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004161.pub2&amp;doi=10.1002/14651858.CD004161.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004161.pub2&amp;doi=10.1002/14651858.CD004161.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004161.pub2&amp;doi=10.1002/14651858.CD004161.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004161.pub2&amp;doi=10.1002/14651858.CD004161.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004161.pub2&amp;doi=10.1002/14651858.CD004161.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004161.pub2&amp;doi=10.1002/14651858.CD004161.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004161.pub2&amp;doi=10.1002/14651858.CD004161.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004161.pub2&amp;doi=10.1002/14651858.CD004161.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004161.pub2&amp;doi=10.1002/14651858.CD004161.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004161.pub2&amp;doi=10.1002/14651858.CD004161.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004161.pub2&amp;doi=10.1002/14651858.CD004161.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="eLIOL3Be";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004161\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004161\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004161\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004161\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004161.pub2",title:"Risperidone (depot) for schizophrenia",firstPublishedDate:"Apr 14, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004161.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004161.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004161.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004161.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004161.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004161.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004161.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004161.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004161.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004161.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5710 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004161.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/full#CD004161-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/full#CD004161-sec-0302"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/full#CD004161-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/full#CD004161-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/full#CD004161-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/full#CD004161-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/full#CD004161-sec-0101"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/full#CD004161-sec-0241"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/appendices#CD004161-sec-0314"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/table_n/CD004161StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/table_n/CD004161StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Risperidone (depot) for schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/information#CD004161-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Stephanie Sampson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/information#CD004161-cr-0003">Prakash Hosalli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/information#CD004161-cr-0004">Vivek A Furtado</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004161.pub2/information#CD004161-cr-0005">John M Davis</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/information/en#CD004161-sec-0343">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 April 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004161.pub2">https://doi.org/10.1002/14651858.CD004161.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004161-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004161-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004161-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004161-abs-0008">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004161-abs-0001" lang="en"> <section id="CD004161-sec-0001"> <h3 class="title" id="CD004161-sec-0001">Background</h3> <p>Risperidone is the first new generation antipsychotic drug made available in a long‐acting injection formulation. </p> </section> <section id="CD004161-sec-0002"> <h3 class="title" id="CD004161-sec-0002">Objectives</h3> <p>To examine the effects of depot risperidone for treatment of schizophrenia or related psychoses in comparison with placebo, no treatment or other antipsychotic medication. </p> <p>To critically appraise and summarise current evidence on the resource use, cost and cost‐effectiveness of risperidone (depot) for schizophrenia. </p> </section> <section id="CD004161-sec-0003"> <h3 class="title" id="CD004161-sec-0003">Search methods</h3> <p>We searched the Cochrane Schizophrenia Group's Register (December 2002, 2012, and October 28, 2015). We also checked the references of all included studies, and contacted industry and authors of included studies. </p> </section> <section id="CD004161-sec-0004"> <h3 class="title" id="CD004161-sec-0004">Selection criteria</h3> <p>Randomised clinical trials comparing depot risperidone with other treatments for people with schizophrenia and/or schizophrenia‐like psychoses. </p> </section> <section id="CD004161-sec-0005"> <h3 class="title" id="CD004161-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected trials, assessed trial quality and extracted data. For dichotomous data, we calculated the risk ratio (RR), with 95% confidence interval (CI). For continuous data, we calculated mean differences (MD). We assessed risk of bias for included studies and created 'Summary of findings' tables using GRADE. </p> </section> <section id="CD004161-sec-0006"> <h3 class="title" id="CD004161-sec-0006">Main results</h3> <p>Twelve studies, with a total of 5723 participants were randomised to the following comparison treatments: </p> <p><i>Risperidone depot versus placebo</i> </p> <p>Outcomes of relapse and improvement in mental state were neither measured or reported. In terms of other primary outcomes, more people receiving placebo left the study early by 12 weeks (1 RCT, n=400, RR 0.74 95% CI 0.63 to 0.88, <i>very low quality evidence</i> ), experienced severe adverse events in short term (1 RCT, n=400, RR 0.59 95% CI 0.38 to 0.93, <i>very low quality evidence</i> ). There was however, no difference in levels of weight gain between groups (1 RCT, n=400, RR 2.11 95% CI 0.48 to 9.18, <i>very low quality evidence</i>). </p> <p><i>Risperidone depot versus general oral antipsychotics</i> </p> <p>The outcome of improvement in mental state was not presented due to high levels of attrition, nor were levels of severe adverse events explicitly reported. Most primary outcomes of interest showed no difference between treatment groups. However, more people receiving depot risperidone experienced nervous system disorders (long‐term:1 RCT, n=369, RR 1.34 95% CI 1.13 to 1.58, <i>very‐low quality evidence</i>). </p> <p><i>Risperidone depot versus oral risperidone</i> </p> <p>Data for relapse and severe adverse events were not reported. All outcomes of interest were rated as <i>moderate quality evidence</i>. Main results showed no differences between treatment groups with equivocal data for change in mental state, numbers leaving the study early, any extrapyramidal symptoms, weight increase and prolactin‐related adverse events. </p> <p><i>Risperidone depot versus oral quetiapine</i> </p> <p>Relapse rates and improvement in mental state were not reported. Fewer people receiving risperidone depot left the study early (long‐term: 1 RCT, n=666, RR 0.84 95% CI 0.74 to 0.95, <i>moderate quality evidence</i> ). Experience of serious adverse events was similar between groups (<i>low quality evidence</i> ), but more people receiving depot risperidone experienced EPS (1 RCT, n=666, RR 1.83 95% CI 1.07 to 3.15, <i>low quality evidence</i> ), had greater weight gain (1 RCT, n=666, RR 1.25 95% CI 0.25 to 2.25, <i>low quality evidence</i> ) and more prolactin‐related adverse events (1 RCT, n=666, RR 3.07 95% CI 1.13 to 8.36<i>, very low quality evidence</i>). </p> <p><i>Risperidone depot versus oral aripiprazole</i> </p> <p>Relapse rates, mental state using PANSS, leaving the study early, serious adverse events and weight increase were similar between groups. However more people receiving depot risperidone experienced prolactin‐related adverse events compared to those receiving oral aripiprazole (2 RCTs, n=729, RR 9.91 95% CI 2.78 to 35.29, <i>very low quality of evidence</i>). </p> <p><i>Risperidone depot versus oral olanzapine</i> </p> <p>Relapse rates were not reported in any of the included studies for this comparison. Improvement in mental state using PANSS and instances of severe adverse events were similar between groups. More people receiving depot risperidone left the study early than those receiving oral olanzapine (1 RCT, n=618, RR 1.32 95% CI 1.10 to 1.58, <i>low quality evidence</i> ) with those receiving risperidone depot also experiencing more extrapyramidal symptoms (1 RCT, n=547, RR 1.67 95% CI 1.19 to 2.36, <i>low quality evidence</i> ). However, more people receiving oral olanzapine experienced weight increase (1 RCT, n=547, RR 0.56 95% CI 0.42 to 0.75, <i>low quality evidence</i>). </p> <p><i>Risperidone depot versus atypical depot antipsychotics (specifically paliperidone palmitate)</i> </p> <p>Relapse rates were not reported and rates of response using PANSS, weight increase, prolactin‐related adverse events and glucose‐related adverse events were similar between groups. Fewer people left the study early due to lack of efficacy from the risperidone depot group (long term: 1 RCT, n=749, RR 0.60 95% CI 0.45 to 0.81, <i>low quality evidence</i> ), but more people receiving depot risperidone required use of EPS‐medication (2 RCTs, n=1666, RR 1.46 95% CI 1.18 to 1.8, <i>moderate quality evidence</i>). </p> <p><i>Risperidone depot versus typical depot antipsychotics</i> </p> <p>Outcomes of relapse, severe adverse events or movement disorders were not reported. Outcomes relating to improvement in mental state demonstrated no difference between groups (<i>low quality evidence</i> ). However, more people receiving depot risperidone compared to other typical depots left the study early (long‐term:1 RCT, n=62, RR 3.05 95% CI 1.12 to 8.31, <i>low quality evidence</i>). </p> </section> <section id="CD004161-sec-0007"> <h3 class="title" id="CD004161-sec-0007">Authors' conclusions</h3> <p>Depot risperidone may be more acceptable than placebo injection but it is hard to know if it is any more effective in controlling the symptoms of schizophrenia. The active drug, especially higher doses, may be associated with more movement disorders than placebo. People already stabilised on oral risperidone may continue to maintain benefit if treated with depot risperidone and avoid the need to take tablets, at least in the short term. In people who are happy to take oral medication the depot risperidone is approximately equal to oral risperidone. It is possible that the depot formulation, however, can bring a second‐generation antipsychotic to people who do not reliably adhere to treatment. People with schizophrenia who have difficulty adhering to treatment, however, are unlikely to volunteer for a clinical trial. Such people may gain benefit from the depot risperidone with no increased risk of extrapyramidal side effects. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004161-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004161-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD004161-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD004161-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004161-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD004161-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD004161-abs-0004">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004161-abs-0002" lang="en"> <h3>Long‐acting preparation of risperidone for schizophrenia</h3> <p><b>Review question</b> </p> <p>Risperidone is a newer antipsychotic drug that was the first available as a long‐lasting injection (a depot injection). The review examines the clinical effects of depot risperidone for people with schizophrenia. </p> <p><b>Background</b> </p> <p>People with schizophrenia often hear voices and see things (hallucinations) and have strange beliefs (delusions). People can also become withdrawn, socially isolated, tired and apathetic. The main treatment for these symptoms of schizophrenia is antipsychotic drugs. However, these drugs can have serious side effects, such as weight gain, uncontrollable shaking, tremors, spasms and tiredness. These side effects often mean that people stop taking their medication (non‐ compliance), which may lead to relapse. </p> <p><b>Study characteristics</b> </p> <p>The review was updated in 2015 and includes 12 studies with 5723 people who received risperidone depot or a range of other treatments (placebo, general oral antipsychotics, oral risperidone, oral quetiapine, oral aripiprazole, oral olanzapine, atypical/newer depot antipsychotics, older depot antipsychotics). </p> <p><b>Key results</b> </p> <p>It is difficult to know from the results of this review if depot risperidone is any more effective in treating the symptoms of schizophrenia than placebo or other treatments. For people who are happy to take oral medication, depot risperidone is about equal to oral risperidone. People on oral risperidone may continue to benefit if treated with depot risperidone, without the need to take tablets. However, in high doses, depot risperidone can have serious side effects, particularly movement disorders, uncontrollable shaking, spasms and tremors. Depot risperidone may bring this new antipsychotic to people who stop taking their tablets, so helping reduce relapse and with little increased risk of side effects. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of evidence presented is, in the main, low and at best moderate. There is the need for large, long‐term and well reported trials on depot risperidone for people with schizophrenia. Depot injections are often used on people who refuse treatment. Such people are difficult to include in studies. </p> <p>Written by a consumer, Ben Gray, Senior Peer Researcher, McPin Foundation. <a href="http://mcpin.org/" target="_blank">http://mcpin.org/</a> </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004161-sec-0302" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004161-sec-0302"></div> <h3 class="title" id="CD004161-sec-0303">Implications for practice</h3> <section id="CD004161-sec-0303"> <section id="CD004161-sec-0304"> <h5 class="title">1. For people with schizophrenia</h5> <p>Based on the evidence from the one study (<a href="./references#CD004161-bbs2-0006" title="Anonymous . Injectible, long‐acting risperidone effective. Journal of Pharmacy Technology2001;4:157. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4‐8th May, Stockholm, Sweden)2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey)2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum; 2002 Jun 23‐27; Montreal, Canada)2002;5(Suppl 1):S188. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;53(3 Suppl.1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta (TM), a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cliag UK Ltd2002. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5‐9, 2002, Barcelona‐Spain2002;12(Supplement 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160(6):1125‐32. ">Kane 2002*</a>), depot risperidone may be more acceptable than placebo injection but it is hard to know if it is any more effective in controlling the symptoms of schizophrenia. The active drug, especially at higher doses, may be associated with more movement disorders than placebo. People already stabilised on oral risperidone may continue to maintain benefit if treated with depot risperidone and avoid the need to take tablets, at least in the short term. In people who are happy to take oral medication the depot, risperidone is approximately equal to oral risperidone as seen within the considerable limitations of the two relevant studies. It is possible that the depot formulation, however, can bring a second‐generation antipsychotic to people who do not adhere to treatment. People with schizophrenia who have difficulty adhering to treatment, however, are unlikely to volunteer for a clinical trial. Such people may gain benefit from the depot risperidone with no increased risk of extrapyramidal side effects (EPS). </p> </section> <section id="CD004161-sec-0305"> <h5 class="title">2. For clinicians</h5> <p>For reasonably well and stable people, it may mean they can avoid taking regular oral doses but adverse affects are not well reported. When given to more severely ill people, few benefits were demonstrated in the short term, although it may increase compliance with injections compared with placebo. Use of depot risperidone, especially at the higher doses, is weakly associated with movement disorders. </p> <p>Review of the evidence on the efficacy of depot formulations of first‐generation antipsychotics in comparison with oral formulations indicates that there is only a very modest advantage of depot. There is very little difference between depot and oral formulations in most studies. Patients who volunteer for research are often co‐operative patients who will take their medication, particularly if they are seen every few weeks for ratings, reminding them of the importance of adherence to the medication schedule. It is possible that depot risperidone may have a unique benefit in non‐compliant patients, but the included studies do not address this issue. </p> </section> <section id="CD004161-sec-0306"> <h5 class="title">3. For managers</h5> <p>Currently, no data are available on satisfaction with care or long‐term benefits and we know of no cost‐benefit analysis of depot risperidone. In view of this, it is unclear whether the increased costs, which would be incurred purchasing the drug and the additional arrangements needed to administer it, would be justified. </p> </section> </section> <h3 class="title" id="CD004161-sec-0307">Implications for research</h3> <section id="CD004161-sec-0307"> <section id="CD004161-sec-0308"> <h5 class="title">1. General</h5> <p>Researchers should provide more details when reporting trials so that it is clear how many people really made significant progress. There should be more effort to assess people at the end of designated study period even if they have failed to complete all follow‐up ratings. See <a href="#CD004161-tbl-0009">Table 1</a> for a suggested design of future study. </p> <div class="table" id="CD004161-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Suggested design of study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised, fully explicit description of methods of randomisation and allocation concealment.<br/> Blinding: single, tested.<br/> Setting: community rather than hospital.<br/> Duration: 12 weeks treatment, and then follow‐up to at least 52 weeks. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: schizophrenia (ICD/DSM/CCMD).<br/> N = 300.*<br/> Age: adults.<br/> Sex: both. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Depot risperidone. N = 150.</p> <p>2. Standard care. N = 150.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>General: time to all‐cause treatment failure marked by its discontinuation, relapse, general impression of clinician (CGI), career/other, compliance with treatment., healthy days,<br/> Mental state: BPRS and PANSS.<br/> Global state: CGI (Clinical Global Impression).<br/> Quality of life. QOL (Quality of Life Questionnaire).<br/> Family burden: FBQ (Family Burden Questionnaire).<br/> Social functioning: return to everyday living for 80% of time.*<br/> Adverse events: any adverse event recorded.<br/> Economic outcomes. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>* Powered to be able to identify a difference of ˜ 20% between groups for primary outcome with adequate degree of certainty. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BPRS: Brief Psychiatric Rating Scale<br/> CGI: Clinical Global Impression<br/> PANSS: Positive and Negative Syndrome Scale </p> </div> </div> </section> <section id="CD004161-sec-0309"> <h5 class="title">2. Specific</h5> <section id="CD004161-sec-0310"> <h6 class="title">2.1 Reviews</h6> <p>Excluded studies with data relevant to other reviews are highlighted in <a href="#CD004161-tbl-0010">Table 2</a>. Existing reviews are always in the process of update and the older broad multi‐comparison titles may be broken down into smaller single comparison reviews. Several of the good studies we had to exclude would find a home in these reviews. </p> <div class="table" id="CD004161-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Excluded studies and suggestions for relevant reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Excluded study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Existing review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Suggested future review titles</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004161-bbs2-0014" title="BouchardRH , MeretteC , PourcherE , DemersMF , VilleneuveJ , Roy GagnonMH , et al. The Quebec Schizophrenia Study Group. Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. Journal of Clinical Psychopharmacology2000;20(3):295‐304. [MEDLINE: 20289861] ">Bouchard 2000</a>; <a href="./references#CD004161-bbs2-0019" title="GallhoferB . Cognitive dysfunction in schizophrenia: comparison of treatment with a novel atypical antipsychotic agent versus conventional neuroleptic drugs. 8th Congress of the European College of Neuropsychopharmacology; 1995 Sep 30 ‐ Oct 4; Venice, Italy. 1995. ">Gallhofer 1995</a>; <a href="./references#CD004161-bbs2-0022" title='KogeorgosJ , KanellosP , MichalakeasA , IoannidisJ . Sulpiride and risperidone vs. "classical neuroleptics" in schizophrenia: a follow‐up study. 8th Congress of the European College of Neuropsychopharmacology; 1995 Sep 30 ‐ Oct 4; Venice, Italy. 1995. '>Kogeorgos 1995</a>; </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral risperidone vs conventional antipsychotic drugs (haloperidol, fluphenazine, chlorpromazine, trifluoperazine), not depot risperidone. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risperidone vs typical antipsychotic medication for schizophrenia (<a href="./references#CD004161-bbs2-0071" title="HunterR , KennedyE , SongF , GadonL , IrvingCB . Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD000440] ">Hunter 2003</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risperidone vs haloperidol, risperidone vs fluphenazine, risperidone vs chlorpromazine, risperidone vs trifluoperazine. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004161-bbs2-0026" title="LittrellKH . Patients switched from depot antipsychotics to oral risperidone or olanzapine: an open‐label randomized trial. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington, USA. 1999. [MEDLINE: 95283955] ">Littrell 1999</a>; <a href="./references#CD004161-bbs2-0033" title="RitchieC , AmesD , ChiuE , O'ConnorD , HallK , HassettA . Schizophrenia cohort study of olanzapine v risperidone in the elderly (score): analysis of conversion period. International Psychogeriatrics (Abstracts of the 9th Congress of the International Psychogeriatric Association, &quot;Challenges for the New Millennium: Professional, Cultural and Regional Diversity&quot;; 1999 Aug 15‐20; Vancouver, Canada)1999;11(Suppl 1):157‐8. ">Ritchie 1999</a>; <a href="./references#CD004161-bbs2-0034" title="RobinsonG , WheelerA , ByrdJ , VisserS . Longer‐term effects of switching from typical to atypical antipsychotics in patients with stable schizophrenia. Journal of the European College of Neuropsychopharmacology2000;10(Suppl 3):S291. ">Robinson 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral risperidone vs atypical antipsychotics (olanzapine), not depot risperidone.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risperidone vs olanzapine for schizophrenia (<a href="./references#CD004161-bbs2-0073" title="JayaramMB , HosalliP , StroupTS . Risperidone versus olanzapine for schizophrenia. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD005237.pub2] ">Jayaram 2006</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004161-bbs2-0029" title="MacFaddenW , BossieCA , TurkozI , HaskinsJT . Risperidone long acting therapy in stable patients with recently diagnosed schizophrenia. International Clinical Psychopharmacology2010;25(2):75‐82. MacfaddenW , BossieC , TurkozI , DiekampB , IbachB , HaskinsJT . Effect of long acting injectable risperidone on clinical outcomes in recently diagnosed stable schizophrenia patients. Proceedings of the XXVI Collegium Internationale Neuro Psychopharmacologicum congress; 2008 Jul 13‐17; Munich, Germany. 2008. MacfaddenW , BossieC , TurkozI , DorsonP , HaskinsT . Effect of long acting injectable risperidone on clinical outcomes in stable schizophrenia patients with early illness. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA2008. ">Macfadden 2008</a>; <a href="./references#CD004161-bbs2-0036" title="SimpsonGM , MahmoudRA , LasserRA , KujawaM , BossieCA , TurkozI , et al. A 1‐year double‐blind study of 2 doses of long‐acting risperidone in stable patients with schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry2006;67:1194‐203. ">Simpson 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose comparison (25 mg vs 50 mg of risperidone depot).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risperidone dose for schizophrenia (<a href="./references#CD004161-bbs2-0081" title="LiC , XiaJ , WangJ . Risperidone dose for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007474.pub2] ">Li 2009</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This could also generate further comparisons for this current review.</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD004161-sec-0311"> <h6 class="title">2.2 Trials</h6> <p>This review highlights the need for good quality controlled clinical trials to assess the effect and clinical outcomes of using depot risperidone for people with schizophrenia. Such studies are difficult and need different designs if they are to be informative. Depots are used for people who do not want to take oral medication. Such people are difficult to randomise. If they are avoided, in the case of <a href="./references#CD004161-bbs2-0002" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;3(Suppl 1):174. ChueP , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Promotional slides on file from Janssen‐Cliag UK Ltd2002. ">Chue 2002</a>, the reasonably complete results are difficult to apply. If this difficult group is not avoided, as in the case of <a href="./references#CD004161-bbs2-0006" title="Anonymous . Injectible, long‐acting risperidone effective. Journal of Pharmacy Technology2001;4:157. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4‐8th May, Stockholm, Sweden)2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey)2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum; 2002 Jun 23‐27; Montreal, Canada)2002;5(Suppl 1):S188. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;53(3 Suppl.1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta (TM), a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cliag UK Ltd2002. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5‐9, 2002, Barcelona‐Spain2002;12(Supplement 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160(6):1125‐32. ">Kane 2002*</a>, the explanatory design results in such a degree of attrition as to render results almost entirely without meaning. Pragmatic design could help deal with these problems. People appropriate for depot risperidone, if in agreement, could be randomised to an oral antipsychotic or depot risperidone. Outcomes could then be gathered for events that would be recorded in routine data (discontinuation of medication, specific adverse events, hospitalisation, global improvement whether or not the person stayed on the allocated treatment). </p> <p>According to the manufacturers of risperidone, Janssen‐Cilag Limited, the reason why there are so few studies on depot risperidone is that the compound is unmodified, and is merely delivered differently. More real world trials are required, to establish the efficacy and safety of depot risperidone. </p> </section> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004161-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004161-sec-0015"></div> <div class="table" id="CD004161-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">RISPERIDONE DEPOT compared with PLACEBO for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>RISPERIDONE DEPOT compared with PLACEBO for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> RISPERIDONE DEPOT<br/> <b>Comparison:</b> PLACEBO </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> PLACEBO</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> RISPERIDONE DEPOT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: Relapse ‐ long term</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: clinically significant improvement in mental state ‐ long term</b><sup>1</sup> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study reported PANSS responder rate, but unusable due to high attrition.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leaving the study early: Any reason ‐ all doses risperidone depot ‐ short term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>694 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>513 per 1000</b> <br/> (437 to 611) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.74</b> <br/> (0.63 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: General: Severe adverse event ‐ any dose risperidone depot ‐ short term</b> <br/> Spontaneous reporting by study participants </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>235 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>138 per 1000</b> <br/> (89 to 218) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.59</b> <br/> (0.38 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: Specific: Weight gain ‐ all doses of depot risperidone ‐ short term</b> <br/> Spontaneous reporting by study participants </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b> <br/> (10 to 187) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.11</b> <br/> (0.48 to 9.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Not reported: only included study (<a href="./references#CD004161-bbs2-0006" title="Anonymous . Injectible, long‐acting risperidone effective. Journal of Pharmacy Technology2001;4:157. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4‐8th May, Stockholm, Sweden)2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey)2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum; 2002 Jun 23‐27; Montreal, Canada)2002;5(Suppl 1):S188. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;53(3 Suppl.1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta (TM), a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cliag UK Ltd2002. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5‐9, 2002, Barcelona‐Spain2002;12(Supplement 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160(6):1125‐32. ">Kane 2002*</a>) reported PANSS responder rate, but these data were unusable due to high levels of attrition.<br/> <sup>2</sup> Risk of bias: 'very serious' ‐ high attrition in one included study (<a href="./references#CD004161-bbs2-0006" title="Anonymous . Injectible, long‐acting risperidone effective. Journal of Pharmacy Technology2001;4:157. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4‐8th May, Stockholm, Sweden)2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey)2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum; 2002 Jun 23‐27; Montreal, Canada)2002;5(Suppl 1):S188. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;53(3 Suppl.1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta (TM), a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cliag UK Ltd2002. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5‐9, 2002, Barcelona‐Spain2002;12(Supplement 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160(6):1125‐32. ">Kane 2002*</a>) of greater than 50% overall. Research supported by Johnson and Johnson/ Janssen, producers of depot risperidone.<br/> <sup>3</sup> Imprecision: 'serious' ‐ only one small study reported data for this comparison.<br/> <sup>4</sup> Control risk: mean baseline presented for one individual study.<br/> <sup>5</sup> Imprecision: 'serious' ‐ adverse events were reported spontaneously by participants, rather than systematically assessed by the researchers. This could effect the precision of the results as there is only one study (<a href="./references#CD004161-bbs2-0006" title="Anonymous . Injectible, long‐acting risperidone effective. Journal of Pharmacy Technology2001;4:157. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4‐8th May, Stockholm, Sweden)2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey)2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum; 2002 Jun 23‐27; Montreal, Canada)2002;5(Suppl 1):S188. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;53(3 Suppl.1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta (TM), a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cliag UK Ltd2002. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5‐9, 2002, Barcelona‐Spain2002;12(Supplement 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160(6):1125‐32. ">Kane 2002*</a>) addressing this comparison.<br/> <sup>6</sup> Imprecision: 'serious'‐ the method of measuring weight gain and threshold for reporting it were not described. This could effect the precision of the results as there is only one study (<a href="./references#CD004161-bbs2-0006" title="Anonymous . Injectible, long‐acting risperidone effective. Journal of Pharmacy Technology2001;4:157. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4‐8th May, Stockholm, Sweden)2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey)2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum; 2002 Jun 23‐27; Montreal, Canada)2002;5(Suppl 1):S188. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;53(3 Suppl.1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta (TM), a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cliag UK Ltd2002. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5‐9, 2002, Barcelona‐Spain2002;12(Supplement 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160(6):1125‐32. ">Kane 2002*</a>) addressing this comparison. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004161-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">RISPERIDONE DEPOT compared with GENERAL ORAL ANTIPSYCHOTICS for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>RISPERIDONE DEPOT compared with GENERAL ORAL ANTIPSYCHOTICS for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> RISPERIDONE DEPOT<br/> <b>Comparison:</b> GENERAL ORAL ANTIPSYCHOTICS </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> GENERAL ORAL ANTIPSYCHOTICS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> RISPERIDONE DEPOT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Global state: Relapse (any reason) ‐ long term</b> <br/> Number of participants relapsing in each treatment arm. </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.13</b> <br/> (0.84 to 5.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>63<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Criteria for relapse were derived from <a href="./references#CD004161-bbs2-0054" title="CsernanskyJG , MahmoodR , BrennerR , Risperidone‐USA‐79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine2002;346:16‐22. ">Csernansky 2002</a>.&lt;BR/&gt; </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>161 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>343 per 1000</b> <br/> (135 to 874) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: clinically significant improvement in mental state ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes relating to mental state were unusable due to high study attrition.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early: Any reason ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.24</b> <br/> (0.98 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>467<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>322 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>399 per 1000</b> <br/> (315 to 505) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>387 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>480 per 1000</b> <br/> (379 to 608) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: General: Severe adverse event ‐ any dose risperidone depot ‐ short term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Severe adverse events" were not explicitly reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse events: Specific ‐ prolactin‐related ‐ long term</b> <br/> It is unclear how adverse events were reported </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 10.27</b> <br/> (0.59 to 180.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>85<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b><sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>103 per 1000</b> <br/> (6 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b><sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> <br/> (59 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b><sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> <br/> (118 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events: Specific ‐ weight increase ‐ long term</b> <br/> It is unclear how adverse events were reported </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.33</b> <br/> (0.56 to 3.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>85<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b> <br/> (96 to 541) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b> <br/> (96 to 542) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events: Nervous system disorders (inc. EPS) ‐ long term</b> <br/> It is unclear how adverse events were reported </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.34</b> <br/> (1.13 to 1.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>369<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b> <br/> (96 to 541) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b> <br/> (96 to 542) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Assumed risk: mean baseline presented for one individual study.<br/> <sup>2</sup> Risk of bias: 'very serious' ‐ a high level of attrition (&gt; 50%), the open‐label nature of this study and the fact that it was supported by the manufacturers of depot risperidone result in a very serious risk of bias.<br/> <sup>3</sup> Imprecision: 'serious' ‐ the sample size for this outcome was small (n = 63).<br/> <sup>4</sup> Assumed risk: median control group risk from the studies.<br/> <sup>5</sup> Assumed risk: control risk relates to 'low' (0%).<br/> <sup>6</sup> Serious risk of imprecision due to the small sample size of this study. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004161-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">RISPERIDONE DEPOT compared with ORAL RISPERIDONE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>RISPERIDONE DEPOT compared with ORAL RISPERIDONE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> RISPERIDONE DEPOT<br/> <b>Comparison:</b> ORAL RISPERIDONE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ORAL RISPERIDONE</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> RISPERIDONE DEPOT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: Relapse ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes relating to relapse were not available for this comparison.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: average PANSS total score at endpoint (non‐ITT data)</b> <br/> PANSS total scores (30 to 210) Higher scores are worse. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: average PANSS total score at endpoint (non‐ITT data) in the intervention groups was<br/> <b>1.05 higher</b> <br/> (0.77 lower to 2.88 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>591<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early: Any reason ‐ short term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.28</b> <br/> (0.92 to 1.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>690<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>145 per 1000</b><sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>185 per 1000</b> <br/> (133 to 259) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b><sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> <br/> (72 to 140) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: General: Severe adverse event ‐ any dose risperidone depot ‐ short term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Severe adverse events" were not explicitly reported by these studies.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events: Movement disorder ‐ any extra pyramidal symptoms ‐ short term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.05</b> <br/> (0.59 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>640<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>65 per 1000</b><sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>69 per 1000</b> <br/> (39 to 123) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>65 per 1000</b><sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b> <br/> (38 to 122) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: Specific: Mean (SD) weight increase in kg ‐ short term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean adverse events: specific: mean (SD) weight increase in kg ‐ short term in the control groups was<br/> <b>0.2 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean adverse events: specific: mean (SD) weight increase in kg ‐ short term in the intervention groups was<br/> <b>0.2 higher</b> <br/> (0.35 lower to 0.75 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>640<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: Specific ‐ prolactin‐related</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.5</b> <br/> (0.15 to 1.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>640<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b><sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b> <br/> (4 to 41) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: 'serious' ‐ both studies received funding support from the manufacturers of risperidone depot<br/> <sup>2</sup> Assumed risk: median control group risk from the studies.<br/> <sup>3</sup> Assumed risk: mean baseline presented for one individual study.<br/> <sup>4</sup> Risk of bias: 'serious' ‐ this research was supported by the manufacturers of risperidone depot. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004161-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">RISPERIDONE DEPOT compared with ORAL QUETIAPINE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>RISPERIDONE DEPOT compared with ORAL QUETIAPINE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> RISPERIDONE DEPOT<br/> <b>Comparison:</b> ORAL QUETIAPINE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ORAL QUETIAPINE</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> RISPERIDONE DEPOT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: Relapse ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Criteria for relapse were derived from <a href="./references#CD004161-bbs2-0054" title="CsernanskyJG , MahmoodR , BrennerR , Risperidone‐USA‐79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine2002;346:16‐22. ">Csernansky 2002</a>. &lt;BR/&gt; Outcomes relating to relapse were reported, but were unusable due to study attrition. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: clinically significant improvement in mental state ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes relating to mental state were unusable due to high study attrition.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Leaving the study early: Any reason ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.84</b> <br/> (0.74 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>666<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>644 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>541 per 1000</b> <br/> (477 to 612) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: General ‐ serious</b> <br/> Recorded at each follow‐up visit. </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.84</b> <br/> (0.62 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>666<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>229 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>192 per 1000</b> <br/> (142 to 259) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: Movement disorder ‐ any extra pyramidal symptom</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.83</b> <br/> (1.07 to 3.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>666<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>102 per 1000</b> <br/> (60 to 176) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: Specific: Mean (SD) weight increase in kg ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean adverse events: specific: mean (SD) weight increase in kg ‐ long term in the intervention groups was<br/> <b>1.25 higher</b> <br/> (0.25 to 2.25 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>666<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events: Specific ‐ prolactin‐related</b> <br/> Reported by participants at follow‐up visits </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.07</b> <br/> (1.13 to 8.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>666<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b> <br/> (17 to 124) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b> <br/> (17 to 125) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Assumed risk: mean baseline risk used for one included study.<br/> <sup>2</sup> Risk of bias: 'serious' ‐ this study was supported by the manufacturers of risperidone depot.<br/> <sup>3</sup> Risk of bias: 'serious' ‐ this study was open‐label in nature.<br/> <sup>4</sup> Risk of bias: 'very serious' ‐ study attrition was high (&gt; 50%). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004161-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">RISPERIDONE DEPOT compared with ORAL ARIPIPRAZOLE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>RISPERIDONE DEPOT compared with ORAL ARIPIPRAZOLE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> RISPERIDONE DEPOT<br/> <b>Comparison:</b> ORAL ARIPIPRAZOLE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ORAL ARIPIPRAZOLE</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> RISPERIDONE DEPOT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Global state: Relapse (any reason) ‐ long term</b> <br/> Assessed by 5 blinded raters in accordance with study criteria (see comment). </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.05</b> <br/> (0.83 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>349<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Criteria for relapse were derived from <a href="./references#CD004161-bbs2-0054" title="CsernanskyJG , MahmoodR , BrennerR , Risperidone‐USA‐79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine2002;346:16‐22. ">Csernansky 2002</a>. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>436 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>458 per 1000</b> <br/> (362 to 580) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: Average change scores‐ long term</b> <br/> PANSS total score (30 to 210), higher scores are worse. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: average change scores‐ long term in the intervention groups was<br/> <b>0.1 lower</b> <br/> (3.15 lower to 2.95 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>349<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early: Any reason ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.83</b> <br/> (0.53 to 1.3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>723<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>387 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>321 per 1000</b> <br/> (205 to 503) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>531 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>441 per 1000</b> <br/> (281 to 690) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events: General ‐ serious</b> <br/> Unclear how these events were reported </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.96</b> <br/> (0.66 to 1.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>729<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>190 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>182 per 1000</b> <br/> (125 to 264) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>177 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>170 per 1000</b> <br/> (117 to 246) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events: Movement disorder ‐ any extra pyramidal symptoms</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.19</b> <br/> (0.91 to 1.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>729<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>285 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>339 per 1000</b> <br/> (259 to 442) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>196 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>233 per 1000</b> <br/> (178 to 304) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: Specific ‐ weight increase</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.57</b> <br/> (0.38 to 6.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>374<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>69 per 1000</b> <br/> (17 to 284) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events: Specific ‐ prolactin‐related</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 9.91</b> <br/> (2.78 to 35.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>729<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>90 per 1000</b> <br/> (25 to 319) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b> <br/> (17 to 212) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Assumed risk: mean baseline risk presented for one individual study.<br/> <sup>2</sup> Risk of bias: 'very serious' ‐ a number of the study authors were employed by the manufacturers of risperidone depot at the time of the study.<br/> <sup>3</sup> Risk of bias: 'serious' ‐ serious risk of bias due to the open nature label of the study.<br/> <sup>4</sup> Assumed risk: median control group risk from the studies.<br/> <sup>5</sup> Risk of bias: 'very serious' ‐ serious risk of bias as both studies were open‐label and supported by the manufacturers of risperidone depot.<br/> <sup>6</sup> Imprecision: 'serious' ‐ possibly serious risk of imprecision in <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a> as the aripiprazole arm of this study was very small (n = 45) compared to the risperidone depot (n = 329) arm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004161-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">RISPERIDONE DEPOT compared with ORAL OLANZAPINE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>RISPERIDONE DEPOT compared with ORAL OLANZAPINE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> RISPERIDONE DEPOT<br/> <b>Comparison:</b> ORAL OLANZAPINE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ORAL OLANZAPINE</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> RISPERIDONE DEPOT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: Relapse ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes relating to relapse were not reported for this comparison.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: Average change scores ‐ long term</b> <br/> PANSS total score (30‐210), high scores are worse. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: average change scores ‐ long term in the intervention groups was<br/> <b>0.1 higher</b> <br/> (3.96 lower to 4.16 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>361<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early: Any reason ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.32</b> <br/> (1.1 to 1.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>618<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>377 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>497 per 1000</b> <br/> (414 to 595) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>377 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>498 per 1000</b> <br/> (415 to 596) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: General ‐ serious</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.1</b> <br/> (0.8 to 1.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>547<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>210 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>231 per 1000</b> <br/> (168 to 317) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: Movement disorder ‐ any extra pyramidal symptoms</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.67</b> <br/> (1.19 to 2.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>547<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b> <br/> (179 to 354) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: Specific ‐ weight increase</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.56</b> <br/> (0.42 to 0.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>547<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>360 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>202 per 1000</b> <br/> (151 to 270) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: 'very serious' ‐ serious risk of bias due to study attrition in excess of 50%.<br/> <sup>2</sup> Risk of bias: 'serious' ‐ serious risk of bias as this study was supported by the manufacturers of risperidone depot, and some of the authors are employed by the same.<br/> <sup>3</sup> Risk of bias: 'serious' ‐ serious risk of bias due to the open‐label nature of the study.<br/> <sup>4</sup> Assumed risk: mean baseline risk from one included study. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004161-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">RISPERIDONE DEPOT compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>RISPERIDONE DEPOT compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> RISPERIDONE DEPOT<br/> <b>Comparison:</b> ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> RISPERIDONE DEPOT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: Relapse ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes relating to relapse were not reported for this comparison.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mental state: PANSS responders (ITT data) ‐ medium term</b> <br/> PANSS responders‐ participants achieving a &gt;30% improvement in total score </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.01</b> <br/> (0.83 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1326<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>585 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>591 per 1000</b> <br/> (486 to 720) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>619 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>625 per 1000</b> <br/> (514 to 761) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early: lack of efficacy ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.60</b> <br/> (0.45 to 0.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>749<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>361 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>307 per 1000</b> <br/> (275 to 340) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>280 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>238 per 1000</b> <br/> (213 to 263) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events: Movement disorder requiring the use of anti‐EPS medication ‐ medium term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.46</b> <br/> (1.18 to 1.8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1666<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2,3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>122 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>178 per 1000</b> <br/> (144 to 220) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>182 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>266 per 1000</b> <br/> (215 to 328) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: Body weight (mean increase) ‐ medium/long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean adverse events: body weight (mean increase) ‐ medium/long term in the intervention groups was<br/> <b>0.18 higher</b> <br/> (0.36 lower to 0.72 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2350<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events: Any prolactin‐related ‐ medium term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.02</b> <br/> (0.61 to 1.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1666<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b> <br/> (20 to 55) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b> <br/> (29 to 82) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: Any glucose‐related ‐ medium/long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> <br/> (9 to 36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.79</b> <br/> (0.89 to 3.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2413<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Assumed risk: median control group risk from the studies.<br/> <sup>2</sup> Risk of bias: 'serious' ‐ <a href="./references#CD004161-bbs2-0008" title="LiH , RuiQ , NingX , XuH , GuN . A comparative study of paliperidone palmitate and risperidone long‐acting injectable therapy in schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:1002‐8. ">Li 2011</a> was open‐label and supported by the manufacturer of risperidone depot.<br/> <sup>3</sup> Risk of bias: 'serious' ‐ <a href="./references#CD004161-bbs2-0010" title="PandinaG , LaneR , Gassmann‐MayerC , HoughD , RemmerieB , SimpsonG . A randomised double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Proceedings of the 27th International College of Neuropsychopharmacology Congress; 2010 June 6‐10; Hong Kong. 2010. PandinaG , LaneR , GopalS , Gassman‐MayerC , HoughD , RemmerieB , et al. A randomized double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Biological Psychiatry2010;67(9):77‐8. PandinaG , LaneR , GopalS , Gassmann‐MayerC , HoughD , RemmerieB , et al. A double‐blind study of paliperidone palmitate and risperidone long‐acting injectable in adults with schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:218‐26. ">Pandina 2011</a> was supported by the manufacturer of risperidone depot.<br/> <sup>4</sup> Risk of bias: 'serious' ‐ as the attrition rate of <a href="./references#CD004161-bbs2-0004" title="FleischhackerWW , GopalS , LaneR , Gassmann‐Mayer , LimP , HoughD , et al. A randomized trial of paliperidone palmitate and risperidone long acting injectable in schizophrenia. International Journal of Neuropsychopharmacology2012;15:107‐18. ">Fleischhacker 2011</a> was in excess of 50%, and the study was supported by the manufacturer of risperidone depot.<br/> <sup>5</sup> Possible imprecision: the rate of movement disorder requiring anti‐EPS medication may not be a reflection of the true rate of movement disorders. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004161-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">RISPERIDONE DEPOT compared with TYPICAL DEPOT ANTIPSYCHOTICS for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>RISPERIDONE DEPOT compared with TYPICAL DEPOT ANTIPSYCHOTICS for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> RISPERIDONE DEPOT<br/> <b>Comparison:</b> TYPICAL DEPOT ANTIPSYCHOTICS </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> TYPICAL DEPOT ANTIPSYCHOTICS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> RISPERIDONE DEPOT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: Relapse ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes relating to relapse were not reported for this comparison.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: Total average scores (PANSS, high score = worse) ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: total average scores (PANSS, high score = worse) ‐ long term in the intervention groups was<br/> <b>1.8 higher</b> <br/> (10.04 lower to 13.64 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early for any reason ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.05</b> <br/> (1.12 to 8.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>62<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b><sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>407 per 1000</b> <br/> (149 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b><sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>406 per 1000</b> <br/> (149 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: General: Severe adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Severe adverse events" were not explicitly reported for this comparison.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: related to movement disorder, weight gain, prolactin levels and glucose metabolism ‐ medium/long term</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes relating to specific adverse events were not reported in such as way as to be useable. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: 'serious' ‐ due to the open‐label nature of this study.<br/> <sup>2</sup> Imprecision: 'serious' ‐ due to the small size of the single study.<br/> <sup>3</sup> Assumed risk: median control group risk from the studies. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004161-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004161-sec-0016"></div> <section id="CD004161-sec-0017"> <h3 class="title" id="CD004161-sec-0017">Description of the condition</h3> <p>Schizophrenia is a major, often chronic, psychiatric disease that close to seven people in every 1000 will be affected by at some point during their lifetime (<a href="./references#CD004161-bbs2-0087" title="McGrathJ , SahaS , ChantD , WelhamJ . Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiologic Reviews2008;30(1):67‐76. ">McGrath 2008</a>). Antipsychotic drugs are effective for treating acute episodes and for preventing relapse (<a href="./references#CD004161-bbs2-0056" title="DavisJM , CasperR . Antipsychotic drugs: clinical pharmacology and therapeutic use. Drugs1977;14(4):260‐82. ">Davis 1977</a>; <a href="./references#CD004161-bbs2-0057" title="DavisJM , AndriukaitisS . The natural course of schizophrenia and effective maintenance drug treatment. Journal of Clinical Psychopharmacology1986;6(1 Suppl):2S‐10S. ">Davis 1986</a>). These drugs are usually given orally, but compliance is poor and ranges from 20% to 89% with an average of 50% (<a href="./references#CD004161-bbs2-0063" title="FentonWS , BlylerCR , HeinssenRK . Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophrenia Bulletin1997;23(4):637‐51. [MEDLINE: 9366000] ">Fenton 1997</a>; <a href="./references#CD004161-bbs2-0100" title="YoungJL , ZonanaHV , SheplerL . Medication noncompliance in schizophrenia: codification and update. Bulletin of the American Academy of Psychiatry and the Law1986;14(2):105‐22. ">Young 1986</a>). This means that, on average, half the patients treated with these drugs will not comply with prescribed medication. This is probably due to a combination of various factors such as the erosion of insight that accompanies psychotic illnesses, adverse effects and human nature. </p> </section> <section id="CD004161-sec-0018"> <h3 class="title" id="CD004161-sec-0018">Description of the intervention</h3> <p>Long‐acting depot antipsychotics, given by injection into the muscle, should be helpful in increasing compliance with medication. In studies comparing one depot with another, attrition rates are markedly lower than in studies comparing oral preparations, but in trials comparing an oral with a depot preparation, there are no differences in the attrition rates between groups (<a href="./references#CD004161-bbs2-0044" title="AdamsCE , FentonMK , QuraishiS , DavidAS . Systematic meta‐review of depot antipsychotic drugs for people with schizophrenia. British Journal of Psychiatry2001;179:290‐9. ">Adams 2001</a>). This is likely to be due to a limitation in the design of the relevant studies, as people participating in randomised trials are more likely to be compliant. This is an area where 'real world' or 'pragmatic' randomised trials are indicated. </p> <p>The newer generation of antipsychotics, often called atypical, seem to cause less of the movement disorders associated with older drugs. This group of compounds may be equally clinically effective (<a href="./references#CD004161-bbs2-0095" title="SmallJG , HirschSR , ArvanitisLA , MillerBG , LinkCG , Seroquel Study Group. Quetiapine in patients with schizophrenia. A high‐ and low‐dose double‐ blind comparison with placebo. Archives of General Psychiatry1997;54(6):549‐57. ">Small 1997</a>), and be more acceptable to people with schizophrenia, than older drugs such as haloperidol (<a href="./references#CD004161-bbs2-0077" title="LeuchtS , Pitschel‐WalzG , AbrahamD , KisslingW . Efficacy and extrapyramidal side‐effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta‐analysis of randomized controlled trials. Schizophrenia Research1999;35(1):51‐68. ">Leucht 1999</a>; <a href="./references#CD004161-bbs2-0084" title="MarderSR , MeibachRC . Risperidone in the treatment of schizophrenia. American Journal of Psychiatry1994;151(6):825‐35. ">Marder 1994</a>; <a href="./references#CD004161-bbs2-0096" title="TollefsonGD , BeasleyCMJr , TamuraRN , TranPV , PotvinJH . Blind, controlled, long‐term study of the comparative incidence of treatment‐emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry1997;154(9):1248‐54. ">Tollefson 1997</a>) although this is disputed (<a href="./references#CD004161-bbs2-0065" title="GeddesJ , FreemantleN , HarrisonP , BebbingtonP . Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta‐regression analysis. BMJ2000;321(7273):1371‐6. ">Geddes 2000</a>). Atypical drugs have gained popularity amongst clinicians but, along with their cost, a lack of a depot preparation has been cited as a significant obstacle to their frequent use (<a href="./references#CD004161-bbs2-0093" title="SarfatiY , OlivierV , BouhassiraM . New antipsychotics in the treatment of schizophrenia. A European survey. Encephale1999;25(6):658‐66. ">Sarfati 1999</a>). </p> <p>Risperidone is an atypical antipsychotic, first made available for the care of those with schizophrenia in 1986. Since then clinical trials have been conducted to evaluate its efficacy and safety and studies have indicated that it may be superior to older drugs (<a href="./references#CD004161-bbs2-0084" title="MarderSR , MeibachRC . Risperidone in the treatment of schizophrenia. American Journal of Psychiatry1994;151(6):825‐35. ">Marder 1994</a>). When oral risperidone is compared with haloperidol, it appears to have marginal benefits in terms of clinical improvement and is less likely to cause movement disorders (<a href="./references#CD004161-bbs2-0071" title="HunterR , KennedyE , SongF , GadonL , IrvingCB . Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD000440] ">Hunter 2003</a>). Risperidone is the first newer drug to be available in a long‐acting injection formulation. </p> </section> <section id="CD004161-sec-0019"> <h3 class="title" id="CD004161-sec-0019">How the intervention might work</h3> <p>Risperidone is one of the new or second‐generation "atypical" antipsychotics, developed in the late 1980s. It is known to block dopamine D2 and 5HT2 (serotonin) receptors in the brain, with a high ratio of 5HT2 to D2 blockade. It also blocks alpha1 and alpha2 adrenoceptors, H1 receptors and has no effect on beta adrenoceptors, muscarinic cholinoceptors or peptidergic receptors (<a href="./references#CD004161-bbs2-0072" title="JanssenPA , NiemegeersCJ , AwoutersF , SchellekensKH , MegensAA , MeertTF . Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin‐S2 and dopamine‐D2 antagonistic properties. Journal of Pharmacology and Experimental Therapeutics1988;244(2):685‐93. ">Janssen 1988</a>). </p> <p>The depot formulation of risperidone has unmodified risperidone encapsulated in biodegradable polymer microspheres, which are then suspended in an aqueous solution. Once the microspheres are injected into the muscle, the polymers begin to degrade and the drug is released at a set rate. This takes place over the course of several weeks, with the highest plasma concentration occurring approximately one month after injection (<a href="./references#CD004161-bbs2-0092" title="RamstackJM , GrandolfiGP , MannaertE , D'HooreP , LasserRA . Risperdal CONSTA™: Prolonged‐release injectable delivery of risperidone using Medisorb® Microsphere Technology. Schizophrenia2003;60:314. ">Ramstack 2003</a>). </p> </section> <section id="CD004161-sec-0020"> <h3 class="title" id="CD004161-sec-0020">Why it is important to do this review</h3> <p>In terms of the costs of schizophrenia, this was estimated at about £6.7 billion in England in 2004/05, of which the direct costs were £2 million while the indirect costs accounted for the rest (<a href="./references#CD004161-bbs2-0083" title="MangaloreR , KnappM . Cost of schizophrenia in England. Journal of Mental Health Policy and Economics2007;10(1):23‐41. ">Mangalore 2007</a>). The cost of risperidone (depot) itself is expensive compared to other typical antipsychotics, at £142.76 for a 50 mg vial. The maximum monthly dose of risperidone (depot) is 100 mg per month, which costs £285.52 per month (<a href="./references#CD004161-bbs2-0049" title="BMJ Group and Pharmaceautical Press. British National Formulary No. 63. Antipsychotic drugs. BNF2012. ">BNF 2012</a>). These newer, atypical antipsychotics in comparison are more expensive than typical antipsychotics, with olanzapine available at £13.11 for 28 x 5 mg tablets, and clozapine (Clozaril) at £21.56 for 28 x 100 mg tablets. </p> <p>It is important to complement the clinical effectiveness of risperidone (depot) with its cost‐effectiveness. Davies et al. (<a href="./references#CD004161-bbs2-0055" title="DaviesLM , LewisS , JonesPB , BarnesTR , GaughranF , HayhurstK , et al. Cost‐effectiveness of first‐ v. second‐generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. British Journal of Psychiatry2007;191:14‐22. ">Davies 2007</a>) conducted a study on cost‐effectiveness of first‐generation antipsychotics (i.e. flupentixol, trifluoperazine, chlorpromazine) and the second‐generation antipsychotics (i.e. risperidone, olanzapine, amisulpiride). The study findings argue that there is no evidence to suggest that atypical (second‐generation) antipsychotics are more cost‐effective than typical (first‐generation) antipsychotics. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004161-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004161-sec-0021"></div> <p>To examine the effects of depot risperidone for treatment of schizophrenia or related psychoses in comparison with placebo, no treatment or other antipsychotic medication. </p> <p>If possible, to critically appraise and summarise current evidence on the resource use, cost and cost‐effectiveness of risperidone (depot) for schizophrenia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004161-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004161-sec-0022"></div> <section id="CD004161-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004161-sec-0024"> <h4 class="title">Types of studies</h4> <p>All relevant randomised controlled trials (RCTs). Where a trial was described as 'double‐blind' but it was implied that the study was randomised, these trials were included in a sensitivity analysis. If there was no substantive difference within primary outcomes (see <a href="#CD004161-sec-0031">Types of outcome measures</a>) when these 'implied randomisation' studies were added, then they were included in the final analysis. If there was a substantive difference, only clearly randomised trials were utilised and the results of the sensitivity analysis described in the text. We excluded quasi‐randomised studies, such as those allocating by using alternate days of the week. </p> </section> <section id="CD004161-sec-0025"> <h4 class="title">Types of participants</h4> <p>People with schizophrenia and schizophrenia‐like disorders such as schizophreniform disorder, delusional disorder or schizoaffective disorder, diagnosed by any criteria. People with 'serious/chronic mental illness' or 'psychotic illness' were also included. Where possible, people with dementia, depression and problems primarily associated with substance misuse were excluded. </p> </section> <section id="CD004161-sec-0026"> <h4 class="title">Types of interventions</h4> <section id="CD004161-sec-0027"> <h5 class="title">1. Risperidone</h5> <p>Administered by long‐acting intramuscular injection, any dose.</p> </section> <section id="CD004161-sec-0028"> <h5 class="title">2. Placebo or no treatment</h5> </section> <section id="CD004161-sec-0029"> <h5 class="title">3. Other antipsychotic drugs (depot)</h5> <p>Any dose, administered in depot form.</p> </section> <section id="CD004161-sec-0030"> <h5 class="title">4. Other antipsychotic drugs (oral)</h5> <p>Any dose, administered in oral form. Oral drugs were divided into two subgroups; typical and atypical. For the purposes of this review atypicals were amisulpiride, aripiprazole, clozapine, clothiapine, loxapine, molindone, risperidone, olanzapine, quetiapine, sulpiride, zotepine, ziprasidone. </p> </section> </section> <section id="CD004161-sec-0031"> <h4 class="title">Types of outcome measures</h4> <p>All outcomes were reported for the short term (up to 12 weeks), medium term (13‐26 weeks), and long term (more than 26 weeks). </p> <section id="CD004161-sec-0032"> <h5 class="title">Primary outcomes</h5> <section id="CD004161-sec-0033"> <h6 class="title">1. Global state</h6> <p>1.1 Relapse</p> </section> <section id="CD004161-sec-0034"> <h6 class="title">2. Mental state</h6> <p>2.1 Clinically important change in general mental state</p> </section> </section> <section id="CD004161-sec-0035"> <h5 class="title">Secondary outcomes</h5> <section id="CD004161-sec-0036"> <h6 class="title">1. Death ‐ suicide and natural causes</h6> </section> <section id="CD004161-sec-0037"> <h6 class="title">2. Global state</h6> <p>2.1 Time to relapse<br/> 2.2 Clinically important change in global state<br/> 2.3 Any change in global state<br/> 2.4 Average endpoint global state score<br/> 2.5 Average change in global state scores </p> </section> <section id="CD004161-sec-0038"> <h6 class="title">3. Service outcomes</h6> <p>3.1 Hospitalisation<br/> 3.2 Time to hospitalisation<br/> 3.3 Duration of stay in hospital </p> </section> <section id="CD004161-sec-0039"> <h6 class="title">4. Mental state</h6> <p>4.1 Change in general mental state<br/> 4.2 Average endpoint general mental state score<br/> 4.3 Average change in general mental state scores<br/> 4.4 Clinically important change in specific symptoms<br/> 4.5 Change in specific symptoms<br/> 4.6 Average endpoint specific symptom score<br/> 4.7 Average change in specific symptom scores </p> </section> <section id="CD004161-sec-0040"> <h6 class="title">5. Leaving the study early</h6> <p>5.1 For specific reasons<br/> 5.2 For general reasons </p> </section> <section id="CD004161-sec-0041"> <h6 class="title">6. General functioning</h6> <p>6.1 Clinically important change in general functioning<br/> 6.2 Any change in general functioning<br/> 6.3 Average endpoint general functioning score<br/> 6.4 Average change in general functioning scores<br/> 6.5 Clinically important change in specific aspects of functioning, such as social or life skills<br/> 6.6 Any change in specific aspects of functioning, such as social or life skills<br/> 6.7 Average endpoint specific aspects of functioning, such as social or life skills<br/> 6.8 Average change in specific aspects of functioning, such as social or life skills </p> </section> <section id="CD004161-sec-0042"> <h6 class="title">7. Behaviour</h6> <p>7.1 Clinically important change in general behaviour<br/> 7.2 Any change in general behaviour<br/> 7.3 Average endpoint general behaviour score<br/> 7.4 Average change in general behaviour scores<br/> 7.5 Clinically important change in specific aspects of behaviour<br/> 7.6 Any change in specific aspects of behaviour<br/> 7.7 Average endpoint specific aspects of behaviour<br/> 7.8 Average change in specific aspects of behaviour </p> </section> <section id="CD004161-sec-0043"> <h6 class="title">8. Adverse effects</h6> <p>8.1 Clinically important general adverse effects<br/> 8.2 Any general adverse effects<br/> 8.3 Average endpoint general adverse effect score<br/> 8.4 Average change in general adverse effect scores<br/> 8.5 Clinically important change in specific adverse effects<br/> 8.6 Any change in specific adverse effects<br/> 8.7 Average endpoint specific adverse effects<br/> 8.8 Average change in specific adverse effects </p> </section> <section id="CD004161-sec-0044"> <h6 class="title">9. Engagement with services</h6> <p>9.1 Clinically important engagement<br/> 9.2 Any engagement<br/> 9.3 Average endpoint engagement score<br/> 9.4 Average change in engagement scores </p> </section> <section id="CD004161-sec-0045"> <h6 class="title">10. Satisfaction with treatment</h6> <p>10.1 Recipient of care not satisfied with treatment<br/> 10.2 Recipient of care average satisfaction score<br/> 10.3 Recipient of care average change in satisfaction scores<br/> 10.4 Carer not satisfied with treatment<br/> 10.5 Carer average satisfaction score<br/> 10.6 Carer average change in satisfaction scores </p> </section> <section id="CD004161-sec-0046"> <h6 class="title">11. Quality of life</h6> <p>11.1 Clinically important change in quality of life<br/> 11.2 Any change in quality of life<br/> 11.3 Average endpoint quality of life score<br/> 11.4 Average change in quality of life scores<br/> 11.5 Clinically important change in specific aspects of quality of life<br/> 11.6 Any change in specific aspects of quality of life<br/> 11.7 Average endpoint specific aspects of quality of life<br/> 11.8 Average change in specific aspects of quality of life </p> </section> <section id="CD004161-sec-0047"> <h6 class="title">12. Economic outcomes</h6> <p>12.1 Average change in total cost of medical and mental health care<br/> 12.2 Total indirect and direct costs<br/> 12.3 Direct resource use:<br/> 12.3.1 Outpatients ‐ number of contacts (GP consultation, psychiatrist, psychologists, psychiatric nurse, counsellor, social worker)<br/> 12.3.2 Hospitalisation (taking battery of tests, patients’ physical, psychiatric and psychological profile and psychological assessment, number of days, relapse)<br/> 12.3.3 Medication (different types of antipsychotics to include dose and frequency, treatment of side effects)<br/> 12.3.4 Psychological therapies (different types of psychological therapies to include session numbers and frequency)<br/> 12.3.5 Other resources (day centres, night shelter) and transportation for medical care visits<br/> 12.4 Indirect resource use:<br/> 12.4.1 Family, relatives' and friends' resources<br/> 12.4.2 Police, criminal justice system<br/> 12.4.3 Benefits paid, social security payments<br/> 12.4.4 Employment agency workers, absence from work, loss of productivity<br/> 12.5 Cost‐effectiveness ratios represented by incremental cost‐effectiveness (ICER)<br/> 12.6 Cost‐utilities represented by incremental costs per quality‐adjusted life year (QALY) or disability‐adjusted life year (DALY)<br/> 12.7 Cost benefit represented by net Benefit Ratio, others. </p> </section> <section id="CD004161-sec-0048"> <h6 class="title">13. 'Summary of findings' table</h6> <p>We used the GRADE approach to interpret findings (<a href="./references#CD004161-bbs2-0094" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359‐83. ">Schünemann 2008</a>) and used GRADE profiler (<a href="http://www.ims.cochrane.org/revman/gradepro" target="_blank">GRADEPRO</a>) to import data from RevMan 5 (<a href="http://www.ims.cochrane.org/revman" target="_blank">Review Manager</a>) to create 'Summary of findings' tables. These tables provide outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient‐care and decision making. We selected the following main outcomes for inclusion in the 'Summary of findings' table. </p> <p>1. Relapse ‐ long term.<br/> 2. Clinically significant improvement in mental state ‐ long term.<br/> 3. Leaving the study early for any reason ‐ medium/long term.<br/> 4. Severe adverse effects ‐ medium/long term.<br/> 5. Adverse events related to movement disorder, weight gain, prolactin levels and glucose metabolism ‐ medium/long term. </p> </section> </section> </section> </section> <section id="CD004161-sec-0049"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD004161-sec-0050"> <h4 class="title">Electronic searches</h4> <section id="CD004161-sec-0051"> <h5 class="title">Cochrane Schizophrenia Group’s Trials Register</h5> <p>On October 28, 2015, the Trials Search Co‐ordinator (TSC) searched the Cochrane Schizophrenia Group’s Study‐Based Register of Trials using the following search strategy: </p> <p>(*Risperidone* AND *Injection*) in Intervention Field of STUDY</p> <p>In such a study‐based register, searching the major concept retrieves all the synonym keywords and relevant studies because all the studies have already been organised based on their interventions and linked to the relevant topics. </p> <p>The Cochrane Schizophrenia Group’s Register of Trials is compiled by systematic searches of major resources (including AMED, BIOSIS, CINAHL, EMBASE, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, handsearches, grey literature, and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">Group’s Module</a>). There is no language, date, document type, or publication status limitations for inclusion of records into the register. </p> <p>For previous searches, please see <a href="./appendices#CD004161-sec-0315">Appendix 1</a>. </p> </section> </section> <section id="CD004161-sec-0052"> <h4 class="title">Searching other resources</h4> <section id="CD004161-sec-0053"> <h5 class="title">1. Reference searching</h5> <p>The review authors inspected references of all identified studies for more studies.</p> </section> <section id="CD004161-sec-0054"> <h5 class="title">2. Personal contact</h5> <p>The review authors attempted to contact the first author of each study considered for inclusion in the review for more information regarding unpublished trials or any available data. </p> </section> <section id="CD004161-sec-0055"> <h5 class="title">3. Drug companies</h5> <p>The review authors contacted Janssen‐Cilag Limited for further data.</p> </section> </section> </section> <section id="CD004161-sec-0056"> <h3 class="title" id="CD004161-sec-0056">Data collection and analysis</h3> <p>For details of previous data collection and analysis methods see <a href="./appendices#CD004161-sec-0328">Appendix 2</a>. </p> <section id="CD004161-sec-0057"> <h4 class="title">Selection of studies</h4> <p>For this update, review author PH and TN (see <a href="#CD004161-sec-0312">Acknowledgements</a>) independently inspected citations from the searches and identified relevant abstracts. A random 20% sample was independently re‐inspected by SS to ensure reliability. Where disputes arose, the full‐text report was acquired for more detailed scrutiny. If citations met inclusion criteria, we obtained full‐text reports for more detailed inspection. Again, a random 20% of reports were re‐inspected by SS in order to ensure reliable selection. Where it was not possible to resolve disagreement by discussion, we attempted to contact the authors of the study for clarification and added these studies to the list awaiting classification. </p> <p>With regards to selecting studies for economic evaluations, review authors (SS and VF) categorised studies as per the following:<br/> <br/> <b>Type A</b> ‐ Full economic evaluation (within the framework of RCT): studies that focus on cost‐effectiveness analysis, cost‐utility analysis and cost‐benefit analysis.<br/> <b>Type B</b> ‐ Partial economic evaluation (within the framework of RCT): studies that focus on cost‐analysis and cost‐minimisation studies of Risperidone (depot).<br/> <b>Type C</b> ‐ Randomised trials that reported limited information, such as estimates of resources use or costs associated with Risperidone (depot). </p> </section> <section id="CD004161-sec-0058"> <h4 class="title">Data extraction and management</h4> <section id="CD004161-sec-0059"> <h5 class="title">1. Extraction</h5> <p>For this update PH, and TN extracted data from all included studies. In addition, to ensure reliability, SS independently extracted data from a random sample of these studies, comprising 10% of the total. Again, any disagreement was discussed, decisions documented and, if necessary, authors of studies contacted for clarification. With any remaining problems, we contacted editorial team (<a href="./references#CD004161-bbs2-0051" title="Cost‐Effectiveness Analysis Registry (CEA). https://research.tufts‐nemc.org/cear4/ accessed 11/09/13. ">CEA</a>) to help clarify issues and these final decisions were documented. Data presented only in graphs and figures were extracted whenever possible, but included only if two review authors independently had the same result. We attempted to contact authors through an open‐ended request in order to obtain missing information or for clarification whenever necessary. </p> <p>For the economic analysis had VF and SS found Type A and B studies (see <a href="https://archie.cochrane.org/sections/documents/view?version=z1511171520444779582034426896480%26format=REVMAN#CRIT_STUDIES" target="_blank">Types of studies</a>), they would have investigated whether appraisal had already been undertaken by <a href="http://www.crd.york.ac.uk/crdweb/homepage.asp" target="_blank">NHS EED</a> using their search tool derived for this purpose. If appraisal had not been undertaken, VF and SS would have applied the <a href="http://www.crd.york.ac.uk/crdweb/homepage.asp" target="_blank">NHS EED</a> tool to the data. In this current review, should there only be Type C studies available, we would extract outcome data directly from the already‐included effectiveness studies. We recognise that much information would be lacking to get results that are both valid and reliable. </p> </section> <section id="CD004161-sec-0060"> <h5 class="title">2. Management</h5> <section id="CD004161-sec-0061"> <h6 class="title">2.1 Forms</h6> <p>We extracted data onto standard, simple forms.</p> </section> <section id="CD004161-sec-0062"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if:<br/> a. the psychometric properties of the measuring instrument have been described in a peer‐reviewed journal (<a href="./references#CD004161-bbs2-0085" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); and<br/> b. the measuring instrument has not been written or modified by one of the trialists for that particular trial. </p> <p>Ideally, the measuring instrument should either be i. a self‐report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly, and we noted in <a href="#CD004161-sec-0102">Description of studies</a> whether or not this was the case. </p> </section> <section id="CD004161-sec-0063"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>There are advantages of both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided primarily to use endpoint data, and only use change data if the former were not available. We combined endpoint and change data in the analysis as we used mean differences (MD) rather than standardised mean differences (SMD) throughout (<a href="./references#CD004161-bbs2-0070" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>, Chapter 9.4.5.2). </p> </section> <section id="CD004161-sec-0064"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we aimed to apply the following standards to relevant data before inclusion:<br/> a) standard deviations (SDs) and means are reported in the paper or obtainable from the authors;<br/> b) when a scale starts from the finite number zero, the SD, when multiplied by two, is less than the mean, as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution, (<a href="./references#CD004161-bbs2-0045" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313(7066):1200. ">Altman 1996</a>);<br/> c) if a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS) (<a href="./references#CD004161-bbs2-0074" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), which can have values from 30 to 210), the calculation described above was modified to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S‐S min), where S is the mean score and S min is the minimum score.<br/> <br/> Endpoint scores on scales often have a finite start and end point and these rules can be applied. We entered skewed endpoint data from studies of less than 200 participants in additional tables rather than into an analysis. However, skewed data pose less of a problem when looking at mean if the sample size is large, we therefore, entered skewed endpoint data from studies with over 200 participants into syntheses.When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not and we entered skewed change data into analysis. </p> </section> <section id="CD004161-sec-0065"> <h6 class="title">2.5 Common measure</h6> <p>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD004161-sec-0066"> <h6 class="title">2.6 Conversion of continuous to binary</h6> <p>Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD004161-bbs2-0091" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) or the Positive and Negative Syndrome Scale (PANSS, <a href="./references#CD004161-bbs2-0074" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), this could be considered as a clinically significant response (<a href="./references#CD004161-bbs2-0078" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelRR . What does the PANSS mean?. Schizophrenia Research2005;79(2‐3):231‐8. [PUBMED: 15982856] ">Leucht 2005</a>; <a href="./references#CD004161-bbs2-0079" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry2005;187:366‐71. [PUBMED: 16199797] ">Leucht 2005a</a>). If data based on these thresholds were not available, we used the primary cut‐off presented by the original authors. </p> </section> <section id="CD004161-sec-0067"> <h6 class="title">2.7 Direction of graphs</h6> <p>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for risperidone depot. Where keeping to this made it impossible to avoid outcome titles with clumsy double‐negatives (e.g. 'Not un‐improved'), we reported data where the left of the line indicates an unfavourable outcome. This was noted in the relevant graphs. </p> </section> </section> </section> <section id="CD004161-sec-0068"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For this update, PH and TN worked independently by using criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004161-bbs2-0070" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>) to assess trial quality. This new set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. </p> <p>Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the studies in order to obtain additional information. </p> <p>We have noted the level of risk of bias in both the text of the review and in the <a href="./full#CD004161-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD004161-sec-0069"> <h4 class="title">Measures of treatment effect</h4> <section id="CD004161-sec-0070"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes, we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI)*. It has been shown that RR is more intuitive (<a href="./references#CD004161-bbs2-0050" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie1999;54(4):405‐11. [PUBMED: 10667106] ">Boissel 1999</a>) than odds ratios (ORs) and that ORs tend to be interpreted as RR by clinicians (<a href="./references#CD004161-bbs2-0058" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000. ">Deeks 2000</a>). We did not calculate the Number Needed to Treat/Harm (NNT/H). The NNT/H statistic with its CIs is intuitively attractive to clinicians but is problematic both in its accurate calculation in meta‐analyses and interpretation (<a href="http://archie.cochrane.org/sections/documents/view?version=10522344846093567587120911135455%26format=REVMAN#REF-Hutton-2009" target="_blank">Hutton 2009</a>). For binary data presented in the 'Summary of findings' tables, where possible, we calculated illustrative comparative risks. </p> </section> <section id="CD004161-sec-0071"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes, we estimated mean difference (MD) between groups. We prefer not to calculate effect size measures (standardised mean difference SMD). However, if scales of very considerable similarity were used, we presumed there was a small difference in measurement, and we would have calculated effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD004161-sec-0072"> <h4 class="title">Unit of analysis issues</h4> <section id="CD004161-sec-0073"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra‐class correlation in clustered studies, leading to a 'unit of analysis' error (<a href="./references#CD004161-bbs2-0059" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623‐9. ">Divine 1992</a>), whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<a href="./references#CD004161-bbs2-0048" title="BlandJM , KerrySM . Statistics notes. Trials randomised in clusters. BMJ1997;315(7108):600. ">Bland 1997</a>; <a href="./references#CD004161-bbs2-0066" title="GullifordMC , UkoumunneOC , ChinnS . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149(9):876‐83. ">Gulliford 1999</a>). </p> <p>Where clustering was not accounted for in primary studies, we presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review, we will seek to contact first authors of studies to obtain intra‐class correlation coefficients (ICCs) for their clustered data and to adjust for this by using accepted methods (<a href="./references#CD004161-bbs2-0066" title="GullifordMC , UkoumunneOC , ChinnS . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149(9):876‐83. ">Gulliford 1999</a>). Where clustering has been incorporated into the analysis of primary studies, we presented these data as if from a non‐cluster randomised study, but adjusted for the clustering effect. </p> <p>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC [Design effect = 1+(m‐1)*ICC] (<a href="./references#CD004161-bbs2-0060" title="DonnerA , KlarN . Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine2002;21:2971‐80. ">Donner 2002</a>). If the ICC was not reported it was assumed to be 0.1 (<a href="./references#CD004161-bbs2-0097" title="UkoumunneOC , GullifordMC , ChinnS , SterneJAC , BurneyPGJ . Methods for evaluating area‐wide and organisation‐based intervention in health and health care: a systematic review. Health Technology Assessment1999;3(5):1‐75. ">Ukoumunne 1999</a>). </p> <p>If cluster studies have been appropriately analysed taking into account ICCs and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique. </p> </section> <section id="CD004161-sec-0074"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash‐out phase. For the same reason cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD004161-bbs2-0062" title="ElbourneD , AltmanDG , HigginsJPT , CurtinaF , WorthingtondHV , VaileA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). As both effects are very likely in severe mental illness, if we had included cross‐over trials, we planned only to use the data from the first phase of cross‐over studies. </p> </section> <section id="CD004161-sec-0075"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>Where a study involves more than two treatment arms, if relevant, the additional treatment arms were presented in comparisons. Where the additional treatment arms were not relevant, we did not reproduce these data. </p> </section> </section> <section id="CD004161-sec-0076"> <h4 class="title">Dealing with missing data</h4> <section id="CD004161-sec-0077"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD004161-bbs2-0099" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). We chose that, for any particular outcome, should more than 50% of data be unaccounted for, we did not reproduce these data or use them within analyses, except for the outcomes of leaving the study early and adverse events. If, however, more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we marked such data with (*) to indicate that such a result may well be prone to bias. This was the case for three studies (<a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>; <a href="./references#CD004161-bbs2-0006" title="Anonymous . Injectible, long‐acting risperidone effective. Journal of Pharmacy Technology2001;4:157. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4‐8th May, Stockholm, Sweden)2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey)2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum; 2002 Jun 23‐27; Montreal, Canada)2002;5(Suppl 1):S188. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;53(3 Suppl.1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta (TM), a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cliag UK Ltd2002. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5‐9, 2002, Barcelona‐Spain2002;12(Supplement 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160(6):1125‐32. ">Kane 2002*</a><a href="./references#CD004161-bbs2-0011" title="QuinnA , CamachoF , MitchellD , ChueP , MallaA . Open‐label randomized exploratory investigation of Risperdal* Consta* and oral antipsychotics treatment of early psychosis. Autumn Conference of the International Society for CNS Clinical Trials and Methodology, October 1‐3. Marina Del Rey, California, 2012. ">Quinn 2012*</a>). </p> </section> <section id="CD004161-sec-0078"> <h5 class="title">2. Binary</h5> <p>In the case where attrition for a binary outcome was between 0% and 50%, and where these data were not clearly described, we presented data on a 'once‐randomised‐always‐analyse' basis (an intention‐to‐treat analysis). Those leaving the study early were all assumed to have the same rates of negative outcome as those who completed, with the exception of the outcome of death and adverse effects. For these outcomes, the rate of those who stayed in the study ‐ in that particular arm of the trial ‐ were used for those who did not. We undertook a sensitivity analysis to test how prone the primary outcomes were to change when data only from people who completed the study to that point were compared to the intention‐to‐treat analysis using the above assumptions. </p> </section> <section id="CD004161-sec-0079"> <h5 class="title">3. Continuous</h5> <section id="CD004161-sec-0080"> <h6 class="title">3.1 Attrition</h6> <p>In the case where attrition for a continuous outcome was between 0% and 50%, and data only from people who completed the study to that point were reported, we presented and used these data. </p> </section> <section id="CD004161-sec-0081"> <h6 class="title">3.2 Standard deviations</h6> <p>If standard deviations (SDs) were not reported, we first tried to obtain the missing values from the authors. If not available, where there are missing measures of variance for continuous data, but an exact standard error (SE) and confidence intervals available for group means, and either a P value or T value available for differences in mean, we can calculate them according to the rules described in the <i>Cochrane Handbook for Systematic reviews of Interventions</i> (<a href="./references#CD004161-bbs2-0070" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>): When only the SE is reported, SDs are calculated by the formula SD = SE * square root (n). Chapters 7.7.3 and 16.1.3 of the <i>Cochrane Handbook for Systematic reviews of Interventions</i> (<a href="./references#CD004161-bbs2-0070" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>) present detailed formulae for estimating SDs from P values, T or F values, confidence intervals, ranges or other statistics. If these formulae do not apply, we can calculate the SDs according to a validated imputation method which is based on the SDs of the other included studies (<a href="./references#CD004161-bbs2-0064" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(7):7‐10. ">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study’s outcome and thus to lose information. However, we did not impute any data in this review. </p> </section> <section id="CD004161-sec-0082"> <h6 class="title">3.3 Last observation carried forward</h6> <p>We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<a href="./references#CD004161-bbs2-0080" title="LeuchtS , EngelRR , BaumlJ , DavisJM . Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin2007;33(1):183‐91. [PUBMED: 16905632] ">Leucht 2007</a>). Therefore, where LOCF data had been used in the trial, if less than 50% of the data had been assumed, we reproduced these data and indicated that they are the product of LOCF assumptions. </p> </section> </section> </section> <section id="CD004161-sec-0083"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD004161-sec-0084"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations which we had not predicted would arise. When such situations or participant groups arose, these were fully discussed. </p> </section> <section id="CD004161-sec-0085"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise. When such methodological outliers arise these were fully discussed. </p> </section> <section id="CD004161-sec-0086"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD004161-sec-0087"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD004161-sec-0088"> <h6 class="title">3.2 Employing the I<sup>2</sup> statistic </h6> <p>Heterogeneity between studies was investigated by considering the I<sup>2</sup> method alongside the Chi<sup>2</sup> 'P' value. The I<sup>2</sup> provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD004161-bbs2-0069" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). The importance of the observed value of an I<sup>2</sup> depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. 'P' value from Chi<sup>2</sup> test, or a confidence interval for I<sup>2</sup>). An I<sup>2</sup> estimate greater than or equal to around 70% accompanied by a statistically significant Chi<sup>2</sup> statistic, was interpreted as evidence of substantial levels of heterogeneity (Section 9.5.2 ‐ <a href="./references#CD004161-bbs2-0070" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). When substantial levels of heterogeneity were found in the primary outcome, we explored reasons for the heterogeneity (<a href="#CD004161-sec-0091">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD004161-sec-0089"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD004161-bbs2-0061" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. ">Egger 1997</a>). These are described in Section 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004161-bbs2-0070" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We planned not to use funnel plots for outcomes where there were less than 10studies in each analysis, or where all studies were of similar sizes. If funnel plots had been possible, we planned to seek statistical advice in their interpretation. </p> </section> <section id="CD004161-sec-0090"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random‐effects model. It puts added weight onto small studies, which often are the most biased ones. Depending on the direction of effect these studies can either inflate or deflate the effect size. We chose the random‐effects model for all analyses. </p> </section> <section id="CD004161-sec-0091"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD004161-sec-0092"> <h5 class="title">1. Subgroup analyses ‐ only primary outcomes</h5> <section id="CD004161-sec-0093"> <h6 class="title">1.1 Clinical state, stage or problem</h6> <p>We proposed to undertake this review and provide an overview of the effects of risperidone depot for people with schizophrenia in general. In addition, however, we tried to report data on subgroups of people in the same clinical state, stage and with similar problems. </p> </section> </section> <section id="CD004161-sec-0094"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>If inconsistency was high, this was reported. First, we investigated whether data had been entered correctly. Second, if data were correct, we visually inspected the graph and removed outlying studies to see if heterogeneity was restored. For this review, we decided that should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, data were presented. If not, data were not pooled and issues discussed. We know of no supporting research for this 10% cut‐off but are investigating use of prediction intervals as an alternative to this unsatisfactory state. </p> <p>When unanticipated clinical or methodological heterogeneity were obvious, we simply stated hypotheses regarding these for future reviews or versions of this review. We did not anticipate undertaking analyses relating to these. </p> </section> </section> <section id="CD004161-sec-0095"> <h4 class="title">Sensitivity analysis</h4> <section id="CD004161-sec-0096"> <h5 class="title">1. Implication of randomisation</h5> <p>We aimed to include trials in a sensitivity analysis if they were described in some way as to imply randomisation. For the primary outcomes, we included these studies and if there was no substantive difference when the implied randomised studies were added to those with a better description of randomisation, then all data were used from these studies. </p> </section> <section id="CD004161-sec-0097"> <h5 class="title">2. Assumptions for lost binary data</h5> <p>Where assumptions had to be made regarding people lost to follow‐up (see <a href="#CD004161-sec-0076">Dealing with missing data</a>), we compared the findings of the primary outcomes when we used our assumption compared with completer data only. If there was a substantial difference, we reported results and discussed them, but continued to employ our assumption. </p> <p>Where assumptions had to be made regarding missing SDs data (see <a href="#CD004161-sec-0076">Dealing with missing data</a>), we compared the findings on primary outcomes when we used our assumption compared with complete data only. A sensitivity analysis was undertaken to test how prone results were to change when 'completer' data only were compared to the imputed data using the above assumption. If there was a substantial difference, we reported results and discussed them, but continued to employ our assumption. </p> </section> <section id="CD004161-sec-0098"> <h5 class="title">3. Risk of bias</h5> <p>We analysed the effects of excluding trials that were judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available) allocation concealment, blinding and outcome reporting for the meta‐analysis of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, then we included data from these trials in the analysis </p> </section> <section id="CD004161-sec-0099"> <h5 class="title">4. Imputed values</h5> <p>Had we included cluster‐randomised trials, we planned to undertake a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect in such trials. </p> <p>If substantial differences were noted in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we did not pool data from the excluded trials with the other trials contributing to the outcome, but presented them separately. </p> </section> <section id="CD004161-sec-0100"> <h5 class="title">5. Fixed‐effect and random‐effects</h5> <p>All data were synthesised using a random‐effects , however, we also synthesised data for the primary outcome using a fixed‐effect model to evaluate whether the greater weights assigned to larger trials with greater event rates, altered the significance of the results compared to the more evenly distributed weights in the fixed‐effect model. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004161-sec-0101" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004161-sec-0101"></div> <section id="CD004161-sec-0102"> <h3 class="title">Description of studies</h3> <p>Salient features of the included and excluded studies are given in the tables (<a href="./references#CD004161-sec-0348" title="">Characteristics of included studies</a>; <a href="./references#CD004161-sec-0349" title="">Characteristics of excluded studies</a>). </p> <section id="CD004161-sec-0103"> <h4 class="title">Results of the search</h4> <section id="CD004161-sec-0104"> <h5 class="title">1. Overall</h5> <p>The original published version of this review (<a href="./references#CD004161-bbs2-0101" title="HosalliP , DavisJM . Depot risperidone for schizophrenia. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD004161; PUBMED: 14584007] ">Hosalli 2003</a>) included two studies and excluded 11, with two studies awaiting classification. The search updates in 2010, 2012 and 2015 identified 181 references with no additional records identified through other sources. No duplicates were found. We screened 181 records. Twenty‐eight potentially relevant full‐text reports were obtained and scrutinised, and 17 of these reports did not meet the inclusion criteria (see <a href="./references#CD004161-sec-0349" title="">Characteristics of excluded studies</a>), and were added to the excluded studies. Ten studies were added to included studies and one study was added to awaiting classification (<a href="#CD004161-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD004161-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram: 2010 and 2012, 2015 updated search" data-id="CD004161-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram: 2010 and 2012, 2015 updated search</p> </div> </div> </div> </section> </section> <section id="CD004161-sec-0105"> <h4 class="title">Included studies</h4> <p>Twelve studies, reported as 15 conference presentations and 13 full‐text papers met the selection criteria and are included in this update. </p> <section id="CD004161-sec-0106"> <h5 class="title">1. Study design</h5> <p>All 12 included studies were randomised and eight featured some form of blinding ‐ ranging from blinding of raters in otherwise open‐label studies to blinding of all participants and investigators; four studies were expressly or implied as 'open‐label' but employed blinded raters (<a href="./references#CD004161-bbs2-0001" title="BaiYM , ChenTT , WuB , HungCH , LinWK , HuTM , et al. A comparative efficacy and safety study of long‐acting risperidone injection and risperidone oral tablets among hospitalized patients: 12‐week randomized, single‐blind study. Pharmacopsychiatry2006;39(4):135‐41. ">Bai 2006</a>; <a href="./references#CD004161-bbs2-0003" title="CovellNH , McEvoyJP , SchoolerNR , StroupTS , JacksonCT , RojasIA , et al. Effectiveness of switching from long‐acting injectable fluphenazine or haloperidol decanoate to long‐acting injectable risperidone microspheres: an open‐label, randomized control trial. Journal of Clinical Psychiatry2012;73(5):669‐75. ">Covell 2012</a>; <a href="./references#CD004161-bbs2-0008" title="LiH , RuiQ , NingX , XuH , GuN . A comparative study of paliperidone palmitate and risperidone long‐acting injectable therapy in schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:1002‐8. ">Li 2011</a>; <a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a>). Study duration also varied considerably; three studies were short term at 12 to 13 weeks (<a href="./references#CD004161-bbs2-0001" title="BaiYM , ChenTT , WuB , HungCH , LinWK , HuTM , et al. A comparative efficacy and safety study of long‐acting risperidone injection and risperidone oral tablets among hospitalized patients: 12‐week randomized, single‐blind study. Pharmacopsychiatry2006;39(4):135‐41. ">Bai 2006</a>; <a href="./references#CD004161-bbs2-0002" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;3(Suppl 1):174. ChueP , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Promotional slides on file from Janssen‐Cliag UK Ltd2002. ">Chue 2002</a>; <a href="./references#CD004161-bbs2-0010" title="PandinaG , LaneR , Gassmann‐MayerC , HoughD , RemmerieB , SimpsonG . A randomised double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Proceedings of the 27th International College of Neuropsychopharmacology Congress; 2010 June 6‐10; Hong Kong. 2010. PandinaG , LaneR , GopalS , Gassman‐MayerC , HoughD , RemmerieB , et al. A randomized double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Biological Psychiatry2010;67(9):77‐8. PandinaG , LaneR , GopalS , Gassmann‐MayerC , HoughD , RemmerieB , et al. A double‐blind study of paliperidone palmitate and risperidone long‐acting injectable in adults with schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:218‐26. ">Pandina 2011</a>); <a href="./references#CD004161-bbs2-0003" title="CovellNH , McEvoyJP , SchoolerNR , StroupTS , JacksonCT , RojasIA , et al. Effectiveness of switching from long‐acting injectable fluphenazine or haloperidol decanoate to long‐acting injectable risperidone microspheres: an open‐label, randomized control trial. Journal of Clinical Psychiatry2012;73(5):669‐75. ">Covell 2012</a> was medium term, while seven followed up participants for two years (<a href="./references#CD004161-bbs2-0004" title="FleischhackerWW , GopalS , LaneR , Gassmann‐Mayer , LimP , HoughD , et al. A randomized trial of paliperidone palmitate and risperidone long acting injectable in schizophrenia. International Journal of Neuropsychopharmacology2012;15:107‐18. ">Fleischhacker 2011</a>; <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>; <a href="./references#CD004161-bbs2-0006" title="Anonymous . Injectible, long‐acting risperidone effective. Journal of Pharmacy Technology2001;4:157. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4‐8th May, Stockholm, Sweden)2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey)2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum; 2002 Jun 23‐27; Montreal, Canada)2002;5(Suppl 1):S188. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;53(3 Suppl.1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta (TM), a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cliag UK Ltd2002. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5‐9, 2002, Barcelona‐Spain2002;12(Supplement 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160(6):1125‐32. ">Kane 2002*</a>; <a href="./references#CD004161-bbs2-0008" title="LiH , RuiQ , NingX , XuH , GuN . A comparative study of paliperidone palmitate and risperidone long‐acting injectable therapy in schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:1002‐8. ">Li 2011</a>; <a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a>; <a href="./references#CD004161-bbs2-0011" title="QuinnA , CamachoF , MitchellD , ChueP , MallaA . Open‐label randomized exploratory investigation of Risperdal* Consta* and oral antipsychotics treatment of early psychosis. Autumn Conference of the International Society for CNS Clinical Trials and Methodology, October 1‐3. Marina Del Rey, California, 2012. ">Quinn 2012*</a>; <a href="./references#CD004161-bbs2-0012" title="BarnettPG , ScottJY , KrystalJH , RosenheckRA . Cost and cost‐effectiveness in a randomized trial of long‐acting risperidone for schizophrenia. Journal of Clinical Psychiatry2012;73:696‐702. RosenheckRA , KrystalJH , LewR , BarnettPG , FioreL , ValleyD , et al. Long‐ acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine March 3, 2011;364(9):842‐51. ">Rosenheck 2011</a>). One study (<a href="./references#CD004161-bbs2-0007" title="KeksN , InghamM , KhanA , KarcherK . Long‐acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open‐label study. British Journal of Psychiatry2007;191:131‐9. KeksN , KhanA , AugustynsI , RabinowitzJ , InghamM . Non‐inferiority efficacy trial of risperidone long‐acting injection (RLAI) vs. olanzapine tablets (OLA). Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006. ">Keks 2007</a>), combined short‐ and medium‐term outcomes, with analyses at 12 weeks and one‐year of follow‐up. The majority of studies took place in the community, and were well‐represented internationally, with studies conducted in Taiwan (<a href="./references#CD004161-bbs2-0001" title="BaiYM , ChenTT , WuB , HungCH , LinWK , HuTM , et al. A comparative efficacy and safety study of long‐acting risperidone injection and risperidone oral tablets among hospitalized patients: 12‐week randomized, single‐blind study. Pharmacopsychiatry2006;39(4):135‐41. ">Bai 2006</a>) and the remaining as multi‐centre studies, conducted within the USA (<a href="./references#CD004161-bbs2-0003" title="CovellNH , McEvoyJP , SchoolerNR , StroupTS , JacksonCT , RojasIA , et al. Effectiveness of switching from long‐acting injectable fluphenazine or haloperidol decanoate to long‐acting injectable risperidone microspheres: an open‐label, randomized control trial. Journal of Clinical Psychiatry2012;73(5):669‐75. ">Covell 2012</a>; <a href="./references#CD004161-bbs2-0006" title="Anonymous . Injectible, long‐acting risperidone effective. Journal of Pharmacy Technology2001;4:157. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4‐8th May, Stockholm, Sweden)2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey)2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum; 2002 Jun 23‐27; Montreal, Canada)2002;5(Suppl 1):S188. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;53(3 Suppl.1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta (TM), a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cliag UK Ltd2002. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5‐9, 2002, Barcelona‐Spain2002;12(Supplement 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160(6):1125‐32. ">Kane 2002*</a>; <a href="./references#CD004161-bbs2-0012" title="BarnettPG , ScottJY , KrystalJH , RosenheckRA . Cost and cost‐effectiveness in a randomized trial of long‐acting risperidone for schizophrenia. Journal of Clinical Psychiatry2012;73:696‐702. RosenheckRA , KrystalJH , LewR , BarnettPG , FioreL , ValleyD , et al. Long‐ acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine March 3, 2011;364(9):842‐51. ">Rosenheck 2011</a>), Canada (<a href="./references#CD004161-bbs2-0011" title="QuinnA , CamachoF , MitchellD , ChueP , MallaA . Open‐label randomized exploratory investigation of Risperdal* Consta* and oral antipsychotics treatment of early psychosis. Autumn Conference of the International Society for CNS Clinical Trials and Methodology, October 1‐3. Marina Del Rey, California, 2012. ">Quinn 2012*</a>), China (<a href="./references#CD004161-bbs2-0008" title="LiH , RuiQ , NingX , XuH , GuN . A comparative study of paliperidone palmitate and risperidone long‐acting injectable therapy in schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:1002‐8. ">Li 2011</a>), Europe (<a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>; <a href="./references#CD004161-bbs2-0007" title="KeksN , InghamM , KhanA , KarcherK . Long‐acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open‐label study. British Journal of Psychiatry2007;191:131‐9. KeksN , KhanA , AugustynsI , RabinowitzJ , InghamM . Non‐inferiority efficacy trial of risperidone long‐acting injection (RLAI) vs. olanzapine tablets (OLA). Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006. ">Keks 2007</a>); and international multi‐centre studies (<a href="./references#CD004161-bbs2-0002" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;3(Suppl 1):174. ChueP , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Promotional slides on file from Janssen‐Cliag UK Ltd2002. ">Chue 2002</a>; <a href="./references#CD004161-bbs2-0004" title="FleischhackerWW , GopalS , LaneR , Gassmann‐Mayer , LimP , HoughD , et al. A randomized trial of paliperidone palmitate and risperidone long acting injectable in schizophrenia. International Journal of Neuropsychopharmacology2012;15:107‐18. ">Fleischhacker 2011</a>; <a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a>; <a href="./references#CD004161-bbs2-0010" title="PandinaG , LaneR , Gassmann‐MayerC , HoughD , RemmerieB , SimpsonG . A randomised double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Proceedings of the 27th International College of Neuropsychopharmacology Congress; 2010 June 6‐10; Hong Kong. 2010. PandinaG , LaneR , GopalS , Gassman‐MayerC , HoughD , RemmerieB , et al. A randomized double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Biological Psychiatry2010;67(9):77‐8. PandinaG , LaneR , GopalS , Gassmann‐MayerC , HoughD , RemmerieB , et al. A double‐blind study of paliperidone palmitate and risperidone long‐acting injectable in adults with schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:218‐26. ">Pandina 2011</a>). </p> </section> <section id="CD004161-sec-0107"> <h5 class="title">2. Participants</h5> <p>A total of n = 5723 participants who received the intervention were included, with the majority of studies providing data as to male and female participants; a total of n = 3140 male and n = 2112 female participants were included, with a mean age of around 40 years. All studies used the Diagnostic and Statistical Mannual version 1V (DSM‐IV) (<a href="./references#CD004161-bbs2-0046" title="American Psychiatric Association. Diagnostic and sStatistical Manual of Mental Disorders : DSM‐IV‐TR. Washington, DC: American Psychiatric Association, 2000. ">APA 2000</a>) to define schizophrenia; so for at least six continuous months a participant must have shown some evidence of schizophrenia, and for at least one month must have shown at least two symptoms of frank psychosis. These symptoms would have included delusions, hallucinations, incoherent speech, disorganised or catatonic behaviour, or flat affect. To meet DSM IV criteria, the symptoms must be disabling in such a way that social and occupational functioning is impaired; these symptoms should not be the direct result of a physical disorder or of substance misuse. Most studies randomised people who had been experiencing schizophrenia for some years; often specifying that they need to have had schizophrenia for at least one year before diagnosis. </p> <p>Further criteria for selecting participants varied from study to study, depending on exactly what was being investigated, but general exclusion criteria were reasonably consistent; people with a history of violence to themselves or others, or of recent suicide attempts were not permitted to take part. Nor were those with active DSM‐IV diagnosed substance dependence or general ill health, including serious psychiatric problems other than schizophrenia. Tolerance to risperidone was an important factor that all studies addressed; most potential participants underwent a screening period at the start of their trial to establish that they could tolerate risperidone; this was sometimes waived if they had already demonstrated this (i.e. they were currently treated with the drug). </p> </section> <section id="CD004161-sec-0108"> <h5 class="title">3. Interventions</h5> <p>The prescribing of depot risperidone was consistent across the board; 25, 37.5 and 50 mg injections every two weeks were the most common dosages, with participants typically initiated on 25 mg/two weeks, which was then stepped up in 12.5 mg increments if their symptoms worsened. Three earlier studies (<a href="./references#CD004161-bbs2-0002" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;3(Suppl 1):174. ChueP , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Promotional slides on file from Janssen‐Cliag UK Ltd2002. ">Chue 2002</a>; <a href="./references#CD004161-bbs2-0006" title="Anonymous . Injectible, long‐acting risperidone effective. Journal of Pharmacy Technology2001;4:157. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4‐8th May, Stockholm, Sweden)2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey)2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum; 2002 Jun 23‐27; Montreal, Canada)2002;5(Suppl 1):S188. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;53(3 Suppl.1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta (TM), a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cliag UK Ltd2002. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5‐9, 2002, Barcelona‐Spain2002;12(Supplement 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160(6):1125‐32. ">Kane 2002*</a>; <a href="./references#CD004161-bbs2-0007" title="KeksN , InghamM , KhanA , KarcherK . Long‐acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open‐label study. British Journal of Psychiatry2007;191:131‐9. KeksN , KhanA , AugustynsI , RabinowitzJ , InghamM . Non‐inferiority efficacy trial of risperidone long‐acting injection (RLAI) vs. olanzapine tablets (OLA). Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006. ">Keks 2007</a>) included depot risperidone up to 75 mg, but such high doses were not used by the most recent studies. Because it can take several weeks for therapeutic plasma levels of the drug to build‐up, oral supplementation, either with oral risperidone or the participant's previous oral antipsychotic, was typically used for the initial two to four weeks. </p> <p>The trials involving oral antipsychotics either compared depot risperidone versus another specific single antipsychotic or to more than one antipsychotic. Only one study compared depot risperidone with placebo (<a href="./references#CD004161-bbs2-0006" title="Anonymous . Injectible, long‐acting risperidone effective. Journal of Pharmacy Technology2001;4:157. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4‐8th May, Stockholm, Sweden)2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey)2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum; 2002 Jun 23‐27; Montreal, Canada)2002;5(Suppl 1):S188. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;53(3 Suppl.1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta (TM), a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cliag UK Ltd2002. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5‐9, 2002, Barcelona‐Spain2002;12(Supplement 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160(6):1125‐32. ">Kane 2002*</a>). Of the studies comparing depot risperidone with another single antipsychotic, two used oral risperidone at 2 mg to 6 mg per day (<a href="./references#CD004161-bbs2-0001" title="BaiYM , ChenTT , WuB , HungCH , LinWK , HuTM , et al. A comparative efficacy and safety study of long‐acting risperidone injection and risperidone oral tablets among hospitalized patients: 12‐week randomized, single‐blind study. Pharmacopsychiatry2006;39(4):135‐41. ">Bai 2006</a>; <a href="./references#CD004161-bbs2-0002" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;3(Suppl 1):174. ChueP , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Promotional slides on file from Janssen‐Cliag UK Ltd2002. ">Chue 2002</a>); one study investigated5 mg to 20 mg/day oral olanzapine (<a href="./references#CD004161-bbs2-0007" title="KeksN , InghamM , KhanA , KarcherK . Long‐acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open‐label study. British Journal of Psychiatry2007;191:131‐9. KeksN , KhanA , AugustynsI , RabinowitzJ , InghamM . Non‐inferiority efficacy trial of risperidone long‐acting injection (RLAI) vs. olanzapine tablets (OLA). Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006. ">Keks 2007</a>), and one compared depot risperidone against 5 mg to 30 mg/day oral aripiprazole (<a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a>). <a href="./references#CD004161-bbs2-0003" title="CovellNH , McEvoyJP , SchoolerNR , StroupTS , JacksonCT , RojasIA , et al. Effectiveness of switching from long‐acting injectable fluphenazine or haloperidol decanoate to long‐acting injectable risperidone microspheres: an open‐label, randomized control trial. Journal of Clinical Psychiatry2012;73(5):669‐75. ">Covell 2012</a> compared either haloperidol decanoate or fluphenazine (no doses prescribed, but used at 'clinician's judgement'; <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a> was mainly concerned with quetiapine at up to 750 mg/day, but also featured a smaller aripiprazole arm of 10 mg to 30 mg per day. The remaining three studies randomised patients to receive depot risperidone or to remain on their current oral antipsychotic; in the case of <a href="./references#CD004161-bbs2-0011" title="QuinnA , CamachoF , MitchellD , ChueP , MallaA . Open‐label randomized exploratory investigation of Risperdal* Consta* and oral antipsychotics treatment of early psychosis. Autumn Conference of the International Society for CNS Clinical Trials and Methodology, October 1‐3. Marina Del Rey, California, 2012. ">Quinn 2012*</a>, only second‐generation "atypical" drugs were used, specifically risperidone, olanzapine and quetiapine; <a href="./references#CD004161-bbs2-0012" title="BarnettPG , ScottJY , KrystalJH , RosenheckRA . Cost and cost‐effectiveness in a randomized trial of long‐acting risperidone for schizophrenia. Journal of Clinical Psychiatry2012;73:696‐702. RosenheckRA , KrystalJH , LewR , BarnettPG , FioreL , ValleyD , et al. Long‐ acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine March 3, 2011;364(9):842‐51. ">Rosenheck 2011</a> provides no details of which drugs were used. </p> <p>Paliperidone palmitate (PP) is the active metabolite of risperidone, but features a different administration schedule and dosages to depot risperidone; PP doses can be given either in milligrams (mg), for the overall volume injected, or in milligram equivalents (mg eq), which refers to the fraction of the drug that is actually pharmacologically active. So 39 mg of PP is given as 25 mg eq, 78 mg is 50 mg eq, etc. The injection schedule of this drug only requires monthly intra‐muscular injections to maintain therapeutic levels and oral supplementation is not needed, so in the non open‐label PP studies (<a href="./references#CD004161-bbs2-0004" title="FleischhackerWW , GopalS , LaneR , Gassmann‐Mayer , LimP , HoughD , et al. A randomized trial of paliperidone palmitate and risperidone long acting injectable in schizophrenia. International Journal of Neuropsychopharmacology2012;15:107‐18. ">Fleischhacker 2011</a>; <a href="./references#CD004161-bbs2-0008" title="LiH , RuiQ , NingX , XuH , GuN . A comparative study of paliperidone palmitate and risperidone long‐acting injectable therapy in schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:1002‐8. ">Li 2011</a>; <a href="./references#CD004161-bbs2-0010" title="PandinaG , LaneR , Gassmann‐MayerC , HoughD , RemmerieB , SimpsonG . A randomised double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Proceedings of the 27th International College of Neuropsychopharmacology Congress; 2010 June 6‐10; Hong Kong. 2010. PandinaG , LaneR , GopalS , Gassman‐MayerC , HoughD , RemmerieB , et al. A randomized double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Biological Psychiatry2010;67(9):77‐8. PandinaG , LaneR , GopalS , Gassmann‐MayerC , HoughD , RemmerieB , et al. A double‐blind study of paliperidone palmitate and risperidone long‐acting injectable in adults with schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:218‐26. ">Pandina 2011</a>) oral placebo and bi‐weekly placebo injections were used. </p> </section> <section id="CD004161-sec-0109"> <h5 class="title">4. Outcomes</h5> <section id="CD004161-sec-0110"> <h6 class="title">4.1 Global state</h6> <p>The Clinical Global Impression (CGI) scale was utilised in some manner by the majority of the included studies, with data provided either as mean (SD or SE) endpoint or change scores, or as percentages of participants who were either not ill or mildly ill. Much data were unusable due to the high level of attrition in some studies and inconsistent reporting in others. Another rating scale used to assess global state was the Schedule for Deficit Syndrome (SDS) scale. </p> <p>Other outcomes that give an impression of the general condition of somebody with schizophrenia, such as levels of relapse and remission, the proportion of participants who needed concomitant benzodiazepine and how long they were able to stay on the study drug are also included here. </p> <p>Where relapse was included as an outcome, the investigators typically used the criteria for relapse in <a href="./references#CD004161-bbs2-0054" title="CsernanskyJG , MahmoodR , BrennerR , Risperidone‐USA‐79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine2002;346:16‐22. ">Csernansky 2002</a>. Briefly, these consist of worsening of psychiatric condition (i.e. requiring hospitalisation or increased care), Positive and Negative Syndrome Scale (PANSS) or CGI scores that are markedly higher than the baseline, self‐harm or suicidal/homicidal ideation, discontinuing the study drug due to ineffectiveness, requiring additional antipsychotic medications or non protocol doses of the study drugs. </p> </section> <section id="CD004161-sec-0111"> <h6 class="title">4.2 Mental state</h6> <p>PANSS was the key mental state assessment scale; each study reported changes in PANSS total scores, with some also including the subscales and factor scores. Unfortunately, as with CGI, high attrition prevented us from including PANSS scores from every study in the analysis. </p> </section> <section id="CD004161-sec-0112"> <h6 class="title">4.3 General functioning</h6> <p>The Global Assessment of Functioning (GAF) scale was used by <a href="./references#CD004161-bbs2-0001" title="BaiYM , ChenTT , WuB , HungCH , LinWK , HuTM , et al. A comparative efficacy and safety study of long‐acting risperidone injection and risperidone oral tablets among hospitalized patients: 12‐week randomized, single‐blind study. Pharmacopsychiatry2006;39(4):135‐41. ">Bai 2006</a> and data for the Personal and Social Performance (PSP) scale were available from <a href="./references#CD004161-bbs2-0008" title="LiH , RuiQ , NingX , XuH , GuN . A comparative study of paliperidone palmitate and risperidone long‐acting injectable therapy in schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:1002‐8. ">Li 2011</a> and <a href="./references#CD004161-bbs2-0010" title="PandinaG , LaneR , Gassmann‐MayerC , HoughD , RemmerieB , SimpsonG . A randomised double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Proceedings of the 27th International College of Neuropsychopharmacology Congress; 2010 June 6‐10; Hong Kong. 2010. PandinaG , LaneR , GopalS , Gassman‐MayerC , HoughD , RemmerieB , et al. A randomized double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Biological Psychiatry2010;67(9):77‐8. PandinaG , LaneR , GopalS , Gassmann‐MayerC , HoughD , RemmerieB , et al. A double‐blind study of paliperidone palmitate and risperidone long‐acting injectable in adults with schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:218‐26. ">Pandina 2011</a>. </p> </section> <section id="CD004161-sec-0113"> <h6 class="title">4.4 Service utilisation</h6> <p>The primary outcomes for <a href="./references#CD004161-bbs2-0012" title="BarnettPG , ScottJY , KrystalJH , RosenheckRA . Cost and cost‐effectiveness in a randomized trial of long‐acting risperidone for schizophrenia. Journal of Clinical Psychiatry2012;73:696‐702. RosenheckRA , KrystalJH , LewR , BarnettPG , FioreL , ValleyD , et al. Long‐ acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine March 3, 2011;364(9):842‐51. ">Rosenheck 2011</a> centred around the use of medical and psychiatric health services; the data for these outcomes were obtained through the VA health services, which potentially side‐steps the issue of low follow‐up interview rates as these data would be available for participants who missed interviews but nonetheless remained a part of the study. Data on in‐patient and out‐patient care were available, and include rates of hospitalisation and mean (SD) numbers of visits to individual or group psychiatry sessions, as well as other psychiatric and general healthcare services. </p> </section> <section id="CD004161-sec-0114"> <h6 class="title">4.5 Quality of life</h6> <p>It is disappointing that more studies did not include measures to assess quality of life (QoL) on the trial drugs. Several studies did make use of various QoL questionnaires, but high attrition means that the results could not be used. The one exception to this is in <a href="./references#CD004161-bbs2-0001" title="BaiYM , ChenTT , WuB , HungCH , LinWK , HuTM , et al. A comparative efficacy and safety study of long‐acting risperidone injection and risperidone oral tablets among hospitalized patients: 12‐week randomized, single‐blind study. Pharmacopsychiatry2006;39(4):135‐41. ">Bai 2006</a>, which made use of the Medical Outcome Study Short‐Form Health Survey (SF‐36). </p> </section> <section id="CD004161-sec-0115"> <h6 class="title">4.6 Economic outcomes</h6> <p>Very few studies involved any assessment of the economic outcomes associated with treatment with depot risperidone. The two exceptions are <a href="./references#CD004161-bbs2-0012" title="BarnettPG , ScottJY , KrystalJH , RosenheckRA . Cost and cost‐effectiveness in a randomized trial of long‐acting risperidone for schizophrenia. Journal of Clinical Psychiatry2012;73:696‐702. RosenheckRA , KrystalJH , LewR , BarnettPG , FioreL , ValleyD , et al. Long‐ acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine March 3, 2011;364(9):842‐51. ">Rosenheck 2011</a> and <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a> which presented these outcomes in papers published separately to the main study report. Lack of standard deviations and the format in which some of these outcomes were presented makes it difficult to use them in a quantitative analysis, but we have commented on the key findings in a qualitative manner. </p> </section> <section id="CD004161-sec-0116"> <h6 class="title">4.7 Satisfaction with treatment</h6> <p>Only one trial addressed this in a manner that did not fall foul of the 50% attrition limit; <a href="./references#CD004161-bbs2-0001" title="BaiYM , ChenTT , WuB , HungCH , LinWK , HuTM , et al. A comparative efficacy and safety study of long‐acting risperidone injection and risperidone oral tablets among hospitalized patients: 12‐week randomized, single‐blind study. Pharmacopsychiatry2006;39(4):135‐41. ">Bai 2006</a> recorded patient satisfaction with their current treatment using a five‐point scale, very good to poor. However, no evidence to validate this method was presented, consequently we decided not to include the data. </p> </section> <section id="CD004161-sec-0117"> <h6 class="title">4.8 Leaving the study early</h6> <p>All studies reported the number of participants leaving the study early from both groups, and provided a breakdown of the main reasons given for doing so. </p> </section> <section id="CD004161-sec-0118"> <h6 class="title">4.9 Adverse effects</h6> <p>Adverse events were reported by all of the included studies. <a href="./references#CD004161-bbs2-0002" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;3(Suppl 1):174. ChueP , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Promotional slides on file from Janssen‐Cliag UK Ltd2002. ">Chue 2002</a> reported overall rates of adverse events in both groups, and the numbers withdrawing from the study as a result of side effects. No details were given regarding the nature of these adverse events or how they were recorded. The abstracts available for this review state that body weight was measured and laboratory tests were undertaken. The reports state that there were no differences between oral and depot groups, but present no numbers. <a href="./references#CD004161-bbs2-0002" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;3(Suppl 1):174. ChueP , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Promotional slides on file from Janssen‐Cliag UK Ltd2002. ">Chue 2002</a> also used the Extrapyramidal Symptom Rating Scale (ESRS), but again, no numerical data were reported. <a href="./references#CD004161-bbs2-0006" title="Anonymous . Injectible, long‐acting risperidone effective. Journal of Pharmacy Technology2001;4:157. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4‐8th May, Stockholm, Sweden)2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey)2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum; 2002 Jun 23‐27; Montreal, Canada)2002;5(Suppl 1):S188. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;53(3 Suppl.1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta (TM), a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cliag UK Ltd2002. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5‐9, 2002, Barcelona‐Spain2002;12(Supplement 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160(6):1125‐32. ">Kane 2002*</a> reported rates of individual adverse events spontaneously reported by participants, and reported these for all people in the study, not just those who completed the trial. Median ESRS scores were also reported for each group at baseline and change at endpoint. Pain and swelling at injection sites rated by investigators and patients were also reported. </p> <p><a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a> gave rates of adverse events that occurred in &gt;10% of participants in either group, as well as serious, prolactin‐ and glucose‐related events. The results of laboratory tests for levels of prolactin, glucose, cholesterol and triglycerides were also provided. Adverse events occurring in more than 5% of participants were reported in <a href="./references#CD004161-bbs2-0012" title="BarnettPG , ScottJY , KrystalJH , RosenheckRA . Cost and cost‐effectiveness in a randomized trial of long‐acting risperidone for schizophrenia. Journal of Clinical Psychiatry2012;73:696‐702. RosenheckRA , KrystalJH , LewR , BarnettPG , FioreL , ValleyD , et al. Long‐ acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine March 3, 2011;364(9):842‐51. ">Rosenheck 2011</a>; there was no discussion of how these events were identified or reported. They were also grouped under quite general subheadings, so "nervous system disorders" comprises all extrapyramidal symptoms (EPS), as well as the likes of headache, somnolence and dizziness. </p> </section> </section> <section id="CD004161-sec-0119"> <h5 class="title">5. Outcome measures used in this review</h5> <section id="CD004161-sec-0120"> <h6 class="title">5.1 Global state</h6> <p><i>5.1.1 Global functioning. Clinical Global Impression ‐ CGI</i> (<a href="./references#CD004161-bbs2-0067" title="GuyW . Early clinical drug evaluation (ECDEU) assessment manual for psychopharmacology. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: National Institute of Mental Health, 1976:217‐22. ">Guy 1976</a>)<br/> A rating instrument commonly used in studies on schizophrenia that enables clinicians to quantify severity of illness and overall clinical improvement during therapy. A seven‐point scoring system is usually used with low scores indicating decreased severity and/or greater recovery. </p> <p><i>5.1.2 Global Assessement of Functioning ‐ GAF</i> (DSM‐IV‐TR, <a href="./references#CD004161-bbs2-0046" title="American Psychiatric Association. Diagnostic and sStatistical Manual of Mental Disorders : DSM‐IV‐TR. Washington, DC: American Psychiatric Association, 2000. ">APA 2000</a>) </p> <p>The GAF rating scale is presented in DSM‐IV as a quick method for assessing psychological, social and occupational function to give an impression of an individual's overall level of functioning relating to their mental health. Scoring is from zero to 100. Very high scores indicate absent or minimal symptoms that have little effect on functioning, very low scores (below 20) indicate a serious danger that somebody will hurt themselves or others. </p> <p><i>5.1.3 Schedule for Deficit Syndrome ‐ SDS</i> (<a href="./references#CD004161-bbs2-0076" title="KirkpatrickB , BuchananRW , McKennyPD , AlphsLD , CarpenterWT . The schedule for the deficit syndrome: An instrument for research in schizophrenia. Psychiatry Research1989;30(2):119‐23. ">Kirkpatrick 1989</a>) </p> <p>This tool is used to evaluate the presence of negative or deficit‐related symptoms, SDS regards these as flattened affect, poverty of speech, diminished emotional range, curbing of interest and diminished sense of purpose. If a person with schizophrenia has had two or more of the listed symptoms for 12 months, and they were not caused by other factors such as substance dependence or depression, then they are diagnosed with deficit syndrome. Severity is rated from zero to four, higher scores are worse, for each criteria. </p> </section> <section id="CD004161-sec-0121"> <h6 class="title">5.2 Mental state</h6> <p><i>5.2.1 Positive and Negative Symptom Scale ‐ PANSS</i> (<a href="./references#CD004161-bbs2-0075" title="KaySR , FiszbeinA , OplerLA . The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin1987;13:261‐76. ">Kay 1987</a>)<br/> This scale was developed to evaluate the positive, negative and general symptoms in schizophrenia. The PANSS has 30 items, and each item can be defined on a seven‐point scoring system varying from one (absent) to seven (extreme). This scale is divided into three subscales for measuring the severity of general psychopathology, positive symptoms (PANSS‐P) and negative symptoms (PANSS‐N). A low score indicates lesser severity. </p> </section> <section id="CD004161-sec-0122"> <h6 class="title">5.3 General functioning</h6> <p><i>5.3.1 Personal and Social Performance Scale ‐ PSP</i> (<a href="./references#CD004161-bbs2-0090" title="NafeesB , vanHanswijck de JongeP , StullD , PascoeK , PriceM , ClarkeA , et al. Reliability and validity of the Personal and Social Performance scale in patients with schizophrenia. Schizophrenia Research2012;140(1‐3):71‐6. ">Nafees 2012</a>) </p> <p>The PSP scale measures an individual's functioning within society and is assessed through a 10 to 15 minute structured interview looking at four domains (socially useful activities, personal and social relationships, self‐care and disturbing and aggressive behaviours). An overall score between zero and 100 is derived from the individual factor scores; a higher score indicates better personal and social functioning. </p> </section> <section id="CD004161-sec-0123"> <h6 class="title">5.4 Quality of life</h6> <p><i>5.4.1 Medical Outcome Study Short‐Form Health Survey ‐ SF‐36</i> (<a href="./references#CD004161-bbs2-0098" title="WareJEJr , SherbourneCD . The MOS 36‐item short‐form health survey (SF‐36). I. Conceptual framework and item selection.. Medical Care1992;30(6):473‐83. ">Ware 1992</a>) </p> <p>SF‐36 rates health‐related quality of life in eight main components (physical function, role limitations due to physical problems, bodily pain, general health, mental health, role limitations due to emotional problems, social function and vitality), each scored from zero to 100, higher scores are better. </p> </section> <section id="CD004161-sec-0124"> <h6 class="title">5.5 Adverse effects</h6> <p>The majority of the following scales were used by the study investigators to obtain dichotomised results relating to specific adverse effects ‐ the data and analysis section of this review presents predominantly dichotomised data relating to adverse effects. </p> <p><i>5.5.1 Extrapyramidal Symptom Rating Scale ‐ ESRS</i> (<a href="./references#CD004161-bbs2-0052" title="ChouinardG , Ross‐ChouinardA , AnnableL . Extrapyramidal symptom rating scale. Canadian Journal of Neurological Science1980;7:233. ">Chouinard 1980</a>)<br/> This scale consists of a questionnaire relating to parkinsonian symptoms (nine items), a physician's examination for parkinsonism and dyskinetic movements (eight items) and a clinical global impression of tardive dyskinesia. High scores indicate severe levels of movement disorder. </p> <p><i>5.5.2 Barnes Akathisia Scale ‐ BARS</i> (<a href="./references#CD004161-bbs2-0047" title="BarnesTR . A rating scale for drug‐induced akathisia. British Journal of Psychiatry1989;154:672‐6. ">Barnes 1989</a>) </p> <p>This rating scale assesses drug‐induced akathisia (restlessness or the urge to move). Individuals are rated on their observable level of restlessness while sitting (objective), their awareness of the urge to move and the distress, if any, that this causes (subjective) and on a global assessment. Higher scores indicate more severe akathisia. </p> <p><i>5.5.3 Abnormal Involuntary Movement Scale ‐ AIMS</i> (<a href="./references#CD004161-bbs2-0089" title="MunetzMR , BenjaminS . How to examine patients using the Abnormal Involuntary Movement Scale. Hospital Community Psychiatry1988;39(11):1172‐7. ">Munetz 1988</a>) </p> <p>This 12‐item scale is used to assess the severity of dyskinesia in an individual. Items such as movement of the jaw or the extremities are rated on a scale from zero (none) to four (severe) and combined to give a total score. </p> <p><i>5.5.4 The Udvalg for Kliniske Undersgelser side effects rating scale ‐ UKU</i> (<a href="./references#CD004161-bbs2-0082" title="LingjaerdO , AhlforsUG , BechP , DenckerSJ , ElgenK . The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients. Acta Psychiatrica Scandinavica1987;76(s334):1‐100. ">Lingjaerd 1987</a>) </p> <p>The UKU is a tool for recording side effects of neuroleptic treatment in a standardised manner, items are scored from zero, absent or normal, to three, severe. </p> <p><i>5.5.5 Arizona Sexual Experiences Scale ‐ ASEX (</i><a href="./references#CD004161-bbs2-0086" title="McGahueyCA , GelenbergAJ , LaukesCA , MorenoFA , DelgadoPL , McKnightKM , et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. Journal of Sex and Marital Therapy2000;26(1):25‐40. ">McGahuey 2000</a><i>)</i> </p> <p>The ASEX scale is a five‐item rating scale that quantifies sexual experiences (including drive/ arousal/ satisfaction from or ability to reach orgasm) with total scores ranging from five to 30, with higher scores indicating greater sexual dysfunction </p> </section> </section> </section> <section id="CD004161-sec-0125"> <h4 class="title">Excluded studies</h4> <p>We have excluded a total of 28 studies (see <a href="./references#CD004161-sec-0349" title="">Characteristics of excluded studies</a>). </p> <section id="CD004161-sec-0126"> <h5 class="title">Studies awaiting assessment</h5> <p>Three studies await further clarification; <a href="./references#CD004161-bbs2-0043" title="TurnerT . Risperidone depot v risperidone tablets: a non‐inferiority efficacy trial in subjects with schizophrenia. National Research Register (http://www.update‐software.com/National/)2000. ">Turner 2000</a> seemed to be an eligible study for the first edition of this review (<a href="./references#CD004161-bbs2-0101" title="HosalliP , DavisJM . Depot risperidone for schizophrenia. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD004161; PUBMED: 14584007] ">Hosalli 2003</a>), but while preparing the updated review we were unable to find any further details. <a href="./references#CD004161-bbs2-0041" title="NasrallahH , DuchesneI , MehnertA , JanagapC . Long‐acting risperidone improves quality of life. Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002. NasrallahH , DuchesneI , MehnertA , JanagapC . Long‐acting risperidone injection improves quality of life. International Journal of Neuropsychopharmacology2002;5(Suppl 1):S189. NasrallahH , DuchesneI , MehnertA , JanagapC . Long‐acting, injectable risperidone ‐ the first long‐acting, atypical antipsychotic ‐ improves quality of life. European Neuropsychopharmacology2002;12(Suppl 3):S282. NasrallahHA , DuchesneI , MehnertA , JanagapC , EerdekensM . Correction. Journal of Clinical Psychological Medicine [临床精神医学杂志]2004;65(8):1150. NasrallahHA , DuchesneI , MehnertA , JanagapC , EerdekensM . Health‐related quality of life in patients with schizophrenia during treatment with long‐acting, injectable risperidone. Journal of Clinical Psychiatry2004;65(4):531‐6. [MEDLINE: 15119916] ">Nasrallah 2002</a>, both conference abstracts, reports QoL data with depot risperidone but it may be part of one of the included studies (<a href="./references#CD004161-bbs2-0006" title="Anonymous . Injectible, long‐acting risperidone effective. Journal of Pharmacy Technology2001;4:157. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4‐8th May, Stockholm, Sweden)2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey)2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum; 2002 Jun 23‐27; Montreal, Canada)2002;5(Suppl 1):S188. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;53(3 Suppl.1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta (TM), a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cliag UK Ltd2002. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5‐9, 2002, Barcelona‐Spain2002;12(Supplement 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160(6):1125‐32. ">Kane 2002*</a>). Again, the authors have been contacted for more details. <a href="./references#CD004161-bbs2-0042" title="SegarraR , OjedaN , GarciaJ , PenaJ , BravoE , EguiluzJI . Risperidone injectable long acting treatment vs other oral antipsychotics in first episode psychosis: One year longitudinal study. Schizophrenia Research. 2010; Vol. 117, issue 2‐3:495. ">Segarra 2010</a> also appeared to be eligible, but we were unable to extract any usable data from the published conference poster and abstract. We have contacted Dr Segarra for more details of this study. </p> </section> <section id="CD004161-sec-0127"> <h5 class="title">Ongoing studies</h5> <p>We contacted Janssen‐Cilag Limited for further information regarding ongoing studies and were told that such studies existed and the data would be forwarded to us. We are still awaiting these studies and data. </p> </section> </section> </section> <section id="CD004161-sec-0128"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD004161-fig-0002">Figure 2</a> and <a href="#CD004161-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD004161-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="original image" data-id="CD004161-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <div class="figure" id="CD004161-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="original image" data-id="CD004161-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <section id="CD004161-sec-0129"> <h4 class="title">Allocation</h4> <p>All studies were randomised, but there was extreme inconsistency in how well the methods used were reported. Most studies also did not describe how allocation concealment was achieved. At one end of the spectrum, it is simply stated that participants were randomised (<a href="./references#CD004161-bbs2-0001" title="BaiYM , ChenTT , WuB , HungCH , LinWK , HuTM , et al. A comparative efficacy and safety study of long‐acting risperidone injection and risperidone oral tablets among hospitalized patients: 12‐week randomized, single‐blind study. Pharmacopsychiatry2006;39(4):135‐41. ">Bai 2006</a>; <a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a>; <a href="./references#CD004161-bbs2-0011" title="QuinnA , CamachoF , MitchellD , ChueP , MallaA . Open‐label randomized exploratory investigation of Risperdal* Consta* and oral antipsychotics treatment of early psychosis. Autumn Conference of the International Society for CNS Clinical Trials and Methodology, October 1‐3. Marina Del Rey, California, 2012. ">Quinn 2012*</a>) with no further details, with other studies giving more details on the stratification factors used, e.g. site, PANSS score, previous antipsychotic medication (<a href="./references#CD004161-bbs2-0002" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;3(Suppl 1):174. ChueP , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Promotional slides on file from Janssen‐Cliag UK Ltd2002. ">Chue 2002</a>; <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>; <a href="./references#CD004161-bbs2-0012" title="BarnettPG , ScottJY , KrystalJH , RosenheckRA . Cost and cost‐effectiveness in a randomized trial of long‐acting risperidone for schizophrenia. Journal of Clinical Psychiatry2012;73:696‐702. RosenheckRA , KrystalJH , LewR , BarnettPG , FioreL , ValleyD , et al. Long‐ acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine March 3, 2011;364(9):842‐51. ">Rosenheck 2011</a>). While the implication is that all studies used computer‐generated schemes to randomise participants, this is only explicitly stated in a handful of cases. Descriptions of allocation concealment are neglected by most of the included studies, but methods were similar amongst studies that provide them. Interactive Voice Response Systems (IVRS) were used by <a href="./references#CD004161-bbs2-0004" title="FleischhackerWW , GopalS , LaneR , Gassmann‐Mayer , LimP , HoughD , et al. A randomized trial of paliperidone palmitate and risperidone long acting injectable in schizophrenia. International Journal of Neuropsychopharmacology2012;15:107‐18. ">Fleischhacker 2011</a>, <a href="./references#CD004161-bbs2-0007" title="KeksN , InghamM , KhanA , KarcherK . Long‐acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open‐label study. British Journal of Psychiatry2007;191:131‐9. KeksN , KhanA , AugustynsI , RabinowitzJ , InghamM . Non‐inferiority efficacy trial of risperidone long‐acting injection (RLAI) vs. olanzapine tablets (OLA). Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006. ">Keks 2007</a> and <a href="./references#CD004161-bbs2-0010" title="PandinaG , LaneR , Gassmann‐MayerC , HoughD , RemmerieB , SimpsonG . A randomised double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Proceedings of the 27th International College of Neuropsychopharmacology Congress; 2010 June 6‐10; Hong Kong. 2010. PandinaG , LaneR , GopalS , Gassman‐MayerC , HoughD , RemmerieB , et al. A randomized double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Biological Psychiatry2010;67(9):77‐8. PandinaG , LaneR , GopalS , Gassmann‐MayerC , HoughD , RemmerieB , et al. A double‐blind study of paliperidone palmitate and risperidone long‐acting injectable in adults with schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:218‐26. ">Pandina 2011</a>; this is a system whereby the investigator phones a number, enters the patient details and receives a medication allocation based on the randomisation algorithm. <a href="./references#CD004161-bbs2-0007" title="KeksN , InghamM , KhanA , KarcherK . Long‐acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open‐label study. British Journal of Psychiatry2007;191:131‐9. KeksN , KhanA , AugustynsI , RabinowitzJ , InghamM . Non‐inferiority efficacy trial of risperidone long‐acting injection (RLAI) vs. olanzapine tablets (OLA). Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006. ">Keks 2007</a> set the benchmark for minimising the risk of allocation bias, with a description of the randomisation algorithm and the use of an IVRS. </p> </section> <section id="CD004161-sec-0130"> <h4 class="title">Blinding</h4> <p>The included studies utilised a number of types of blinding, each resulting in different amounts of risk for performance and detection bias. </p> <p>The studies with the least risk were often described as "double blind"; they took measures to ensure that neither the participants nor the investigators monitoring them and rating outcomes would know which treatment a person was actually taking. The study of depot risperidone versus placebo (<a href="./references#CD004161-bbs2-0006" title="Anonymous . Injectible, long‐acting risperidone effective. Journal of Pharmacy Technology2001;4:157. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4‐8th May, Stockholm, Sweden)2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey)2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum; 2002 Jun 23‐27; Montreal, Canada)2002;5(Suppl 1):S188. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;53(3 Suppl.1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta (TM), a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cliag UK Ltd2002. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5‐9, 2002, Barcelona‐Spain2002;12(Supplement 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160(6):1125‐32. ">Kane 2002*</a>) and one of those involving oral antipsychotics (<a href="./references#CD004161-bbs2-0002" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;3(Suppl 1):174. ChueP , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Promotional slides on file from Janssen‐Cliag UK Ltd2002. ">Chue 2002</a>) used placebo injections that were the same volume as those containing the study drug. Two of the paliperidone palmitate (PP) studies (<a href="./references#CD004161-bbs2-0004" title="FleischhackerWW , GopalS , LaneR , Gassmann‐Mayer , LimP , HoughD , et al. A randomized trial of paliperidone palmitate and risperidone long acting injectable in schizophrenia. International Journal of Neuropsychopharmacology2012;15:107‐18. ">Fleischhacker 2011</a>; <a href="./references#CD004161-bbs2-0010" title="PandinaG , LaneR , Gassmann‐MayerC , HoughD , RemmerieB , SimpsonG . A randomised double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Proceedings of the 27th International College of Neuropsychopharmacology Congress; 2010 June 6‐10; Hong Kong. 2010. PandinaG , LaneR , GopalS , Gassman‐MayerC , HoughD , RemmerieB , et al. A randomized double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Biological Psychiatry2010;67(9):77‐8. PandinaG , LaneR , GopalS , Gassmann‐MayerC , HoughD , RemmerieB , et al. A double‐blind study of paliperidone palmitate and risperidone long‐acting injectable in adults with schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:218‐26. ">Pandina 2011</a>) utilised placebos in the PP group so that both groups took the same number of tablets and had the same number of injections. Participants were also precluded from seeing the syringe when they received the injection, as the two drugs were different in appearance. The techniques used for blinding in these studies were of very high quality and present little risk of the blind being broken. </p> <p>All other studies have a significantly higher risk of performance bias as the allocation of interventions was not blinded; this was somewhat mitigated against in <a href="./references#CD004161-bbs2-0001" title="BaiYM , ChenTT , WuB , HungCH , LinWK , HuTM , et al. A comparative efficacy and safety study of long‐acting risperidone injection and risperidone oral tablets among hospitalized patients: 12‐week randomized, single‐blind study. Pharmacopsychiatry2006;39(4):135‐41. ">Bai 2006</a>, <a href="./references#CD004161-bbs2-0008" title="LiH , RuiQ , NingX , XuH , GuN . A comparative study of paliperidone palmitate and risperidone long‐acting injectable therapy in schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:1002‐8. ">Li 2011</a>, <a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a>, and <a href="./references#CD004161-bbs2-0012" title="BarnettPG , ScottJY , KrystalJH , RosenheckRA . Cost and cost‐effectiveness in a randomized trial of long‐acting risperidone for schizophrenia. Journal of Clinical Psychiatry2012;73:696‐702. RosenheckRA , KrystalJH , LewR , BarnettPG , FioreL , ValleyD , et al. Long‐ acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine March 3, 2011;364(9):842‐51. ">Rosenheck 2011</a>, all of which used blinded raters to perform outcome assessments, often via video conference. </p> </section> <section id="CD004161-sec-0131"> <h4 class="title">Incomplete outcome data</h4> <p>There is little risk of attrition bias emerging from incomplete outcome data in most studies. Drop‐out rates are uniformly reported and are normally accompanied by a breakdown of the main reasons for leaving the study early. Overall attrition is greater than 50% in some studies; where this is the case we have not used the data from affected outcomes. In <a href="./references#CD004161-bbs2-0012" title="BarnettPG , ScottJY , KrystalJH , RosenheckRA . Cost and cost‐effectiveness in a randomized trial of long‐acting risperidone for schizophrenia. Journal of Clinical Psychiatry2012;73:696‐702. RosenheckRA , KrystalJH , LewR , BarnettPG , FioreL , ValleyD , et al. Long‐ acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine March 3, 2011;364(9):842‐51. ">Rosenheck 2011</a>, the attrition rate was not simply explained; it was stated that 69.8% of the oral treatment group and 63.6% of the depot risperidone group completed the study, but what this actually means is never made explicitly clear. Indeed, the overall completion rate does not tally with the follow‐up interview rates, which are given as 60% at 12 months, 46% at 18 months and only 29% of participants completing the full two years of follow‐up interviews, with there being no difference between follow‐up rates across the two intervention groups. The implication is that patients could remain in the study and have their health service use available for analysis despite no longer taking part in the follow‐up interviews to assess secondary outcome measures. Generally, across studies, attrition was high, and therefore rated at a 'high' risk of bias ‐ three studies in particular reported losses of greater than 50% (<a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>; <a href="./references#CD004161-bbs2-0006" title="Anonymous . Injectible, long‐acting risperidone effective. Journal of Pharmacy Technology2001;4:157. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4‐8th May, Stockholm, Sweden)2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey)2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum; 2002 Jun 23‐27; Montreal, Canada)2002;5(Suppl 1):S188. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;53(3 Suppl.1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta (TM), a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cliag UK Ltd2002. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5‐9, 2002, Barcelona‐Spain2002;12(Supplement 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160(6):1125‐32. ">Kane 2002*</a>; <a href="./references#CD004161-bbs2-0011" title="QuinnA , CamachoF , MitchellD , ChueP , MallaA . Open‐label randomized exploratory investigation of Risperdal* Consta* and oral antipsychotics treatment of early psychosis. Autumn Conference of the International Society for CNS Clinical Trials and Methodology, October 1‐3. Marina Del Rey, California, 2012. ">Quinn 2012*</a>). </p> </section> <section id="CD004161-sec-0132"> <h4 class="title">Selective reporting</h4> <p><a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a> stated in the methods section of the main study report that CGI‐S was used as an outcome measure, but this outcome is not reported in the results section. As CGI‐S is a very commonly used measure, we have contacted the study authors to try to obtain any unpublished data that may pertain to this, but at the time of writing have had no response. </p> </section> <section id="CD004161-sec-0133"> <h4 class="title">Other potential sources of bias</h4> <p>Author conflicts of interest are reported for all studies, as are funding sources.</p> <p>Most studies included in this review were either partially or fully funded and supported by Jassen‐Cilag/Johnson &amp; Johnson Co. In addition to this, a significant number of authors and investigators are or were employees of Jassen. While it is understandable that a pharmaceutical company has an interest in research regarding their own products, it is perhaps alarming that the only studies that address the questions posed by this review are supported by a party with a vested interest in depot risperidone. </p> </section> </section> <section id="CD004161-sec-0134"> <h3 class="title" id="CD004161-sec-0134">Effects of interventions</h3> <p>See: <a href="./full#CD004161-tbl-0001"><b>Summary of findings for the main comparison</b> RISPERIDONE DEPOT compared with PLACEBO for schizophrenia</a>; <a href="./full#CD004161-tbl-0002"><b>Summary of findings 2</b> RISPERIDONE DEPOT compared with GENERAL ORAL ANTIPSYCHOTICS for schizophrenia</a>; <a href="./full#CD004161-tbl-0003"><b>Summary of findings 3</b> RISPERIDONE DEPOT compared with ORAL RISPERIDONE for schizophrenia</a>; <a href="./full#CD004161-tbl-0004"><b>Summary of findings 4</b> RISPERIDONE DEPOT compared with ORAL QUETIAPINE for schizophrenia</a>; <a href="./full#CD004161-tbl-0005"><b>Summary of findings 5</b> RISPERIDONE DEPOT compared with ORAL ARIPIPRAZOLE for schizophrenia</a>; <a href="./full#CD004161-tbl-0006"><b>Summary of findings 6</b> RISPERIDONE DEPOT compared with ORAL OLANZAPINE for schizophrenia</a>; <a href="./full#CD004161-tbl-0007"><b>Summary of findings 7</b> RISPERIDONE DEPOT compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) for schizophrenia</a>; <a href="./full#CD004161-tbl-0008"><b>Summary of findings 8</b> RISPERIDONE DEPOT compared with TYPICAL DEPOT ANTIPSYCHOTICS for schizophrenia</a> </p> <section id="CD004161-sec-0135"> <h4 class="title">COMPARISON 1: RISPERIDONE DEPOT versus PLACEBO</h4> <p>For this comparison, we found only one relevant study (<a href="./references#CD004161-bbs2-0006" title="Anonymous . Injectible, long‐acting risperidone effective. Journal of Pharmacy Technology2001;4:157. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4‐8th May, Stockholm, Sweden)2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey)2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum; 2002 Jun 23‐27; Montreal, Canada)2002;5(Suppl 1):S188. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;53(3 Suppl.1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta (TM), a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cliag UK Ltd2002. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5‐9, 2002, Barcelona‐Spain2002;12(Supplement 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160(6):1125‐32. ">Kane 2002*</a>, n = 400); apart from one outcome (leaving the study early), all data for this comparison from this 12‐week study, are 'short term'. </p> <section id="CD004161-sec-0136"> <h5 class="title">1.1 Mental state: 1. Change (exacerbation) in specific symptoms</h5> <p>Mental state data were presented as change in specific symptoms. For the outcomes of anxiety, hallucination and nervousness, no differences between groups were found; however, there was statistically significant difference in favour of depot risperidone for levels of agitation (risk ratio (RR) 0.60 95% confidence interval (CI) 0.39 to 0.92) and psychosis (RR 0.52 95% CI 0.33 to 0.83, <a href="./references#CD004161-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD004161-sec-0137"> <h5 class="title">1.2 Leaving the study early: 1. Any reason (by time period)</h5> <p>The number of participants leaving the study early 'very early on' were similar between treatment groups, however data at 12 weeks showed more people left the placebo group early compared to those receiving risperidone depot (RR 0.74 95% CI 0.63 to 0.88, <a href="./references#CD004161-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD004161-sec-0138"> <h5 class="title">1.3 Leaving the study early: 2. Any reason (by doses)</h5> <p>More participants left the study early for any reason from the placebo group compared to those receiving either 'all doses' risperidone depot (RR 0.74 95% CI 0.63 to 0.88), 25 mg risperidone depot (RR 0.74 95% CI 0.59 to 0.94), 50 mg risperidone depot (RR 0.74 95% CI 0.59 to 0.93) or 75 mg risperidone depot (RR 0.75 95% CI 0.60 to 0.94, <a href="./references#CD004161-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD004161-sec-0139"> <h5 class="title">1.4 Leaving the study early: 3. Due to insufficient response (by doses)</h5> <p>For leaving the study early due to insufficient response, there was no statistically significant difference between groups for those receiving 25 mg depot risperidone. However fewer participants left early from the risperidone depot groups for those receiving either all three doses combined (RR 0.53 CI 0.36 to 0.79), 50 mg (RR 0.48 CI 0.27 to 0.83) or 75 mg (RR 0.39 CI 0.21 to 0.72, <a href="./references#CD004161-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD004161-sec-0140"> <h5 class="title">1.5 Adverse events: 1. General: a. Death</h5> <p>No deaths were reported in the risperidone depot group, one death was reported in the placebo group. This difference was not statistically significant (RR 0.11 95% CI 0.00 to 2.65 <a href="./references#CD004161-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD004161-sec-0141"> <h5 class="title">1.6 Adverse events: 1. General: b. Severe adverse event (by doses)</h5> <p>There were no statistically significant differences between groups for severe adverse events by doses (25 mg, 50 mg or 75 mg) of depot risperidone (n = 400, <a href="./references#CD004161-bbs2-0006" title="Anonymous . Injectible, long‐acting risperidone effective. Journal of Pharmacy Technology2001;4:157. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4‐8th May, Stockholm, Sweden)2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey)2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum; 2002 Jun 23‐27; Montreal, Canada)2002;5(Suppl 1):S188. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;53(3 Suppl.1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta (TM), a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cliag UK Ltd2002. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5‐9, 2002, Barcelona‐Spain2002;12(Supplement 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160(6):1125‐32. ">Kane 2002*</a>); however, 'any dose' of risperidone demonstrated a statistically significant difference, favouring risperidone depot, between groups (RR 0.59 CI 0.38 to 0.93, <a href="./references#CD004161-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD004161-sec-0142"> <h5 class="title">1.7 Adverse events: 1. General: c. Adverse event necessitating withdrawal from study (by doses) </h5> <p>There were no statistically significant difference between groups for adverse events necessitation withdrawal from the study by any dose, 25 mg, 50 mg or 75 mg (<a href="./references#CD004161-fig-0010" title="">Analysis 1.7</a>). </p> </section> <section id="CD004161-sec-0143"> <h5 class="title">1.8 Adverse events: 2. Specific: a. Cardiovascular</h5> <p>There was no statistically significant difference between groups for dizziness; however, there was a statistically significant difference between groups for tachycardia, with greater instances in the placebo group (RR 0.32 95% CI 0.11 to 0.98, <a href="./references#CD004161-fig-0011" title="">Analysis 1.8</a>). </p> </section> <section id="CD004161-sec-0144"> <h5 class="title">1.9 Adverse events: 2. Specific: b. Gastrointestinal</h5> <p>There were no statistically significant differences between groups for constipation, diarrhoea, nausea or vomiting (<a href="./references#CD004161-fig-0012" title="">Analysis 1.9</a>) </p> </section> <section id="CD004161-sec-0145"> <h5 class="title">1.10 Adverse events: 2. Specific: c. Movement disorders: a. Extrapyramidal disorder ‐ spontaneously reported (by doses) </h5> <p>There was no statistically significant difference between groups for extrapyramidal disorder when receiving 'all doses', 25 mg, 50 mg or 75 mg depot risperidone (<a href="./references#CD004161-fig-0013" title="">Analysis 1.10</a>). </p> </section> <section id="CD004161-sec-0146"> <h5 class="title">1.11 Adverse events: 2. Specific: d. Movement disorders: b. Hyperkinesia (by doses)</h5> <p>There was no statistically significant difference between groups for hyperkinesia when receiving 'all doses', 25 mg, 50 mg or 75 mg depot risperidone (<a href="./references#CD004161-fig-0014" title="">Analysis 1.11</a>). </p> </section> <section id="CD004161-sec-0147"> <h5 class="title">1.12 Adverse events: 2. Specific: e. Movement disorders: c. Hypertonia (by doses)</h5> <p>There was no statistically significant difference between groups for hypertonia when receiving 'all doses', 25 mg, 50 mg or 75 mg depot risperidone (<a href="./references#CD004161-fig-0015" title="">Analysis 1.12</a>). </p> </section> <section id="CD004161-sec-0148"> <h5 class="title">1.13 Adverse events: 2. Specific: f. Pain</h5> <p>There was no statistically significant difference between groups for headache or other 'unspecified' pain (<a href="./references#CD004161-fig-0016" title="">Analysis 1.13</a>). </p> </section> <section id="CD004161-sec-0149"> <h5 class="title">1.14 Adverse events: 2. Specific: g. Salivation</h5> <p>There was no statistically significant difference between groups for either increased or decreased levels of salivation (<a href="./references#CD004161-fig-0017" title="">Analysis 1.14</a>). </p> </section> <section id="CD004161-sec-0150"> <h5 class="title">1.15 Adverse events: 2. Specific: h. Sleep disturbances</h5> <p>There was no statistically significant difference between groups for either insomnia or somnolence (<a href="./references#CD004161-fig-0018" title="">Analysis 1.15</a>). </p> </section> <section id="CD004161-sec-0151"> <h5 class="title">1.16 Adverse events: 2. Specific: i. Weight gain</h5> <p>There was no statistically significant difference between groups for weight gain with any dose of depot risperidone (1 RCT, n = 400, RR 2.11, 95% CI 0.48 to 9.18) (<a href="./references#CD004161-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD004161-sec-0152"> <h5 class="title">1.17 Adverse events: 2. Specific: j. Others</h5> <p>There was no statistically significant difference between groups for coughing, fatigue, injury or rhinitis (<a href="./references#CD004161-fig-0020" title="">Analysis 1.17</a>). </p> </section> </section> <section id="CD004161-sec-0153"> <h4 class="title">COMPARISON 2: RISPERIDONE DEPOT versus GENERAL ORAL ANTIPSYCHOTICS</h4> <p>Two studies provided data for this comparison (<a href="./references#CD004161-bbs2-0011" title="QuinnA , CamachoF , MitchellD , ChueP , MallaA . Open‐label randomized exploratory investigation of Risperdal* Consta* and oral antipsychotics treatment of early psychosis. Autumn Conference of the International Society for CNS Clinical Trials and Methodology, October 1‐3. Marina Del Rey, California, 2012. ">Quinn 2012*</a>; <a href="./references#CD004161-bbs2-0012" title="BarnettPG , ScottJY , KrystalJH , RosenheckRA . Cost and cost‐effectiveness in a randomized trial of long‐acting risperidone for schizophrenia. Journal of Clinical Psychiatry2012;73:696‐702. RosenheckRA , KrystalJH , LewR , BarnettPG , FioreL , ValleyD , et al. Long‐ acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine March 3, 2011;364(9):842‐51. ">Rosenheck 2011</a>, n = 467). Both studies were two years‐long, and are categorised as 'long term'. </p> <section id="CD004161-sec-0154"> <h5 class="title">2.1 Global state: 1. Relapse (any reason)</h5> <p>There was no statistically significant difference between groups for relapse (n = 63, <a href="./references#CD004161-bbs2-0011" title="QuinnA , CamachoF , MitchellD , ChueP , MallaA . Open‐label randomized exploratory investigation of Risperdal* Consta* and oral antipsychotics treatment of early psychosis. Autumn Conference of the International Society for CNS Clinical Trials and Methodology, October 1‐3. Marina Del Rey, California, 2012. ">Quinn 2012*</a>, <a href="./references#CD004161-fig-0021" title="">Analysis 2.1</a>). </p> </section> <section id="CD004161-sec-0155"> <h5 class="title">2.2 Global state: 2. Needing use of benzodiazepine or sedative drugs</h5> <p>There was no statistically significant difference between groups for requiring use of benzodiazepines or sedative drugs (n = 369, <a href="./references#CD004161-bbs2-0012" title="BarnettPG , ScottJY , KrystalJH , RosenheckRA . Cost and cost‐effectiveness in a randomized trial of long‐acting risperidone for schizophrenia. Journal of Clinical Psychiatry2012;73:696‐702. RosenheckRA , KrystalJH , LewR , BarnettPG , FioreL , ValleyD , et al. Long‐ acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine March 3, 2011;364(9):842‐51. ">Rosenheck 2011</a>, <a href="./references#CD004161-fig-0022" title="">Analysis 2.2</a>). </p> </section> <section id="CD004161-sec-0156"> <h5 class="title">2.3 Service utilisation: 1. Hospitalisation</h5> <p>There was no statistically significant difference between groups for hospitalisation by long term (n = 369, <a href="./references#CD004161-bbs2-0012" title="BarnettPG , ScottJY , KrystalJH , RosenheckRA . Cost and cost‐effectiveness in a randomized trial of long‐acting risperidone for schizophrenia. Journal of Clinical Psychiatry2012;73:696‐702. RosenheckRA , KrystalJH , LewR , BarnettPG , FioreL , ValleyD , et al. Long‐ acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine March 3, 2011;364(9):842‐51. ">Rosenheck 2011</a>, <a href="./references#CD004161-fig-0023" title="">Analysis 2.3</a>). </p> </section> <section id="CD004161-sec-0157"> <h5 class="title">2.4 Service utilisation: 2. Outpatient care ‐ number of outpatient visits (skewed data) </h5> <p>Data for this outcome are considerably skewed, and are best inspected by viewing (<a href="./references#CD004161-fig-0024" title="">Analysis 2.4</a>). </p> </section> <section id="CD004161-sec-0158"> <h5 class="title">2.5 Not receiving allocated study medication</h5> <p>There was no statistically significant difference between risperidone depot and general oral antipsychotics (n = 382, <a href="./references#CD004161-bbs2-0012" title="BarnettPG , ScottJY , KrystalJH , RosenheckRA . Cost and cost‐effectiveness in a randomized trial of long‐acting risperidone for schizophrenia. Journal of Clinical Psychiatry2012;73:696‐702. RosenheckRA , KrystalJH , LewR , BarnettPG , FioreL , ValleyD , et al. Long‐ acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine March 3, 2011;364(9):842‐51. ">Rosenheck 2011</a>, <a href="./references#CD004161-fig-0025" title="">Analysis 2.5</a>). </p> </section> <section id="CD004161-sec-0159"> <h5 class="title">2.6 Leaving the study early: 1. Any reason</h5> <p>There was no statistically significant difference between groups for leaving the study early (n = 467, two randomised controlled trials (RCTs), <a href="./references#CD004161-fig-0026" title="">Analysis 2.6</a>). </p> </section> <section id="CD004161-sec-0160"> <h5 class="title">2.7 Leaving the study early: 2. Specific</h5> <p>There was no statistically significant difference between groups for leaving the study early due to insufficient response or withdrawn consent (n = 382, <a href="./references#CD004161-bbs2-0012" title="BarnettPG , ScottJY , KrystalJH , RosenheckRA . Cost and cost‐effectiveness in a randomized trial of long‐acting risperidone for schizophrenia. Journal of Clinical Psychiatry2012;73:696‐702. RosenheckRA , KrystalJH , LewR , BarnettPG , FioreL , ValleyD , et al. Long‐ acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine March 3, 2011;364(9):842‐51. ">Rosenheck 2011</a>, <a href="./references#CD004161-fig-0027" title="">Analysis 2.7</a>). </p> </section> <section id="CD004161-sec-0161"> <h5 class="title">2.8 Adverse events: 1. General: a. Death</h5> <p>There was no statistically significant difference between groups for instances of death (n = 467, <a href="./references#CD004161-bbs2-0012" title="BarnettPG , ScottJY , KrystalJH , RosenheckRA . Cost and cost‐effectiveness in a randomized trial of long‐acting risperidone for schizophrenia. Journal of Clinical Psychiatry2012;73:696‐702. RosenheckRA , KrystalJH , LewR , BarnettPG , FioreL , ValleyD , et al. Long‐ acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine March 3, 2011;364(9):842‐51. ">Rosenheck 2011</a>, <a href="./references#CD004161-fig-0028" title="">Analysis 2.8</a>). </p> </section> <section id="CD004161-sec-0162"> <h5 class="title">2.9 Adverse events: 2. Specific</h5> <p>There was a statistically significant difference between groups for general disorders and administration site conditions (n = 369, <a href="./references#CD004161-bbs2-0012" title="BarnettPG , ScottJY , KrystalJH , RosenheckRA . Cost and cost‐effectiveness in a randomized trial of long‐acting risperidone for schizophrenia. Journal of Clinical Psychiatry2012;73:696‐702. RosenheckRA , KrystalJH , LewR , BarnettPG , FioreL , ValleyD , et al. Long‐ acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine March 3, 2011;364(9):842‐51. ">Rosenheck 2011</a>, RR 1.31 95% CI 1.02 to 1.69, <a href="./references#CD004161-fig-0029" title="">Analysis 2.9</a>) and headache (n = 85, <a href="./references#CD004161-bbs2-0011" title="QuinnA , CamachoF , MitchellD , ChueP , MallaA . Open‐label randomized exploratory investigation of Risperdal* Consta* and oral antipsychotics treatment of early psychosis. Autumn Conference of the International Society for CNS Clinical Trials and Methodology, October 1‐3. Marina Del Rey, California, 2012. ">Quinn 2012*</a>, RR 2.80 95% CI 1.12 to 7.00 <a href="./references#CD004161-fig-0029" title="">Analysis 2.9</a>), both favouring oral antipsychotics, with no statistically significant difference between groups for other outcomes of anxiety; dizziness; fatigue/somnolence; insomnia; nausea/vomiting; prolactin‐related; weight increase (n = 85, <a href="./references#CD004161-bbs2-0011" title="QuinnA , CamachoF , MitchellD , ChueP , MallaA . Open‐label randomized exploratory investigation of Risperdal* Consta* and oral antipsychotics treatment of early psychosis. Autumn Conference of the International Society for CNS Clinical Trials and Methodology, October 1‐3. Marina Del Rey, California, 2012. ">Quinn 2012*</a>; <a href="./references#CD004161-fig-0029" title="">Analysis 2.9</a>), as well as diabetes mellitus and gastrointestinal adverse events (n = 369, <a href="./references#CD004161-bbs2-0012" title="BarnettPG , ScottJY , KrystalJH , RosenheckRA . Cost and cost‐effectiveness in a randomized trial of long‐acting risperidone for schizophrenia. Journal of Clinical Psychiatry2012;73:696‐702. RosenheckRA , KrystalJH , LewR , BarnettPG , FioreL , ValleyD , et al. Long‐ acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine March 3, 2011;364(9):842‐51. ">Rosenheck 2011</a>, <a href="./references#CD004161-fig-0029" title="">Analysis 2.9</a>). </p> </section> <section id="CD004161-sec-0163"> <h5 class="title">2.10 Adverse events: Nervous system disorders (including extrapyramidal symptoms (EPS))</h5> <p>There was a statistically significant difference between groups for nervous system disorders, favouring the unspecified oral antipsychotics (as prescribed by study's treating physician) (n = 369, <a href="./references#CD004161-bbs2-0012" title="BarnettPG , ScottJY , KrystalJH , RosenheckRA . Cost and cost‐effectiveness in a randomized trial of long‐acting risperidone for schizophrenia. Journal of Clinical Psychiatry2012;73:696‐702. RosenheckRA , KrystalJH , LewR , BarnettPG , FioreL , ValleyD , et al. Long‐ acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine March 3, 2011;364(9):842‐51. ">Rosenheck 2011</a>, RR 1.34 CI 1.13 to 1.58, <a href="./references#CD004161-fig-0030" title="">Analysis 2.10</a>). </p> </section> </section> <section id="CD004161-sec-0164"> <h4 class="title">COMPARISON 3: RISPERIDONE DEPOT versus ORAL RISPERIDONE</h4> <p>Two studies provided data for this comparison (<a href="./references#CD004161-bbs2-0001" title="BaiYM , ChenTT , WuB , HungCH , LinWK , HuTM , et al. A comparative efficacy and safety study of long‐acting risperidone injection and risperidone oral tablets among hospitalized patients: 12‐week randomized, single‐blind study. Pharmacopsychiatry2006;39(4):135‐41. ">Bai 2006</a>; <a href="./references#CD004161-bbs2-0002" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;3(Suppl 1):174. ChueP , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Promotional slides on file from Janssen‐Cliag UK Ltd2002. ">Chue 2002</a>, n = 690); both studies were 12‐weeks long and categorised in the 'short term' (note: <a href="./references#CD004161-bbs2-0002" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;3(Suppl 1):174. ChueP , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Promotional slides on file from Janssen‐Cliag UK Ltd2002. ">Chue 2002</a> had an eight‐week open‐label run‐in period in which participants were stabilised on oral risperidone). </p> <section id="CD004161-sec-0165"> <h5 class="title">3.1 Global state: 1. Moderate to severely ill at end of study period (Clinical Global Impression (CGI) rating) </h5> <p>There was no statistically significant difference between groups for being 'moderate to severely ill at the end of the study period' (n = 640, <a href="./references#CD004161-bbs2-0002" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;3(Suppl 1):174. ChueP , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Promotional slides on file from Janssen‐Cliag UK Ltd2002. ">Chue 2002</a>, <a href="./references#CD004161-fig-0031" title="">Analysis 3.1</a>). </p> </section> <section id="CD004161-sec-0166"> <h5 class="title">3.2 Global state: 2. Mean change from baseline (CGI‐S, greater change = better outcome)</h5> <p>There was no statistically significant difference between groups in mean changes in CGI‐S score from baseline (n = 50, <a href="./references#CD004161-bbs2-0001" title="BaiYM , ChenTT , WuB , HungCH , LinWK , HuTM , et al. A comparative efficacy and safety study of long‐acting risperidone injection and risperidone oral tablets among hospitalized patients: 12‐week randomized, single‐blind study. Pharmacopsychiatry2006;39(4):135‐41. ">Bai 2006</a>, <a href="./references#CD004161-fig-0032" title="">Analysis 3.2</a>). </p> </section> <section id="CD004161-sec-0167"> <h5 class="title">3.3 Global state: 3. Mean (SD) Global Assessment of Functioning (GAF) score change to endpoint </h5> <p>There was no statistically significant difference between risperidone depot and oral risperidone in mean endpoint scores using the GAF (n = 50, <a href="./references#CD004161-bbs2-0001" title="BaiYM , ChenTT , WuB , HungCH , LinWK , HuTM , et al. A comparative efficacy and safety study of long‐acting risperidone injection and risperidone oral tablets among hospitalized patients: 12‐week randomized, single‐blind study. Pharmacopsychiatry2006;39(4):135‐41. ">Bai 2006</a>), <a href="./references#CD004161-fig-0033" title="">Analysis 3.3</a>). </p> </section> <section id="CD004161-sec-0168"> <h5 class="title">3.4 Global state: 4. Needing use of benzodiazepine or sedative drugs</h5> <p>There was no statistically significant difference between risperidone depot and oral risperidone for needing benzodiazepines or sedative drugs (n = 690, two RCTs, <a href="./references#CD004161-fig-0034" title="">Analysis 3.4</a>). </p> </section> <section id="CD004161-sec-0169"> <h5 class="title">3.5 Mental state: 1. Average change/endpoint scores (Positive and Negative Syndrome Scale (PANSS)) </h5> <p>There were no statistically significant differences between for average endpoint scores using the PANSS for mean total scores (2 RCTs, n = 591, MD 1.05, CI ‐0.77 to 2.88); average change in positive symptoms or negative symptoms; disorganised thoughts; hostility/excitement; or anxiety/depression (<a href="./references#CD004161-fig-0035" title="">Analysis 3.5</a>). </p> </section> <section id="CD004161-sec-0170"> <h5 class="title">3.6 Leaving the study early: 1. Any reason</h5> <p>There was no statistically significant difference between risperidone depot and oral risperidone for leaving the study early for any reason (n = 690, 2 RCTs, <a href="./references#CD004161-fig-0036" title="">Analysis 3.6</a>). </p> </section> <section id="CD004161-sec-0171"> <h5 class="title">3.7 Leaving the study early: 2. Specific</h5> <p>There were no statistically significant differences between groups for leaving the study early for adverse events; insufficient response; or withdrawn consent (n = 640, <a href="./references#CD004161-bbs2-0002" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;3(Suppl 1):174. ChueP , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Promotional slides on file from Janssen‐Cliag UK Ltd2002. ">Chue 2002</a>, <a href="./references#CD004161-fig-0037" title="">Analysis 3.7</a>). </p> </section> <section id="CD004161-sec-0172"> <h5 class="title">3.8 Quality of life: Mean (SD) SF‐36 score change/endpoint</h5> <p>In one small study, there was a statistically significant difference favouring depot risperidone for the social functioning component of the SF‐36 scale (n = 50, <a href="./references#CD004161-bbs2-0001" title="BaiYM , ChenTT , WuB , HungCH , LinWK , HuTM , et al. A comparative efficacy and safety study of long‐acting risperidone injection and risperidone oral tablets among hospitalized patients: 12‐week randomized, single‐blind study. Pharmacopsychiatry2006;39(4):135‐41. ">Bai 2006</a>, mean difference (MD) 18.50 95% CI 3.98 to 33.02). There were no statistically significant differences between groups for remaining physical and mental components; vitality; general health; mental health; bodily pain; and physical function (n = 50, <a href="./references#CD004161-bbs2-0001" title="BaiYM , ChenTT , WuB , HungCH , LinWK , HuTM , et al. A comparative efficacy and safety study of long‐acting risperidone injection and risperidone oral tablets among hospitalized patients: 12‐week randomized, single‐blind study. Pharmacopsychiatry2006;39(4):135‐41. ">Bai 2006</a>, <a href="./references#CD004161-fig-0038" title="">Analysis 3.8</a>). </p> </section> <section id="CD004161-sec-0173"> <h5 class="title">3.9 Adverse events: 1. General</h5> <p>There were no statistically significant differences between groups for 'any' adverse events or death (n = 640, <a href="./references#CD004161-bbs2-0002" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;3(Suppl 1):174. ChueP , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Promotional slides on file from Janssen‐Cliag UK Ltd2002. ">Chue 2002</a>, <a href="./references#CD004161-fig-0039" title="">Analysis 3.9</a>). </p> </section> <section id="CD004161-sec-0174"> <h5 class="title">3.10 Adverse events: 1. General: Udvalg for Kliniske Undersgelser (UKU) (average change score) </h5> <p>There was a statistically significant difference between groups, favouring risperidone depot for adverse events using the UKU, short term (n = 50, <a href="./references#CD004161-bbs2-0001" title="BaiYM , ChenTT , WuB , HungCH , LinWK , HuTM , et al. A comparative efficacy and safety study of long‐acting risperidone injection and risperidone oral tablets among hospitalized patients: 12‐week randomized, single‐blind study. Pharmacopsychiatry2006;39(4):135‐41. ">Bai 2006</a>, MD ‐1.99, 95% CI ‐3.59 to ‐0.39, <a href="./references#CD004161-fig-0040" title="">Analysis 3.10</a>). </p> </section> <section id="CD004161-sec-0175"> <h5 class="title">3.11 Adverse events: 2. Specific</h5> <p>There were no statistically significant differences between groups for specific adverse event outcomes of anxiety; psychosis; prolactin‐related; impotence/ejaculation failure; dysmenorrhoea; hyperprolactinaemia galactorrhoea; headache; insomnia or sexual dysfunction (n = 640, <a href="./references#CD004161-bbs2-0002" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;3(Suppl 1):174. ChueP , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Promotional slides on file from Janssen‐Cliag UK Ltd2002. ">Chue 2002</a>, <a href="./references#CD004161-fig-0041" title="">Analysis 3.11</a>). </p> </section> <section id="CD004161-sec-0176"> <h5 class="title">3.12 Adverse events: 2. Specific: Mean (SD) weight increase</h5> <p>There was no statistically significant difference between groups for mean weight increase (kg) (n = 640, <a href="./references#CD004161-bbs2-0002" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;3(Suppl 1):174. ChueP , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Promotional slides on file from Janssen‐Cliag UK Ltd2002. ">Chue 2002</a>, <a href="./references#CD004161-fig-0042" title="">Analysis 3.12</a>). </p> </section> <section id="CD004161-sec-0177"> <h5 class="title">3.13 Adverse events: 3. Movement disorder</h5> <p>There were no statistically significant differences between groups for EPS or tardive dyskinesia (n = 640, <a href="./references#CD004161-bbs2-0002" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;3(Suppl 1):174. ChueP , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Promotional slides on file from Janssen‐Cliag UK Ltd2002. ">Chue 2002</a>); nor was there any statistically significant difference between groups for participants requiring anti‐cholinergic drugs (n = 690, 2 RCTs, <a href="./references#CD004161-fig-0043" title="">Analysis 3.13</a>). </p> </section> <section id="CD004161-sec-0178"> <h5 class="title">3.14 Adverse events: Mean (SD) change in movement disorder rating scales</h5> <p>There were no statistically significant differences between groups for change in movement disorder rating scales using either Abnormal Involuntary Movement Scale (AIMS), Barnes Akathisia Rating Scale (BARS) or Simpson and Angus Rating scale (SAS) (n = 50, <a href="./references#CD004161-bbs2-0001" title="BaiYM , ChenTT , WuB , HungCH , LinWK , HuTM , et al. A comparative efficacy and safety study of long‐acting risperidone injection and risperidone oral tablets among hospitalized patients: 12‐week randomized, single‐blind study. Pharmacopsychiatry2006;39(4):135‐41. ">Bai 2006</a>, <a href="./references#CD004161-fig-0044" title="">Analysis 3.14</a>). </p> </section> </section> <section id="CD004161-sec-0179"> <h4 class="title">COMPARISON 4: RISPERIDONE DEPOT versus ORAL QUETIAPINE</h4> <p>One study provided data for this outcome (n = 666, <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>); as a two‐year study, results are labelled as 'long term'. </p> <section id="CD004161-sec-0180"> <h5 class="title">4.1 Leaving the study early: 1. Any reason</h5> <p>There was a statistically significant difference favouring risperidone depot for participants leaving the study early for any reason (n = 666, <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>, RR 0.84 95% CI 0.74 to 0.95, <a href="./references#CD004161-fig-0045" title="">Analysis 4.1</a>). </p> </section> <section id="CD004161-sec-0181"> <h5 class="title">4.2 Leaving the study early: 2. Specific</h5> <p>There was a statistically significant difference favouring risperidone depot for participants leaving the study early due to relapse (n = 666, <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>, RR 0.54, CI 0.40 to 0.73, <a href="./references#CD004161-fig-0046" title="">Analysis 4.2</a>). </p> </section> <section id="CD004161-sec-0182"> <h5 class="title">4.3 Adverse events: 1. General</h5> <p>There were no statistically significant differences between groups for any general adverse events; serious adverse events or death (n = 666, <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>, <a href="./references#CD004161-fig-0047" title="">Analysis 4.3</a>). </p> </section> <section id="CD004161-sec-0183"> <h5 class="title">4.4 Adverse events: 2. Specifc</h5> <p>For specific adverse events, there were no statistically significant differences between groups for psychiatric symptoms; serious psychiatric symptoms; weight increase; or headache (n = 666, <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>). There was a statistically significant difference favouring risperidone depot for fatigue/somnolence (n = 666, <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>, RR 0.16 95% CI 0.07 to 0.38); however, there was a statistically significant difference favouring quetiapine oral for prolactin‐related adverse events (P = 0.03) (n = 666, <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>, RR 3.07 95% CI 1.13 to 8.36) and hyperprolactinaemia (n = 666, <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>, RR 8.81 95% CI 3.53 to 21.96, <a href="./references#CD004161-fig-0048" title="">Analysis 4.4</a>). </p> </section> <section id="CD004161-sec-0184"> <h5 class="title">4.5 Adverse events: 2. Specific: Mean (SD) weight increase in kg</h5> <p>There was a statistically significant difference between groups favouring oral quetiapine for weight increase (n = 666, <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>, MD 1.25 95% CI 0.25 to 2.25, <a href="./references#CD004161-fig-0049" title="">Analysis 4.5</a>). </p> </section> <section id="CD004161-sec-0185"> <h5 class="title">4.6 Adverse events: 3. Movement disorder</h5> <p>There was a statistically significant difference between groups, favouring oral quetiapine for any EPS (n = 666, <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>), RR 1.83 95% CI 1.07 to 3.15); tremor (RR 5.12 95% CI 1.13 to 23.20), and parkinsonism (RR 2.56 95% CI 1.01 to 6.52). There was no statistically significant difference between groups for further outcomes of tardive dyskinesia; dystonia; and hyperkinesia (n = 666, <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>, <a href="./references#CD004161-fig-0050" title="">Analysis 4.6</a>). </p> </section> </section> <section id="CD004161-sec-0186"> <h4 class="title">COMPARISON 5: RISPERIDONE DEPOT versus ORAL ARIPIPRAZOLE</h4> <p>Two studies provided data for this comparison (n = 730, <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>; <a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a>); both studies were two‐years long, and results are therefore listed as 'long term'. </p> <section id="CD004161-sec-0187"> <h5 class="title">5.1 Global state: 1. Relapse (any reason)</h5> <p>There was no statistically significant difference between risperidone depot and oral aripiprazole (n = 349, <a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a>, RR 1.05 95% CI 0.83 to 1.33, <a href="./references#CD004161-fig-0051" title="">Analysis 5.1</a>). </p> </section> <section id="CD004161-sec-0188"> <h5 class="title">5.2 Global state: 3. Mean time in remission (days)</h5> <p>There was no statistically significant difference between groups for mean time in remission (n = 348, <a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a>, <a href="./references#CD004161-fig-0052" title="">Analysis 5.2</a>). </p> </section> <section id="CD004161-sec-0189"> <h5 class="title">5.3 Mental state: 1. Average change scores (PANSS, negative change = good) 1. Total</h5> <p>There was no statistically significant difference between groups for change in mental state using PANSS (n = 349, <a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a>, <a href="./references#CD004161-fig-0053" title="">Analysis 5.3</a>). </p> </section> <section id="CD004161-sec-0190"> <h5 class="title">5.4 Leaving the study early: 1. Any reason</h5> <p>There was no significant difference between groups for leaving the study early for any reason (2 RCTs n = 723, RR 0.83 95% CI 0.53 to 1.30, <a href="./references#CD004161-fig-0054" title="">Analysis 5.4</a>). This outcome had important levels of heterogeneity (Chi<sup>2</sup> = 5.67; df = 1; P = 0.02; I<sup>2</sup> = 82%). </p> </section> <section id="CD004161-sec-0191"> <h5 class="title">5.5 Leaving the study early: 2. Specific</h5> <p>There were no statistically significant differences between groups for leaving the study early due to adverse events; withdrawn consent (n = 723, 2 RCTs); insufficient response; lost to follow‐up (n = 349, <a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a>); or due to relapse (n = 374, <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>, <a href="./references#CD004161-fig-0055" title="">Analysis 5.5</a>). </p> </section> <section id="CD004161-sec-0192"> <h5 class="title">5.6 Adverse events: 1. General</h5> <p>There were no statistically significant differences between groups for 'any' adverse events; serious adverse events; or death (n = 729, 2 RCTs, <a href="./references#CD004161-fig-0056" title="">Analysis 5.6</a>) </p> </section> <section id="CD004161-sec-0193"> <h5 class="title">5.7 Adverse events: 2. Specific</h5> <p>There was a statistically significant difference favouring oral aripiprazole for prolactin‐related adverse events (n = 729, 2 RCTs, RR 9.91 CI 2.78 to 35.29); decreased appetite (1 RCT, n = 355, RR 1.78 CI 1.00 to 3.16), and dizziness (1 RCT, n = 355, RR 1.89 CI 1.00 to 3.58). <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a> found a statistically significant difference favouring risperidone depot, with higher instances of gastrointestinal adverse effects (1 RCT, n = 374, RR 0.27 CI 0.14 to 0.55), and <a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a> had similar results for upper respiratory track infection (1 RCT, n = 355, RR 0.38 CI 0.16 to 0.89, <a href="./references#CD004161-fig-0057" title="">Analysis 5.7</a>). </p> <p>There were no statistically significant differences between groups for headache; anxiety; depression; psychosis; 'schizophrenia'; nausea/vomiting; diarrhoea; insomnia; pyrexia; nasopharyngitis; glucose‐related; psychiatric symptoms; 'serious' psychiatric symptoms; hyperprolactinaemia; or weight increase (<a href="./references#CD004161-fig-0057" title="">Analysis 5.7</a>). </p> </section> <section id="CD004161-sec-0194"> <h5 class="title">5.8 Adverse events: 2. Specific 12. Mean (SD) weight increase in kg</h5> <p><a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a> found no significant difference between risperidone depot and oral aripiprazole for long‐term mean weight increase (1 RCT, n = 355, MD 1.00 95% CI ‐0.42 to 2.42, <a href="./references#CD004161-fig-0058" title="">Analysis 5.8</a>). </p> </section> <section id="CD004161-sec-0195"> <h5 class="title">5.9 Adverse events: 3. Movement disorder</h5> <p>There were no statistically significant differences between groups for any EPS, tremor or akathisia (<a href="./references#CD004161-fig-0059" title="">Analysis 5.9</a>). </p> </section> </section> <section id="CD004161-sec-0196"> <h4 class="title">COMPARISON 6: RISPERIDONE DEPOT versus ORAL OLANZAPINE</h4> <p>One study provided data for this comparison (n = 361, <a href="./references#CD004161-bbs2-0007" title="KeksN , InghamM , KhanA , KarcherK . Long‐acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open‐label study. British Journal of Psychiatry2007;191:131‐9. KeksN , KhanA , AugustynsI , RabinowitzJ , InghamM . Non‐inferiority efficacy trial of risperidone long‐acting injection (RLAI) vs. olanzapine tablets (OLA). Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006. ">Keks 2007</a>), which at 12 months is labelled as a 'long‐term' study. </p> <section id="CD004161-sec-0197"> <h5 class="title">6.1 Mental state: 1. Average change scores (PANSS, negative change = good)</h5> <p>There were no statistically significant differences between groups in average change scores using the PANSS total on short‐term or long‐term positive symptoms, negative symptoms, disorganised thoughts, hostility/excitement or anxiety/depression components (<a href="./references#CD004161-fig-0060" title="">Analysis 6.1</a>). </p> </section> <section id="CD004161-sec-0198"> <h5 class="title">6.2 Leaving the study early: 1. Any reason</h5> <p>There were higher rates of leaving the study early in the risperidone (depot) group (1 RCT, n = 618, RR 1.32 95% CI 1.10 to 1.58, <a href="./references#CD004161-fig-0061" title="">Analysis 6.2</a>). </p> </section> <section id="CD004161-sec-0199"> <h5 class="title">6.3 Leaving the study early: 2. Specific</h5> <p>There was no statistically significant difference between groups when leaving the study early due to adverse events; insufficient response; or due to weight gain. There was a statistically significant difference between groups for leaving the study early due to withdrawn consent, with higher losses in the risperidone depot group (1 RCT, n = 547, RR 2.54 95% CI 1.56 to 4.16, <a href="./references#CD004161-fig-0062" title="">Analysis 6.3</a>). </p> </section> <section id="CD004161-sec-0200"> <h5 class="title">6.4 Adverse events: 1. General</h5> <p>There were no statistically significant differences between groups for serious adverse events or death (<a href="./references#CD004161-fig-0063" title="">Analysis 6.4</a>). </p> </section> <section id="CD004161-sec-0201"> <h5 class="title">6.5 Adverse events: 2. Specific</h5> <p>There were no statistically significant differences between groups for specific adverse events including anxiety, depression, psychosis, headache, fatigue/somnolence, nasopharyngitis impotence/ejaculation failure, galactorrhoea, serious psychiatric symptoms, serious anxiety, suicide attempt, serious injury, diabetes mellitus, hypoglycaemia, and hyperglycaemia (<a href="./references#CD004161-fig-0064" title="">Analysis 6.5</a>). </p> <p>There was a statistically significant difference favouring risperidone depot for weight increase (1 RCT, n = 547, RR 0.56 95% CI 0.42 to 0.75), however with significant favour of oral olanzapine for agitation (1 RCT, n = 532, RR 1.98 95% CI 1.06 to 3.68), and levels of insomnia ((1 RCT, n = 532, RR 4.59 CI 2.61 to 8.07, <a href="./references#CD004161-fig-0064" title="">Analysis 6.5</a>). </p> </section> <section id="CD004161-sec-0202"> <h5 class="title">6.6 Adverse events: 3. Movement disorder</h5> <p>There were no significant differences between groups for tardive dyskinesia; hypertonia; or dystonia (n = 547, <a href="./references#CD004161-bbs2-0007" title="KeksN , InghamM , KhanA , KarcherK . Long‐acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open‐label study. British Journal of Psychiatry2007;191:131‐9. KeksN , KhanA , AugustynsI , RabinowitzJ , InghamM . Non‐inferiority efficacy trial of risperidone long‐acting injection (RLAI) vs. olanzapine tablets (OLA). Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006. ">Keks 2007</a>). There was a statistically significant difference between groups, favouring oral olanzapine for EPS (1 RCT, n = 547, RR 1.67 CI 1.19 to 2.36), tremor (RR 2.29 95% CI 1.04 to 5.06); hyperkinesia (1 RCT, n = 547, RR 2.02 CI 1.01 to 4.06); and requiring antiparkinson drugs (1 RCT, n = 547, RR 1.26 CI 1.02 to 1.56, <a href="./references#CD004161-fig-0065" title="">Analysis 6.6</a>). </p> </section> </section> <section id="CD004161-sec-0203"> <h4 class="title">COMPARISON 7: RISPERIDONE DEPOT versus ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES)</h4> <p>We pooled all studies comparing risperidone depot with all oral antipsychotics in order to more effectively present estimates of the effects for our primary outcomes in a more concise format (n = 2840, 7 RCTs). </p> <section id="CD004161-sec-0204"> <h5 class="title">7.1 Global state: 1. Relapse (any reason)</h5> <p>There was no significant difference between groups for relapse with either risperidone depot versus aripiprazole (n = 349, <a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a>), or versus 'general oral antipsychotics' (n = 63, <a href="./references#CD004161-bbs2-0011" title="QuinnA , CamachoF , MitchellD , ChueP , MallaA . Open‐label randomized exploratory investigation of Risperdal* Consta* and oral antipsychotics treatment of early psychosis. Autumn Conference of the International Society for CNS Clinical Trials and Methodology, October 1‐3. Marina Del Rey, California, 2012. ">Quinn 2012*</a>, <a href="./references#CD004161-fig-0066" title="">Analysis 7.1</a>). </p> </section> <section id="CD004161-sec-0205"> <h5 class="title">7.2 Mental state: 1. Average scores (PANSS, greater change = better outcome) 1. total</h5> <p>There was no statistically significant difference between groups in PANSS scores when risperidone depot was compared with oral risperidone (n = 591, 2 RCTs); oral olanzapine at short term (n = 377, <a href="./references#CD004161-bbs2-0007" title="KeksN , InghamM , KhanA , KarcherK . Long‐acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open‐label study. British Journal of Psychiatry2007;191:131‐9. KeksN , KhanA , AugustynsI , RabinowitzJ , InghamM . Non‐inferiority efficacy trial of risperidone long‐acting injection (RLAI) vs. olanzapine tablets (OLA). Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006. ">Keks 2007</a>) and long term (n = 361, <a href="./references#CD004161-bbs2-0007" title="KeksN , InghamM , KhanA , KarcherK . Long‐acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open‐label study. British Journal of Psychiatry2007;191:131‐9. KeksN , KhanA , AugustynsI , RabinowitzJ , InghamM . Non‐inferiority efficacy trial of risperidone long‐acting injection (RLAI) vs. olanzapine tablets (OLA). Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006. ">Keks 2007</a>); or oral aripiprazole (n = 349, <a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a>, <a href="./references#CD004161-fig-0067" title="">Analysis 7.2</a>). </p> </section> <section id="CD004161-sec-0206"> <h5 class="title">7.3 Leaving the study early: 1. Any reason</h5> <p>There was no difference between groups in numbers leaving the study early when risperidone depot was compared with oral aripiprazole (n = 723, 2 RCTs); oral risperidone (n = 690, 2 RCTs); or 'any oral antipsychotic' (n = 382, <a href="./references#CD004161-bbs2-0012" title="BarnettPG , ScottJY , KrystalJH , RosenheckRA . Cost and cost‐effectiveness in a randomized trial of long‐acting risperidone for schizophrenia. Journal of Clinical Psychiatry2012;73:696‐702. RosenheckRA , KrystalJH , LewR , BarnettPG , FioreL , ValleyD , et al. Long‐ acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine March 3, 2011;364(9):842‐51. ">Rosenheck 2011</a>). <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a> found a statistically significant difference between groups favouring risperidone depot when compared with oral quetiapine (1 RCT, n = 666, RR 0.84 95% CI 0.74 to 0.95), <a href="./references#CD004161-bbs2-0011" title="QuinnA , CamachoF , MitchellD , ChueP , MallaA . Open‐label randomized exploratory investigation of Risperdal* Consta* and oral antipsychotics treatment of early psychosis. Autumn Conference of the International Society for CNS Clinical Trials and Methodology, October 1‐3. Marina Del Rey, California, 2012. ">Quinn 2012*</a> found similar results for 'any new generation antipsychotic' (1 RCT, n = 77, RR 0.72 95% CI 0.55 to 0.95). <a href="./references#CD004161-bbs2-0007" title="KeksN , InghamM , KhanA , KarcherK . Long‐acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open‐label study. British Journal of Psychiatry2007;191:131‐9. KeksN , KhanA , AugustynsI , RabinowitzJ , InghamM . Non‐inferiority efficacy trial of risperidone long‐acting injection (RLAI) vs. olanzapine tablets (OLA). Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006. ">Keks 2007</a> found there was a statistically significant difference between groups favouring oral olanzapine (1 RCT n = 618 RR 1.32 95% CI 1.10 to 1.58, <a href="./references#CD004161-fig-0068" title="">Analysis 7.3</a>). </p> </section> <section id="CD004161-sec-0207"> <h5 class="title">7.4 Adverse events: 1. Death</h5> <p>There were no statistically significant differences between groups for the outcome of death with risperidone depot was compared with oral olanzapine (n = 618, <a href="./references#CD004161-bbs2-0007" title="KeksN , InghamM , KhanA , KarcherK . Long‐acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open‐label study. British Journal of Psychiatry2007;191:131‐9. KeksN , KhanA , AugustynsI , RabinowitzJ , InghamM . Non‐inferiority efficacy trial of risperidone long‐acting injection (RLAI) vs. olanzapine tablets (OLA). Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006. ">Keks 2007</a>); oral risperidone (n = 640, <a href="./references#CD004161-bbs2-0002" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;3(Suppl 1):174. ChueP , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Promotional slides on file from Janssen‐Cliag UK Ltd2002. ">Chue 2002</a>); 'any oral antipsychotic' (n = 382, <a href="./references#CD004161-bbs2-0012" title="BarnettPG , ScottJY , KrystalJH , RosenheckRA . Cost and cost‐effectiveness in a randomized trial of long‐acting risperidone for schizophrenia. Journal of Clinical Psychiatry2012;73:696‐702. RosenheckRA , KrystalJH , LewR , BarnettPG , FioreL , ValleyD , et al. Long‐ acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine March 3, 2011;364(9):842‐51. ">Rosenheck 2011</a>); oral aripiprazole (n = 729, 2 RCTs); or oral quetiapine (n = 666, <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>, <a href="./references#CD004161-fig-0069" title="">Analysis 7.4</a>). </p> </section> <section id="CD004161-sec-0208"> <h5 class="title">7.5 Adverse events: 1. General: a. any</h5> <p>There were no significant differences between groups for instances of 'any adverse events' when risperidone depot was compared with either oral aripiprazole (n = 729, 2 RCTs); oral risperidone (n = 640, <a href="./references#CD004161-bbs2-0002" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;3(Suppl 1):174. ChueP , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Promotional slides on file from Janssen‐Cliag UK Ltd2002. ">Chue 2002</a>); or oral quetiapine (n = 666, <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>, <a href="./references#CD004161-fig-0070" title="">Analysis 7.5</a>). </p> </section> <section id="CD004161-sec-0209"> <h5 class="title">7.6 Adverse events: 1. General: b. serious</h5> <p>There were no significant differences between groups for instances of 'serious adverse events' when risperidone depot was compared with either oral quetiapine (n = 666, <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>); oral aripiprazole (n = 729, 2 RCTs); or oral olanzapine (n = 547, <a href="./references#CD004161-bbs2-0007" title="KeksN , InghamM , KhanA , KarcherK . Long‐acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open‐label study. British Journal of Psychiatry2007;191:131‐9. KeksN , KhanA , AugustynsI , RabinowitzJ , InghamM . Non‐inferiority efficacy trial of risperidone long‐acting injection (RLAI) vs. olanzapine tablets (OLA). Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006. ">Keks 2007</a>, <a href="./references#CD004161-fig-0071" title="">Analysis 7.6</a>). </p> </section> <section id="CD004161-sec-0210"> <h5 class="title">7.7 Adverse events: 2. Movement disorder: a. any extrapyramidal symptoms (EPS)</h5> <p>There was no statistically significant difference between groups for instances of 'any EPS' when risperidone depot was compared with oral aripiprazole (n = 729, 2 RCTs) or oral risperidone (n = 640, <a href="./references#CD004161-bbs2-0002" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;3(Suppl 1):174. ChueP , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Promotional slides on file from Janssen‐Cliag UK Ltd2002. ">Chue 2002</a>). There were significantly more instances of EPS amongst participants receiving risperidone depot when compared with oral quetiapine <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a> (1 RCT, n = 666, RR 1.83 95% CI 1.07 to 3.15), or oral olanzapine, <a href="./references#CD004161-bbs2-0007" title="KeksN , InghamM , KhanA , KarcherK . Long‐acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open‐label study. British Journal of Psychiatry2007;191:131‐9. KeksN , KhanA , AugustynsI , RabinowitzJ , InghamM . Non‐inferiority efficacy trial of risperidone long‐acting injection (RLAI) vs. olanzapine tablets (OLA). Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006. ">Keks 2007</a> (1 RCT, n = 547, RR 1.67 95% CI 1.19 to 2.36, <a href="./references#CD004161-fig-0072" title="">Analysis 7.7</a>). </p> </section> </section> <section id="CD004161-sec-0211"> <h4 class="title">COMPARISON 8: RISPERIDONE DEPOT VERSUS ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) </h4> <p>Three studies compared risperidone depot with paliperidone palmitate (<a href="./references#CD004161-bbs2-0004" title="FleischhackerWW , GopalS , LaneR , Gassmann‐Mayer , LimP , HoughD , et al. A randomized trial of paliperidone palmitate and risperidone long acting injectable in schizophrenia. International Journal of Neuropsychopharmacology2012;15:107‐18. ">Fleischhacker 2011</a>; <a href="./references#CD004161-bbs2-0008" title="LiH , RuiQ , NingX , XuH , GuN . A comparative study of paliperidone palmitate and risperidone long‐acting injectable therapy in schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:1002‐8. ">Li 2011</a>; <a href="./references#CD004161-bbs2-0010" title="PandinaG , LaneR , Gassmann‐MayerC , HoughD , RemmerieB , SimpsonG . A randomised double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Proceedings of the 27th International College of Neuropsychopharmacology Congress; 2010 June 6‐10; Hong Kong. 2010. PandinaG , LaneR , GopalS , Gassman‐MayerC , HoughD , RemmerieB , et al. A randomized double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Biological Psychiatry2010;67(9):77‐8. PandinaG , LaneR , GopalS , Gassmann‐MayerC , HoughD , RemmerieB , et al. A double‐blind study of paliperidone palmitate and risperidone long‐acting injectable in adults with schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:218‐26. ">Pandina 2011</a>), with a total of n = 2,421. Two of the included studies lasted for 12 months (<a href="./references#CD004161-bbs2-0004" title="FleischhackerWW , GopalS , LaneR , Gassmann‐Mayer , LimP , HoughD , et al. A randomized trial of paliperidone palmitate and risperidone long acting injectable in schizophrenia. International Journal of Neuropsychopharmacology2012;15:107‐18. ">Fleischhacker 2011</a>; <a href="./references#CD004161-bbs2-0008" title="LiH , RuiQ , NingX , XuH , GuN . A comparative study of paliperidone palmitate and risperidone long‐acting injectable therapy in schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:1002‐8. ">Li 2011</a>), as a long‐term study; <a href="./references#CD004161-bbs2-0010" title="PandinaG , LaneR , Gassmann‐MayerC , HoughD , RemmerieB , SimpsonG . A randomised double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Proceedings of the 27th International College of Neuropsychopharmacology Congress; 2010 June 6‐10; Hong Kong. 2010. PandinaG , LaneR , GopalS , Gassman‐MayerC , HoughD , RemmerieB , et al. A randomized double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Biological Psychiatry2010;67(9):77‐8. PandinaG , LaneR , GopalS , Gassmann‐MayerC , HoughD , RemmerieB , et al. A double‐blind study of paliperidone palmitate and risperidone long‐acting injectable in adults with schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:218‐26. ">Pandina 2011</a> was categorised as a medium‐term study lasting for 13 weeks. </p> <section id="CD004161-sec-0212"> <h5 class="title">8.1 Global State: 1. CGI‐S mean change from baseline to endpoint (intention‐treat (ITT) data) </h5> <p>There was no statistically significant difference between groups at medium term (2 RCTs, n = 1326, MD ‐0.07 95% CI ‐ 0.26 to 0.11, <a href="./references#CD004161-fig-0073" title="">Analysis 8.1</a>). This outcome had important levels of heterogeneity (Chi<sup>2</sup> = 2.23; df = 1; P = 0.135; I<sup>2</sup> = 55%). </p> </section> <section id="CD004161-sec-0213"> <h5 class="title">8.2 Global state: Schedule for Deficit Syndrome (SDS) scale (mean change from baseline to endpoint, ITT data) </h5> <p>There was no statistically significant difference between groups at medium term for mean change scores using the SDS scale, <a href="./references#CD004161-bbs2-0010" title="PandinaG , LaneR , Gassmann‐MayerC , HoughD , RemmerieB , SimpsonG . A randomised double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Proceedings of the 27th International College of Neuropsychopharmacology Congress; 2010 June 6‐10; Hong Kong. 2010. PandinaG , LaneR , GopalS , Gassman‐MayerC , HoughD , RemmerieB , et al. A randomized double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Biological Psychiatry2010;67(9):77‐8. PandinaG , LaneR , GopalS , Gassmann‐MayerC , HoughD , RemmerieB , et al. A double‐blind study of paliperidone palmitate and risperidone long‐acting injectable in adults with schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:218‐26. ">Pandina 2011</a>, (1 RCT, n = 913, MD 0.1 CI ‐0.29 to 0.49, <a href="./references#CD004161-fig-0074" title="">Analysis 8.2</a>). </p> </section> <section id="CD004161-sec-0214"> <h5 class="title">8.3 Mental state: 1. PANSS scores ‐ medium term</h5> <p>Medium term PANSS scores from two studies (n = 1326) demonstrate no statistically significant differences in mental state between groups using the PANSS. The majority of data relating to the subscale scores demonstrated moderate to substantial levels of heterogeneity (P = 0.05; I<sup>2</sup> = 73% for anxiety/depression score for endpoint; P = 0.008; I<sup>2</sup> = 86% for changes in positive symptom scores, <a href="./references#CD004161-fig-0075" title="">Analysis 8.3</a>). </p> </section> <section id="CD004161-sec-0215"> <h5 class="title">8.4 Mental state: Improved by 30% in total PANSS score (ITT data)</h5> <p>There was no significant difference between risperidone depot and atypical depot antipsychotics (paliperidone palmitate) at medium term (n = 1326, 2 RCTs), <a href="./references#CD004161-fig-0076" title="">Analysis 8.4</a>. This outcome had important levels of heterogeneity (Chi<sup>2</sup> = 5.31; df = 1; P = 0.021; I<sup>2</sup> = 81%). </p> </section> <section id="CD004161-sec-0216"> <h5 class="title">8.5 General functioning: Personal and Social Performance (PSP) scale (mean change from baseline to endpoint) </h5> <p>There was no significant difference between groups in general functioning using the PSP scale at medium term (n = 1326, 2 RCTs, <a href="./references#CD004161-fig-0077" title="">Analysis 8.5</a>). </p> </section> <section id="CD004161-sec-0217"> <h5 class="title">8.6 Leaving the study early: 1. Any reason</h5> <p>There were no significant differences between groups leaving the study early due to death; adverse events; patient choice/withdrawn consent; lost to follow‐up; pregnancy; 'other' or 'any reason' at medium term. Although there was no significant difference at medium term, significantly more people receiving paliperidone palmitate left the study early due to lack of efficacy in the long term (1 RCT n = 749, RR 0.60 95% CI 0.45 to 0.81, <a href="./references#CD004161-fig-0078" title="">Analysis 8.6</a>). </p> </section> <section id="CD004161-sec-0218"> <h5 class="title">8.7 Adverse events: 1. general</h5> <p><a href="./references#CD004161-bbs2-0004" title="FleischhackerWW , GopalS , LaneR , Gassmann‐Mayer , LimP , HoughD , et al. A randomized trial of paliperidone palmitate and risperidone long acting injectable in schizophrenia. International Journal of Neuropsychopharmacology2012;15:107‐18. ">Fleischhacker 2011</a> found a statistically significant difference in the long term for overall rates of adverse events (1 RCT, n = 747, RR 0.74 95% CI 0.58, 0.95); however, there were no statistically significant differences between groups for general adverse events in the medium term for overall adverse events (n = 1666, 2 RCTs) or medium or long term for; worsening of schizophrenia (n = 1666, 2 RCTs), worsening of psychiatric disorders (n = 1214, <a href="./references#CD004161-bbs2-0010" title="PandinaG , LaneR , Gassmann‐MayerC , HoughD , RemmerieB , SimpsonG . A randomised double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Proceedings of the 27th International College of Neuropsychopharmacology Congress; 2010 June 6‐10; Hong Kong. 2010. PandinaG , LaneR , GopalS , Gassman‐MayerC , HoughD , RemmerieB , et al. A randomized double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Biological Psychiatry2010;67(9):77‐8. PandinaG , LaneR , GopalS , Gassmann‐MayerC , HoughD , RemmerieB , et al. A double‐blind study of paliperidone palmitate and risperidone long‐acting injectable in adults with schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:218‐26. ">Pandina 2011</a>), or death (n = 2415, 3 RCTs), <a href="./references#CD004161-fig-0079" title="">Analysis 8.7</a>. </p> </section> <section id="CD004161-sec-0219"> <h5 class="title">8.8 Adverse events: 2. specific</h5> <p>There were no significant differences between groups for overall rates of specific adverse effects in the medium or long term (n = 2413, 3 RCTs); insomnia in medium or long term (n = 1961, 2 RCTs), headache, psychotic disorder or 'worsening of schizophrenia' (n = 747, <a href="./references#CD004161-bbs2-0004" title="FleischhackerWW , GopalS , LaneR , Gassmann‐Mayer , LimP , HoughD , et al. A randomized trial of paliperidone palmitate and risperidone long acting injectable in schizophrenia. International Journal of Neuropsychopharmacology2012;15:107‐18. ">Fleischhacker 2011</a>), somnolence, weight gain (n = 452, <a href="./references#CD004161-bbs2-0008" title="LiH , RuiQ , NingX , XuH , GuN . A comparative study of paliperidone palmitate and risperidone long‐acting injectable therapy in schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:1002‐8. ">Li 2011</a>) or tachycardia (n = 1199, 2 RCTs). </p> <p>In the medium term, levels of anxiety were significantly greater in participants receiving paliperidone palmitate (1 RCT, n = 1214, RR 0.50 95% CI 0.26 to 0.96); however, at long term, levels of anxiety were significantly greater in participants receiving risperidone depot (1 RCT, n = 747, RR 1.49 95% CI 1.01 to 2.20). People receiving risperidone depot also reported significantly higher instances of constipation at medium term (1 RCT, n = 1214, RR 3.79 CI 1.42 to 10.08). Results were statistically significant for greater pain in injection site at medium term for people receiving paliperidone palmitate (n = 1666, 2 RCTs, RR 0.16 CI 0.07 to 0.38, <a href="./references#CD004161-fig-0080" title="">Analysis 8.8</a>). </p> </section> <section id="CD004161-sec-0220"> <h5 class="title">8.9 Adverse events: 3. Prolactin‐related</h5> <p>There were no statistically significant differences between groups in prolactin‐related adverse events, including amenorrhoea (n = 784, 2 RCTs); galactorrhoea or amenorrhoea‐galactorrhoea syndrome (n = 271, <a href="./references#CD004161-bbs2-0008" title="LiH , RuiQ , NingX , XuH , GuN . A comparative study of paliperidone palmitate and risperidone long‐acting injectable therapy in schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:1002‐8. ">Li 2011</a>); hyperprolactinaemia or increase in serum prolactin (n = 452, <a href="./references#CD004161-bbs2-0008" title="LiH , RuiQ , NingX , XuH , GuN . A comparative study of paliperidone palmitate and risperidone long‐acting injectable therapy in schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:1002‐8. ">Li 2011</a>); erectile dysfunction (n = 701, <a href="./references#CD004161-bbs2-0008" title="LiH , RuiQ , NingX , XuH , GuN . A comparative study of paliperidone palmitate and risperidone long‐acting injectable therapy in schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:1002‐8. ">Li 2011</a>); or 'any' prolactin‐related (n = 1666, 2 RCTs). <a href="./references#CD004161-bbs2-0004" title="FleischhackerWW , GopalS , LaneR , Gassmann‐Mayer , LimP , HoughD , et al. A randomized trial of paliperidone palmitate and risperidone long acting injectable in schizophrenia. International Journal of Neuropsychopharmacology2012;15:107‐18. ">Fleischhacker 2011</a> found that more men receiving risperidone depot experienced a statistically significant abnormally high level of prolactin (1 RCT n = 424, RR 1.68 95% CI 1.32 to 2.14),,<a href="./references#CD004161-fig-0081" title="">Analysis 8.9</a>, with no difference between groups for women. </p> </section> <section id="CD004161-sec-0221"> <h5 class="title">8.10 Adverse events: 4. Movement disorder</h5> <p>In the medium term, there were no significant differences between groups with instances of tardive dyskinesia (n = 1214, <a href="./references#CD004161-bbs2-0010" title="PandinaG , LaneR , Gassmann‐MayerC , HoughD , RemmerieB , SimpsonG . A randomised double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Proceedings of the 27th International College of Neuropsychopharmacology Congress; 2010 June 6‐10; Hong Kong. 2010. PandinaG , LaneR , GopalS , Gassman‐MayerC , HoughD , RemmerieB , et al. A randomized double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Biological Psychiatry2010;67(9):77‐8. PandinaG , LaneR , GopalS , Gassmann‐MayerC , HoughD , RemmerieB , et al. A double‐blind study of paliperidone palmitate and risperidone long‐acting injectable in adults with schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:218‐26. ">Pandina 2011</a>). There were also no significant differences between groups for instances of akathisia and neuroleptic malignant syndrome at medium term (n = 452, <a href="./references#CD004161-bbs2-0008" title="LiH , RuiQ , NingX , XuH , GuN . A comparative study of paliperidone palmitate and risperidone long‐acting injectable therapy in schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:1002‐8. ">Li 2011</a>). Remaining movement disorders were more prevalent in people receiving risperidone depot compared to paliperidone palmitate, with statistically significant differences between groups for tremor (1 RCT, n = 452, RR 1.71 95% CI 1.07 to 2.74) and hyperkinesia (1 RCT, n = 747, RR 1.66 95% CI 1.0 to 2.73). There was a statistically significant difference (P = 0.0004) favouring paliperidone palmitate for requiring use of anti‐EPS medication at medium term (n = 1666, 2 RCTs, RR 1.46 CI 1.18 to 1.80, <a href="./references#CD004161-fig-0082" title="">Analysis 8.10</a>). </p> </section> <section id="CD004161-sec-0222"> <h5 class="title">8.11 Adverse events: 5. Body weight (mean increase)</h5> <p>For this outcome we found three relevant trials (n = 2350). There was no statistically significant difference between groups at medium term (n = 1666, 2 RCTs), however, <a href="./references#CD004161-bbs2-0004" title="FleischhackerWW , GopalS , LaneR , Gassmann‐Mayer , LimP , HoughD , et al. A randomized trial of paliperidone palmitate and risperidone long acting injectable in schizophrenia. International Journal of Neuropsychopharmacology2012;15:107‐18. ">Fleischhacker 2011</a> found a statistically significant difference in favour of paliperidone palmitate at long term (1 RCT, n = 684, MD 1.00 95% CI 0.13 to 1.87, <a href="./references#CD004161-fig-0083" title="">Analysis 8.11</a>). </p> </section> <section id="CD004161-sec-0223"> <h5 class="title">8.12 Adverse events: 6. Mean prolactin level increase (ng/mL)</h5> <p>In this subgroup we found three relevant trials; there were no significant differences between male (n = 1125) and female (n = 807) subgroups in mean prolactin level increase (<a href="./references#CD004161-fig-0084" title="">Analysis 8.12</a>). </p> </section> <section id="CD004161-sec-0224"> <h5 class="title">8.13 Adverse events: 7. Glucose‐related</h5> <p>There were no statistically significant differences between groups for glucose‐related adverse events, including increased blood glucose; hyperglycaemia; diabetes mellitus; glycosuria; ketonuria; urine ketone; hypoglycaemia (n = 747, <a href="./references#CD004161-bbs2-0004" title="FleischhackerWW , GopalS , LaneR , Gassmann‐Mayer , LimP , HoughD , et al. A randomized trial of paliperidone palmitate and risperidone long acting injectable in schizophrenia. International Journal of Neuropsychopharmacology2012;15:107‐18. ">Fleischhacker 2011</a>); and 'any' glucose‐related adverse events at medium term (n = 1666, 2 RCTs) and long term (n = 747, 1 RCT, <a href="./references#CD004161-fig-0085" title="">Analysis 8.13</a>). </p> </section> <section id="CD004161-sec-0225"> <h5 class="title">8.14 Adverse events: 8. Injection site pain (mean (SD) Visual Analogue Scale score (0‐100 mm)) </h5> <p>In one study (<a href="./references#CD004161-bbs2-0004" title="FleischhackerWW , GopalS , LaneR , Gassmann‐Mayer , LimP , HoughD , et al. A randomized trial of paliperidone palmitate and risperidone long acting injectable in schizophrenia. International Journal of Neuropsychopharmacology2012;15:107‐18. ">Fleischhacker 2011</a>), there were no significant differences in mean scores for injection site pain between groups at baseline and endpoint (n = 474, <a href="./references#CD004161-fig-0086" title="">Analysis 8.14</a>). </p> </section> </section> <section id="CD004161-sec-0226"> <h4 class="title">COMPARISON 9: RISPERIDONE DEPOT versus TYPICAL DEPOT ANTIPSYCHOTICS</h4> <p>One study provided data for this outcome (<a href="./references#CD004161-bbs2-0003" title="CovellNH , McEvoyJP , SchoolerNR , StroupTS , JacksonCT , RojasIA , et al. Effectiveness of switching from long‐acting injectable fluphenazine or haloperidol decanoate to long‐acting injectable risperidone microspheres: an open‐label, randomized control trial. Journal of Clinical Psychiatry2012;73(5):669‐75. ">Covell 2012</a>, n = 62), which, as a six‐month study, is categorised as medium term. </p> <section id="CD004161-sec-0227"> <h5 class="title">9.1 Mental state: 1. Average scores (PANNS, high score = worse) 1. total</h5> <p>There were no statistically significant differences between groups in total average change score using PANSS at either short (n = 49), medium (n = 46), or long term (n = 43, <a href="./references#CD004161-fig-0087" title="">Analysis 9.1</a>). </p> </section> <section id="CD004161-sec-0228"> <h5 class="title">9.2 Leaving the study early</h5> <p>There were no significant differences between groups for leaving the study early due to increased psychiatric symptoms; due to EPS effects; due to weight gain and hypertension; or due to participant preference (n = 62, <a href="./references#CD004161-bbs2-0003" title="CovellNH , McEvoyJP , SchoolerNR , StroupTS , JacksonCT , RojasIA , et al. Effectiveness of switching from long‐acting injectable fluphenazine or haloperidol decanoate to long‐acting injectable risperidone microspheres: an open‐label, randomized control trial. Journal of Clinical Psychiatry2012;73(5):669‐75. ">Covell 2012</a>). There was a statistically significant difference between groups for leaving the study early before beginning assigned treatment (RR 7.50 CI 1.00 to 56.44) and by six months (RR 3.05 CI 1.12 to 8.31, <a href="./references#CD004161-fig-0088" title="">Analysis 9.2</a>). </p> </section> <section id="CD004161-sec-0229"> <h5 class="title">9.3 Hospitalisation by six months</h5> <p>There was no significant difference between groups for hospitalisation by medium term (n = 62, <a href="./references#CD004161-bbs2-0003" title="CovellNH , McEvoyJP , SchoolerNR , StroupTS , JacksonCT , RojasIA , et al. Effectiveness of switching from long‐acting injectable fluphenazine or haloperidol decanoate to long‐acting injectable risperidone microspheres: an open‐label, randomized control trial. Journal of Clinical Psychiatry2012;73(5):669‐75. ">Covell 2012</a>, <a href="./references#CD004161-fig-0089" title="">Analysis 9.3</a>). </p> </section> <section id="CD004161-sec-0230"> <h5 class="title">9.4 Adverse events: 1. Continuous outcomes (skewed)</h5> <p>All continuous outcome data for change in body mass index (BMI) and prolactin endpoint levels are skewed and are best inspected by viewing (<a href="./references#CD004161-fig-0090" title="">Analysis 9.4</a>). </p> </section> <section id="CD004161-sec-0231"> <h5 class="title">9.5 Adverse events: 2. Sexual experiences (Arizona Sexual Experiences Scale( ASEX), high score = worse) </h5> <p>There were no statistically significant differences between groups in sexual experiences scores using ASEX at either short (n = 44), medium (n = 41), or long term (n = 40, <a href="./references#CD004161-fig-0091" title="">Analysis 9.5</a>). </p> </section> </section> <section id="CD004161-sec-0232"> <h4 class="title">10. SENSITIVITY ANALYSIS</h4> <section id="CD004161-sec-0233"> <h5 class="title">10.1 Implication of randomisation</h5> <section id="CD004161-sec-0234"> <h6 class="title">10.1.1 Global state: relapse</h6> <p>Both included studies for this outcome were rated as an 'unclear' risk of bias for randomisation and made mention that participants were randomised; however methods of randomisation were not fully described in either study (<a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a>; <a href="./references#CD004161-bbs2-0011" title="QuinnA , CamachoF , MitchellD , ChueP , MallaA . Open‐label randomized exploratory investigation of Risperdal* Consta* and oral antipsychotics treatment of early psychosis. Autumn Conference of the International Society for CNS Clinical Trials and Methodology, October 1‐3. Marina Del Rey, California, 2012. ">Quinn 2012*</a>). </p> </section> <section id="CD004161-sec-0235"> <h6 class="title">10.1.2 Mental state: average scores (PANSS)</h6> <p>Two studies that implied randomisation were removed from data and analysis (<a href="./references#CD004161-bbs2-0001" title="BaiYM , ChenTT , WuB , HungCH , LinWK , HuTM , et al. A comparative efficacy and safety study of long‐acting risperidone injection and risperidone oral tablets among hospitalized patients: 12‐week randomized, single‐blind study. Pharmacopsychiatry2006;39(4):135‐41. ">Bai 2006</a>; <a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a>); there was no significant difference in the estimate of effect after the removal of these studies. </p> </section> </section> <section id="CD004161-sec-0236"> <h5 class="title">10.2 Assumptions for lost binary data</h5> <section id="CD004161-sec-0237"> <h6 class="title">10.2.1 Global state: relapse</h6> <p>For our binary outcome of relapse, there was no significant difference in results when completer‐only data were compared with ITT data. </p> </section> </section> <section id="CD004161-sec-0238"> <h5 class="title">10.3 Risk of bias</h5> <p>All included studies were rated as a 'high' risk of bias across at least one domain; therefore there were no data left to compare for either outcome of relapse, or no clinically important change in mental state. </p> </section> <section id="CD004161-sec-0239"> <h5 class="title">10.4 Imputed values</h5> <p>We did not include any cluster‐randomised trials, and therefore no values were imputed for intra‐class correlation coefficients (ICC) for either relapse, or no clinically important change in mental state. </p> </section> <section id="CD004161-sec-0240"> <h5 class="title">10.5 Fixed‐effect and random‐effects</h5> <p>There was no difference in data when synthesised using a fixed‐effect model for both outcomes of relapse and no clinically important change in mental state. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004161-sec-0241" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004161-sec-0241"></div> <section id="CD004161-sec-0242"> <h3 class="title" id="CD004161-sec-0242">Summary of main results</h3> <section id="CD004161-sec-0243"> <h4 class="title">1. Risperidone depot versus placebo</h4> <section id="CD004161-sec-0244"> <h5 class="title">1.1 Relapse</h5> <p>No direct evidence exists regarding the risk of relapse for risperidone depot versus placebo. The closest available data relate to change in mental state, which is discussed below. </p> </section> <section id="CD004161-sec-0245"> <h5 class="title">1.2 Clinically significant improvement in mental state</h5> <p>Clinically significant improvement in the context of <a href="./references#CD004161-bbs2-0006" title="Anonymous . Injectible, long‐acting risperidone effective. Journal of Pharmacy Technology2001;4:157. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4‐8th May, Stockholm, Sweden)2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey)2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum; 2002 Jun 23‐27; Montreal, Canada)2002;5(Suppl 1):S188. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;53(3 Suppl.1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta (TM), a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cliag UK Ltd2002. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5‐9, 2002, Barcelona‐Spain2002;12(Supplement 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160(6):1125‐32. ">Kane 2002*</a> was defined as being a 20% improvement in total Positive and Negative Syndrome Scale (PANSS) score, but evidence pertaining to this cannot be used in this analysis as more than half of the data were assumed by the authors.To indirectly assess clinically significant changes in mental state, it may possible to look at the incidence of related adverse events; depot risperidone did result in significantly decreased reports of agitation and psychosis, the latter especially could be indicative of a clinical differences. Using adverse events from this study in this way is hampered by the fact that they were only recorded when spontaneously reported by a participant. </p> </section> <section id="CD004161-sec-0246"> <h5 class="title">1.3 Leaving the study early for any reason</h5> <p>Four hundred people were randomised and 370 participants had at least one injection and one post‐baseline assessment. There was no difference between depot risperidone and placebo group for the outcome of leaving the study before one injection (n = 400, RR 1.30 CI 0.55 to 3.08). Fifty‐six per cent of people did not complete the three‐month study (68% in the placebo group, 52% in the depot groups). The attrition rate was higher for those allocated placebo compared with people allocated risperidone depot. There did not seem to be any dose‐related effects, although when the reason for leaving was lack of efficacy, there seemed to be some differences. Higher doses of risperidone depot resulted in slightly less attrition. People randomised to the placebo were more likely to leave the study early than those in the depot risperidone group, and the level of attrition for any reason did not differ between the three doses of risperidone depot. The numbers of people leaving early due to lack of efficacy may be dose‐related; half as many people gave it as their reason in the 75 mg group compared to the 25 mg group. This suggests that there were people for whom higher doses of depot risperidone are required to produce a therapeutic effect. </p> </section> <section id="CD004161-sec-0247"> <h5 class="title">1.4 Severe adverse effects</h5> <p>Severe adverse events were common in <a href="./references#CD004161-bbs2-0006" title="Anonymous . Injectible, long‐acting risperidone effective. Journal of Pharmacy Technology2001;4:157. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4‐8th May, Stockholm, Sweden)2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey)2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum; 2002 Jun 23‐27; Montreal, Canada)2002;5(Suppl 1):S188. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;53(3 Suppl.1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta (TM), a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cliag UK Ltd2002. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5‐9, 2002, Barcelona‐Spain2002;12(Supplement 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160(6):1125‐32. ">Kane 2002*</a>, occurring in 13% to 23% of participants and significantly more often in the placebo group. The authors define a severe adverse event as anything that resulted in death or was life‐threatening, required hospitalisation or prolongation of hospitalisation, resulted in persistent or significant disability or incapacity, or resulted in congenital anomaly or birth defect. No details are given about specific severe adverse events that were reported in each group; this raises the serious possibility that very different events have been bundled together. This in turn could conceal evidence regarding important effects of using depot risperidone, but there is no way to tell with the data reported as they are. </p> </section> <section id="CD004161-sec-0248"> <h5 class="title">1.5 Adverse events related to movement disorder, weight gain, prolactin levels and glucose metabolism </h5> <p>Rates of movement disorder did not differ between depot risperidone and the placebo; the data did show a trend towards more extrapyramidal symptoms (EPS) with increasing doses of depot risperidone, but even at the 75 mg dose of risperidone, this fell short of statistical significance (<a href="./references#CD004161-fig-0013" title="">Analysis 1.10</a>). More studies, with larger sample sizes, would probably produce a significant result, but it is unlikely that such studies will ever be conducted. </p> <p>The number of participants experiencing weight gain did not differ between the interventions.</p> </section> </section> <section id="CD004161-sec-0249"> <h4 class="title">2. Risperidone depot versus general oral antipsychotics</h4> <section id="CD004161-sec-0250"> <h5 class="title">2.1 Relapse</h5> <p><a href="./references#CD004161-bbs2-0011" title="QuinnA , CamachoF , MitchellD , ChueP , MallaA . Open‐label randomized exploratory investigation of Risperdal* Consta* and oral antipsychotics treatment of early psychosis. Autumn Conference of the International Society for CNS Clinical Trials and Methodology, October 1‐3. Marina Del Rey, California, 2012. ">Quinn 2012*</a> found no significant difference in relapse rates between risperidone depot and general oral antipsychotics. </p> </section> <section id="CD004161-sec-0251"> <h5 class="title">2.2 Clinically significant improvement in mental state</h5> <p>Data relating directly to mental state (such as PANSS scores) are not useable due to the high levels of attrition in both <a href="./references#CD004161-bbs2-0011" title="QuinnA , CamachoF , MitchellD , ChueP , MallaA . Open‐label randomized exploratory investigation of Risperdal* Consta* and oral antipsychotics treatment of early psychosis. Autumn Conference of the International Society for CNS Clinical Trials and Methodology, October 1‐3. Marina Del Rey, California, 2012. ">Quinn 2012*</a> and <a href="./references#CD004161-bbs2-0012" title="BarnettPG , ScottJY , KrystalJH , RosenheckRA . Cost and cost‐effectiveness in a randomized trial of long‐acting risperidone for schizophrenia. Journal of Clinical Psychiatry2012;73:696‐702. RosenheckRA , KrystalJH , LewR , BarnettPG , FioreL , ValleyD , et al. Long‐ acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine March 3, 2011;364(9):842‐51. ">Rosenheck 2011</a>. Alternative outcomes that may give some indirect indication of the mental state of participants include the need for benzodiazapine or sedative drugs and the rate of hospitalisation. Neither of these outcomes differed significantly between the treatment groups. </p> </section> <section id="CD004161-sec-0252"> <h5 class="title">2.3 Leaving the study early for any reason</h5> <p>There was no significant difference in the overall rates of study attrition when comparing risperidone depot with general oral antipsychotics, however the general trend was towards risperidone depot group participants being more likely to leave, with the lower limit of the 95% confidence interval only just falling to the left of the line of no effect (<a href="./references#CD004161-fig-0026" title="">Analysis 2.6</a>). </p> </section> <section id="CD004161-sec-0253"> <h5 class="title">2.4 Severe adverse effects</h5> <p>Outcomes relating to severe adverse events were not available.</p> </section> <section id="CD004161-sec-0254"> <h5 class="title">2.5 Adverse events related to movement disorder, weight gain, prolactin levels and glucose metabolism </h5> <p>There was no difference between risperidone depot and general oral antipsychotics for adverse events related to weight gain, prolactin or glucose metabolism. "Nervous system disorders" were more likely to occur in those taking risperidone depot than those on oral treatment; it is unclear precisely what proportion of these events involved movement disorder. </p> </section> </section> <section id="CD004161-sec-0255"> <h4 class="title">3. Risperidone depot versus oral risperidone</h4> <section id="CD004161-sec-0256"> <h5 class="title">3.1 Relapse</h5> <p>Relapse was not an outcome addressed by any usable outcomes from these studies.</p> </section> <section id="CD004161-sec-0257"> <h5 class="title">3.2 Clinically significant improvement in mental state</h5> </section> <section id="CD004161-sec-0258"> <h5 class="title">3.3 Leaving the study early for any reason</h5> <p>Leaving the study early did not occur any more in one treatment arm over the other. The attrition rate in <a href="./references#CD004161-bbs2-0001" title="BaiYM , ChenTT , WuB , HungCH , LinWK , HuTM , et al. A comparative efficacy and safety study of long‐acting risperidone injection and risperidone oral tablets among hospitalized patients: 12‐week randomized, single‐blind study. Pharmacopsychiatry2006;39(4):135‐41. ">Bai 2006</a> was very low, with only one participant from the risperidone depot group and none from the oral group leaving early; this is probably due to its setting being an inpatient psychiatric unit, where the constant presence of various healthcare professionals would ensure that patients adhered to their prescribed medication. Attrition in <a href="./references#CD004161-bbs2-0002" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;3(Suppl 1):174. ChueP , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Promotional slides on file from Janssen‐Cliag UK Ltd2002. ">Chue 2002</a>, a study taking place in the community, was predictably higher. </p> </section> <section id="CD004161-sec-0259"> <h5 class="title">3.4 Severe adverse effects</h5> <p>No distinction was made between serious and general adverse events in either study.</p> </section> <section id="CD004161-sec-0260"> <h5 class="title">3.5 Adverse events related to movement disorder, weight gain, prolactin levels and glucose metabolism </h5> <p>There was no difference between depot and oral risperidone regarding the number experiencing any EPS, which occurred in 6.5% to 6.8% of all participants in <a href="./references#CD004161-bbs2-0002" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;3(Suppl 1):174. ChueP , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Promotional slides on file from Janssen‐Cliag UK Ltd2002. ">Chue 2002</a>. Tardive dyskinesia was reported four times in the depot group of <a href="./references#CD004161-bbs2-0002" title="ChueP , EerdekensM , AugustynsI , LachauxB , MolcanP , ErikssonL , et al. Efficacy and safety of long‐acting risperidone microspheres and risperidone oral tablets. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;3(Suppl 1):174. ChueP , et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS‐INT‐61. Promotional slides on file from Janssen‐Cliag UK Ltd2002. ">Chue 2002</a> and not at all in the oral group, but this was not quite enough to establish a statistical difference between the two. </p> <p>Prolactin‐related adverse events were rare, occurring in 1.2% to 2.5% of participants; with between zero and two people in each group experiencing each of: sexual dysfunction and impotence, galactorrhoea and dysmenorrhoea. The number of participants who experienced a significant amount of weight gain is not known, but there was a small mean increase of 0.5 kg in the depot group and 0.3 kg in the oral group. </p> </section> </section> <section id="CD004161-sec-0261"> <h4 class="title">4. Risperidone depot versus oral quetiapine</h4> <section id="CD004161-sec-0262"> <h5 class="title">4.1 Relapse</h5> <p>Time to relapse was measured as a primary outcome by <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>, but the high level of attrition in the study made most of the data unsuitable for inclusion in our analysis. One outcome that can be included is the number of participants leaving the study early for the specific reason of relapse; individuals in the oral quetiapine group were 46% more likely to leave the study due to relapse than the risperidone depot group. </p> </section> <section id="CD004161-sec-0263"> <h5 class="title">4.2 Clinically significant improvement in mental state</h5> <p>Outcomes relating to mental state suffer from the same high attrition rates that affect so many of the included studies. </p> </section> <section id="CD004161-sec-0264"> <h5 class="title">4.3 Leaving the study early for any reason</h5> <p>Participants in the oral quetiapine group were significantly more likely to leave the study early for any reason, </p> </section> <section id="CD004161-sec-0265"> <h5 class="title">4.4 Severe adverse effects</h5> <p>There was no difference between the two interventions for the rate at which severe adverse events were reported, and the overall rate of severe adverse events in <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a> appears broadly congruent with the other included studies. </p> </section> <section id="CD004161-sec-0266"> <h5 class="title">4.5 Adverse events related to movement disorder, weight gain, prolactin levels and glucose metabolism </h5> <p>Risperidone depot caused more EPS than oral quetiapine among the study population, with ˜10% of the risperidone group reporting any EPS symptom compared to 5.6% of the quetiapine group. The specific symptoms of tremor and "parkinsonism" were more common with risperidone depot. </p> <p>Similar numbers of people in both groups experienced weight gain through the study period, but the mean (SD) increase in weight appears to be greater for risperidone depot. </p> <p>Significantly more prolactin‐related problems occurred in those taking depot risperidone. The rate of hyperprolactinaemia was almost nine times greater than the quetiapine group, and risperidone group members were three times more likely to experience side effects related to prolactin. </p> </section> </section> <section id="CD004161-sec-0267"> <h4 class="title">5. Risperidone depot versus oral aripiprazole</h4> <section id="CD004161-sec-0268"> <h5 class="title">5.1 Relapse</h5> <p><a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a> showed no difference between the two interventions, with just under half of each group relapsing during the study period. These data cannot be compared directly to the relapse data from <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a> due to the attrition level of that study, but the number of individuals leaving the study early due to relapse in <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a> did trend towards favouring risperidone depot for relapse prevention, the very small size of the aripiprazole arm in this study prevents this outcome from reaching statistical significance. </p> </section> <section id="CD004161-sec-0269"> <h5 class="title">5.2 Clinically significant improvement in mental state</h5> <p>Data relating to PANSS responder rates were not available or usable for either study, but <a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a> reported that the overall change in PANSS total score through the study period was virtually the same for both groups, with a mean reduction of around 11 points. </p> </section> <section id="CD004161-sec-0270"> <h5 class="title">5.3 Leaving the study early for any reason</h5> <p>There was substantial heterogeneity relating to this outcome. Meta‐analysis shows no difference between risperidone depot and oral aripiprazole when leaving the study early for any reason, but the participants in each study differed markedly. Drop‐out rates in <a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a> were very similar (n = 349 RR 1.03 [0.74, 1.43]), with around 30% attrition overall, whereas in <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>, those in the aripiprazole group were significantly more likely to leave (n = 384 RR 0.70 [0.58, 0.84]), with 78% dropping out of that group. It is unclear what has contributed to this disparity. </p> </section> <section id="CD004161-sec-0271"> <h5 class="title">5.4 Severe adverse effects</h5> <p>Rates of serious adverse events were the same for both interventions.</p> </section> <section id="CD004161-sec-0272"> <h5 class="title">5.5 Adverse events related to movement disorder, weight gain, prolactin levels and glucose metabolism </h5> <p>Rates of movement disorder did not differ significantly overall between the risperidone depot and oral aripiprazole groups, but this probably does not tell the whole story. Risperidone depot was associated with movement disorder in a greater proportion of participants than aripiprazole in <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>, but the substantial disparity in the size of the two analysis sets prevents those results from achieving statistical significance (n = 384 RR 2.33 [0.58, 9.35]). There were also differences between the studies, with substantially more participants in both groups reporting movement disorder in <a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a>. It is not clear why this is so; whether it is due to methodological differences in the way such events were defined and the data collected, differences in the make up of the study population and their susceptibility to EPS effects or some other factors. </p> <p>Glucose‐related events were reported by 9% to 10% of those in <a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a>, with no difference between the groups. Weight gain was also broadly similar for both interventions, but prolactin‐related adverse events were much more common with risperidone depot and there were no incidences of hyperprolactinaemia with aripiprazole </p> </section> </section> <section id="CD004161-sec-0273"> <h4 class="title">6. Risperidone depot versus oral olanzapine</h4> <section id="CD004161-sec-0274"> <h5 class="title">6.1 Relapse</h5> <p>The only study comparing risperidone depot to oral olanzapine (<a href="./references#CD004161-bbs2-0007" title="KeksN , InghamM , KhanA , KarcherK . Long‐acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open‐label study. British Journal of Psychiatry2007;191:131‐9. KeksN , KhanA , AugustynsI , RabinowitzJ , InghamM . Non‐inferiority efficacy trial of risperidone long‐acting injection (RLAI) vs. olanzapine tablets (OLA). Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006. ">Keks 2007</a>) did not include relapse as an outcome. </p> </section> <section id="CD004161-sec-0275"> <h5 class="title">6.2 Clinically significant improvement in mental state</h5> <p>There is some discrepancy between the stated levels of study attrition (i.e. the completion rate) and the number of participants for whom outcome data are available up to the end of the study period. For depot risperidone, average endpoint PANSS scores are provided for 155 participants, with last observation carried forwards (LOCF) analysis used. However, the number of participants for whom the mean PANSS score change at 12 months (the end of the study) is given was only 116. We are not certain how the difference between the number of participants who completed the study from this group (n = 160) and the number for whom data are available at 12 months (n = 116) can be so great. </p> </section> <section id="CD004161-sec-0276"> <h5 class="title">6.3 Leaving the study early for any reason</h5> <p>Participants taking risperidone depot had a significantly increased risk of leaving the study early; about half of the risperidone depot group compared to a third of the olanzapine arm. Much of this difference can be explained by the decision of the investigators to alter the protocol and exclude the 75 mg risperidone depot group after randomisation had taken place, resulting in 66 participants being excluded from the main analysis. If this is taken into account, the rates of participants leaving the study for other reasons, such as insufficient response, are similar for each intervention. </p> </section> <section id="CD004161-sec-0277"> <h5 class="title">6.4 Severe adverse effects</h5> <p>Severe adverse events were reported at similar rates for both interventions, but what made a particular adverse event "severe" is not explained. Adverse events such as anxiety are reported as both general and severe adverse events Presumably the investigators in <a href="./references#CD004161-bbs2-0007" title="KeksN , InghamM , KhanA , KarcherK . Long‐acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open‐label study. British Journal of Psychiatry2007;191:131‐9. KeksN , KhanA , AugustynsI , RabinowitzJ , InghamM . Non‐inferiority efficacy trial of risperidone long‐acting injection (RLAI) vs. olanzapine tablets (OLA). Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006. ">Keks 2007</a> had some criteria to differentiate severe adverse events, but these are not explained. </p> </section> <section id="CD004161-sec-0278"> <h5 class="title">6.5 Adverse events related to movement disorder, weight gain, prolactin levels and glucose metabolism </h5> <p>Movement disorder was a common adverse event in both groups, but was significantly more common in those receiving risperidone depot, with around 25% experiencing it to some degree, compared to 15% of the olanzapine group. Perhaps unsurprisingly, the usage of anti‐parkinsonian medications was greater in the depot risperidone group as well. Reporting of EPS was not clear in this study; the overall percentage of participants experiencing EPS was given, but it is difficult to see how these data correspond to those in a table which breaks down EPS into separate symptoms, e.g. hyperkinesia, tardive dyskinesia, tremor, etc. In particular, "Extrapyramidal disorder" is listed as a specific outcome in this table, but was apparently only reported by 8% of the risperidone depot group and 4% of the olanzapine group. There is no way to discern precisely what this item encompasses, nor what differentiates it from the overall rate of EPS. We have contacted the study authors for clarification on this point, but have yet to receive a response. </p> <p>Olanzapine caused significantly more weight gain than risperidone depot in the study population; more than 1/3 of participants taking olanzapine are reported to have experienced weight gain greater than 7% of their bodyweight (mean weight gain overall of 4.0 kg), compared to a 1/5 of the risperidone group (mean increase of 1.7 kg overall). </p> <p>Prolactin‐related adverse events were rare and did not differ between the interventions; there were two instances of impotence or ejaculation failure in each arm, and similarly low levels of galactorrhoea. One new diagnosis of diabetes mellitus was made in each group during the study period. </p> </section> </section> <section id="CD004161-sec-0279"> <h4 class="title">7. Risperidone depot versus all oral antipsychotics (primary outcomes)</h4> <section id="CD004161-sec-0280"> <h5 class="title">7.1 Relapse</h5> <p>Data from the three trials (<a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a>, <a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a>, <a href="./references#CD004161-bbs2-0011" title="QuinnA , CamachoF , MitchellD , ChueP , MallaA . Open‐label randomized exploratory investigation of Risperdal* Consta* and oral antipsychotics treatment of early psychosis. Autumn Conference of the International Society for CNS Clinical Trials and Methodology, October 1‐3. Marina Del Rey, California, 2012. ">Quinn 2012*</a>) that measured relapse directly suggest that it occurs at the same rate when depot risperidone treatment is compared to aripiprazole or a variety of second‐generation antipsychotics. When compared to quetiapine, however, depot risperidone treatment leads to only half as many cases of relapse. The precise methods used to define this outcome vary between <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a> and <a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a>, but they are similar enough in appearance (factors such as hospitalisation, PANSS and CGI change being common between the two) that we can be confident they are measuring the same thing. <a href="./references#CD004161-bbs2-0011" title="QuinnA , CamachoF , MitchellD , ChueP , MallaA . Open‐label randomized exploratory investigation of Risperdal* Consta* and oral antipsychotics treatment of early psychosis. Autumn Conference of the International Society for CNS Clinical Trials and Methodology, October 1‐3. Marina Del Rey, California, 2012. ">Quinn 2012*</a> is more problematic, as no definition of relapse is given; such methodological details are probably too much to be asking of a single poster and an abstract, but if a full report becomes available it will be important to confirm this. </p> <p>The quality of some of this evidence is also questionable; <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a> and <a href="./references#CD004161-bbs2-0011" title="QuinnA , CamachoF , MitchellD , ChueP , MallaA . Open‐label randomized exploratory investigation of Risperdal* Consta* and oral antipsychotics treatment of early psychosis. Autumn Conference of the International Society for CNS Clinical Trials and Methodology, October 1‐3. Marina Del Rey, California, 2012. ">Quinn 2012*</a> in particular had a high risk of bias due to their nature as open‐label studies with no evidence of rater blinding. One perhaps very serious methodological weakness of <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a> that may have had an impact on the effect size reported was that follow‐up methods differed between intervention groups. Depot risperidone participants attended physical appointments to receive their medication and undergo assessment of certain outcomes every two weeks, whereas those in the oral quetiapine and aripiprazole groups received phone calls for the same purpose. The depot group participants therefore spent more time with healthcare professionals during the course of the study; even if the exact same questions were asked at in‐person and telephone check‐ups, seeing a patient in the flesh may have made it easier to detect clinical deterioration and adjust doses of concomitant medications and the study drug before a slight deterioration has time to snowball into a full relapse. </p> <p>The regular attention that comes with being prescribed depot rather than oral antipsychotics may be an important aspect of the intervention, but in a randomised clinical trial (RCT) of two drugs there is a case for limiting potential confounders so that the only effect measured is that of the drugs, not that of the drugs plus the intensity of care provided. More studies are needed that address the issue of relapse directly; a RCT comparing relapse and hospitalisation rates between depot and oral risperidone is of particular importance. Using only the currently available evidence comparing depot risperidone with oral quetiapine, it is not possible to tell whether the significant difference in relapse rates is due mainly to the difference in administration methods or due to the different pharmacological properties of risperidone and quetiapine. If oral risperidone is as effective as the depot preparation at preventing relapse, then economic considerations may take on greater importance in prescribing decisions. </p> </section> <section id="CD004161-sec-0281"> <h5 class="title">7.2 Clinically significant improvement in mental state</h5> <p>No comparisons with usable data from these studies give any direct indication as to how many participants achieved clinically significant improvements in mental state, but data regarding average mental state scores are available. Risperidone depot is not significantly different from oral risperidone, olanzapine or aripiprazole in its effect on mental state, as measured through all domains of PANSS, with the average scores for participants in all study arms either improving or remaining largely the same (<a href="./references#CD004161-fig-0067" title="">Analysis 7.2</a>). </p> </section> <section id="CD004161-sec-0282"> <h5 class="title">7.3 Leaving the study early for any reason</h5> <p>People randomised to risperidone depot were as likely to leave the study early as those assigned to aripiprazole (n = 723, RR 0.83, 95% CI 0.53 to 1.30), oral risperidone (n = 690, RR 1.28, 95% CI 0.92 to 1.79), or any oral antipsychotic (n = 382, RR 1.25, 95% CI 0.93 to 1.68). Compared to oral quetiapine and any new‐generation oral antipsychotic, participants in the risperidone depot group were significantly less likely to leave the study early (n = 666, RR 0.84, 95% CI 0.74 to 0.95 and n = 77, RR 0.72, 95% CI 0.55 to 0.95, respectively), and significantly more likely to drop out than participants randomised to olanzapine (n = 618, RR 1.32, 95% CI 1.10 to 1.58). </p> </section> <section id="CD004161-sec-0283"> <h5 class="title">7.4 Severe adverse effects</h5> <p>There is great inconsistency in the reporting of serious adverse effects amongst these studies, which makes any comparisons problematic. When severe effects were reported there were no differences in the rates at which they occurred when comparing depot risperidone to quetiapine, aripiprazole or olanzapine. It is not clear, though, whether the outcome of severe adverse effects if comparable between these studies; of the three trials, none provide a definition of what they consider to be a serious adverse event and the reporting of the specific events is often very vague. <a href="./references#CD004161-bbs2-0007" title="KeksN , InghamM , KhanA , KarcherK . Long‐acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open‐label study. British Journal of Psychiatry2007;191:131‐9. KeksN , KhanA , AugustynsI , RabinowitzJ , InghamM . Non‐inferiority efficacy trial of risperidone long‐acting injection (RLAI) vs. olanzapine tablets (OLA). Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006. ">Keks 2007</a> is the only study to explicitly list the severe adverse events that were reported by more than 2% of either group; of the other two studies, <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a> only gives an overall rate and the rate of the most common serious adverse events (psychiatric symptoms), while <a href="./references#CD004161-bbs2-0009" title="MacFaddenW , Yi‐WenM , HaskinsJT , BossieCA , AlphsL . A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry2010;7(11):23‐31. ">MacFadden 2010</a> states that psychotic disorder and schizophrenia were the most common serious adverse events but gives no details on their precise incidence. </p> <p>With severe adverse events reported in such a scattergun manner throughout these trials, it is impossible to perceive any trends or patterns of severe adverse events emerging for any of the interventions. A rare, but serious, side effect (or side effects) may occur consistently at a rate below the reporting threshold yet remain unreported in the literature. </p> </section> <section id="CD004161-sec-0284"> <h5 class="title">7.5 Economic costs of treatment</h5> <p>An analysis of Medical Resource Utilisation (MRU) using a small subset of relapsed participants from <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a> determined that each individual cost their country's health service an average of €7592 in the three months following their relapse and that this figure was €1525 higher in people who required psychiatric hospitalisation during this time. </p> <p>Drawing too many conclusions from these data are dangerous; this analysis is available only as a single abstract. As such, details on the methods used to produce these figures are sparse; of particular concern is that fact that <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a> was spread out over 124 centres in 25 European countries. It is quite conceivable that there is significant heterogeneity in the health services of these countries that may affect how and where money is spent. The full version of the paper may be able to address this, but until then it is unclear exactly how applicable this evidence is. </p> <p>Despite this, it is still clear that relapse, especially if it involves hospitalisation, is expensive. Using administrative data from the Veterans Administration (VA), the researchers in <a href="./references#CD004161-bbs2-0012" title="BarnettPG , ScottJY , KrystalJH , RosenheckRA . Cost and cost‐effectiveness in a randomized trial of long‐acting risperidone for schizophrenia. Journal of Clinical Psychiatry2012;73:696‐702. RosenheckRA , KrystalJH , LewR , BarnettPG , FioreL , ValleyD , et al. Long‐ acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine March 3, 2011;364(9):842‐51. ">Rosenheck 2011</a> were able to determine the mean (SD) cost of in‐ and out‐patient care, as well as medication costs, in each treatment group per quarter (three months) of follow‐up). They found that the overall costs relating to service use for each group were similar, a result that seems congruent with the finding that there was no difference between groups in levels of post‐randomisation hospitalisation or out‐patient care. Medication costs, however, were substantially higher for depot risperidone. The study drug itself cost more than the control group's medication, but further to this, depot group participants also received nearly $500 of extra oral antipsychotics. They also required $357 more in concomitant medications, leading to approximately $1000 more per quarter being spent on each patient with no quantifiable difference in outcomes. </p> <p>Based solely on these data, it is not possible to claim that depot risperidone is a cost‐effective treatment option for schizophrenia. Generalising these results specifically in terms of absolute amounts spent may be an issue; the study they are based on was of a 90% male population of military veterans with unstable schizophrenia, whose needs could differ substantially from patients in other situations. There is also a reasonable risk that the unblinded nature of follow‐up could have lead to clinical decisions (e.g. whether to hospitalise) being made differently depending on the intervention a person was using, leading to performance bias. However, the data regarding the price of depot risperidone compared to oral treatment are important. </p> <p>In the future, we plan to undertake full economic analysis to complement the above findings. </p> </section> </section> <section id="CD004161-sec-0285"> <h4 class="title">8. Risperidone depot versus atypical depot antipsychotics (paliperidone palmitate (PP)) </h4> <section id="CD004161-sec-0286"> <h5 class="title">8.1 Relapse</h5> <p>As with placebo, there is no direct evidence regarding relapse for this comparison.</p> </section> <section id="CD004161-sec-0287"> <h5 class="title">8.2 Clinically significant improvement in mental state</h5> <p>A clinically significant difference in mental state was considered to be a 30% or greater reduction in total PANSS score by the three studies. For <a href="./references#CD004161-bbs2-0004" title="FleischhackerWW , GopalS , LaneR , Gassmann‐Mayer , LimP , HoughD , et al. A randomized trial of paliperidone palmitate and risperidone long acting injectable in schizophrenia. International Journal of Neuropsychopharmacology2012;15:107‐18. ">Fleischhacker 2011</a>, however, the high level of overall study attrition (55% did not complete) combined with the use of LOCF data means that more than half of the data used to determine this outcome was based on assumptions. Synthesis of the data from <a href="./references#CD004161-bbs2-0008" title="LiH , RuiQ , NingX , XuH , GuN . A comparative study of paliperidone palmitate and risperidone long‐acting injectable therapy in schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:1002‐8. ">Li 2011</a> and <a href="./references#CD004161-bbs2-0010" title="PandinaG , LaneR , Gassmann‐MayerC , HoughD , RemmerieB , SimpsonG . A randomised double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Proceedings of the 27th International College of Neuropsychopharmacology Congress; 2010 June 6‐10; Hong Kong. 2010. PandinaG , LaneR , GopalS , Gassman‐MayerC , HoughD , RemmerieB , et al. A randomized double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Biological Psychiatry2010;67(9):77‐8. PandinaG , LaneR , GopalS , Gassmann‐MayerC , HoughD , RemmerieB , et al. A double‐blind study of paliperidone palmitate and risperidone long‐acting injectable in adults with schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:218‐26. ">Pandina 2011</a> shows there is no difference between depot risperidone and paliperidone palmitate for the number of PANSS responders, though <a href="./references#CD004161-bbs2-0008" title="LiH , RuiQ , NingX , XuH , GuN . A comparative study of paliperidone palmitate and risperidone long‐acting injectable therapy in schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:1002‐8. ">Li 2011</a> did report a greater improvement in total PANSS (RR 3.30 CI 0.24 to 6.36) and positive symptom (P = 0.01, RR 1.80 CI 0.42 to 3.18, <a href="./references#CD004161-fig-0076" title="">Analysis 8.4</a>) scores for those receiving PP. </p> <p>The PANSS responder rates reported by the two studies demonstrate a significant level of heterogeneity, with around 50% of participants in <a href="./references#CD004161-bbs2-0010" title="PandinaG , LaneR , Gassmann‐MayerC , HoughD , RemmerieB , SimpsonG . A randomised double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Proceedings of the 27th International College of Neuropsychopharmacology Congress; 2010 June 6‐10; Hong Kong. 2010. PandinaG , LaneR , GopalS , Gassman‐MayerC , HoughD , RemmerieB , et al. A randomized double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Biological Psychiatry2010;67(9):77‐8. PandinaG , LaneR , GopalS , Gassmann‐MayerC , HoughD , RemmerieB , et al. A double‐blind study of paliperidone palmitate and risperidone long‐acting injectable in adults with schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:218‐26. ">Pandina 2011</a> compared to 70% to 78% in <a href="./references#CD004161-bbs2-0008" title="LiH , RuiQ , NingX , XuH , GuN . A comparative study of paliperidone palmitate and risperidone long‐acting injectable therapy in schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:1002‐8. ">Li 2011</a>, and it is not immediately apparent what has caused this difference. Their respective designs are very similar, with common treatment period duration, the same range of doses used for each intervention and the average final dose for each treatment was also similar (the mean (SD) final PP dose was 104.5 (30.51) mg eq in <a href="./references#CD004161-bbs2-0010" title="PandinaG , LaneR , Gassmann‐MayerC , HoughD , RemmerieB , SimpsonG . A randomised double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Proceedings of the 27th International College of Neuropsychopharmacology Congress; 2010 June 6‐10; Hong Kong. 2010. PandinaG , LaneR , GopalS , Gassman‐MayerC , HoughD , RemmerieB , et al. A randomized double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Biological Psychiatry2010;67(9):77‐8. PandinaG , LaneR , GopalS , Gassmann‐MayerC , HoughD , RemmerieB , et al. A double‐blind study of paliperidone palmitate and risperidone long‐acting injectable in adults with schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:218‐26. ">Pandina 2011</a> and 115.8 (9.07) mg eq in <a href="./references#CD004161-bbs2-0008" title="LiH , RuiQ , NingX , XuH , GuN . A comparative study of paliperidone palmitate and risperidone long‐acting injectable therapy in schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:1002‐8. ">Li 2011</a>, but this difference can probably be accounted for by the analysis set used to determine these figures. <a href="./references#CD004161-bbs2-0008" title="LiH , RuiQ , NingX , XuH , GuN . A comparative study of paliperidone palmitate and risperidone long‐acting injectable therapy in schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:1002‐8. ">Li 2011</a> gave the mean for the per protocol analysis set, while <a href="./references#CD004161-bbs2-0010" title="PandinaG , LaneR , Gassmann‐MayerC , HoughD , RemmerieB , SimpsonG . A randomised double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Proceedings of the 27th International College of Neuropsychopharmacology Congress; 2010 June 6‐10; Hong Kong. 2010. PandinaG , LaneR , GopalS , Gassman‐MayerC , HoughD , RemmerieB , et al. A randomized double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Biological Psychiatry2010;67(9):77‐8. PandinaG , LaneR , GopalS , Gassmann‐MayerC , HoughD , RemmerieB , et al. A double‐blind study of paliperidone palmitate and risperidone long‐acting injectable in adults with schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:218‐26. ">Pandina 2011</a> gave it for the safety analysis set, which includes participants who left the study after only one dose who therefore would not have been titrated onto the higher doses yet). The two important differences are probably blinding and sample size; <a href="./references#CD004161-bbs2-0008" title="LiH , RuiQ , NingX , XuH , GuN . A comparative study of paliperidone palmitate and risperidone long‐acting injectable therapy in schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:1002‐8. ">Li 2011</a> randomised 452 people and was open‐label, whereas <a href="./references#CD004161-bbs2-0010" title="PandinaG , LaneR , Gassmann‐MayerC , HoughD , RemmerieB , SimpsonG . A randomised double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Proceedings of the 27th International College of Neuropsychopharmacology Congress; 2010 June 6‐10; Hong Kong. 2010. PandinaG , LaneR , GopalS , Gassman‐MayerC , HoughD , RemmerieB , et al. A randomized double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Biological Psychiatry2010;67(9):77‐8. PandinaG , LaneR , GopalS , Gassmann‐MayerC , HoughD , RemmerieB , et al. A double‐blind study of paliperidone palmitate and risperidone long‐acting injectable in adults with schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:218‐26. ">Pandina 2011</a> had more than double the study population (n = 1220) and utilised a double‐blind approach. </p> </section> <section id="CD004161-sec-0288"> <h5 class="title">8.3 Leaving the study early for any reason</h5> <p>Participants assigned to depot risperidone were overall less likely to leave the study early for any reason, but it is difficult to reason exactly why that is. It could be related to efficacy; data from mental and global state outcomes show that depot risperidone and PP are essentially equivalent in their effects, yet there was a (not quite statistically significant) trend towards PP group participants being more likely to cite lack of efficacy when leaving the study. As PP is a newer drug (albeit a derivative of risperidone), it is conceivable that the dosing guidelines are less well supported, or that people taking PP were less likely to be dosed appropriately than those allocated to depot risperidone. </p> </section> <section id="CD004161-sec-0289"> <h5 class="title">8.4 Severe adverse effects</h5> <p>Serious adverse events occurred at the same rate for depot risperidone and paliperidone palmitate, being reported by 10% to 13% of participants in all three studies. If the two‐year long trial (<a href="./references#CD004161-bbs2-0004" title="FleischhackerWW , GopalS , LaneR , Gassmann‐Mayer , LimP , HoughD , et al. A randomized trial of paliperidone palmitate and risperidone long acting injectable in schizophrenia. International Journal of Neuropsychopharmacology2012;15:107‐18. ">Fleischhacker 2011</a>) is excluded from this analysis to leave only the shorter follow‐up studies, the rate of serious adverse events goes down to below 5%, which suggests that serious adverse events may be more likely to occur after being on either of the study drugs for a prolonged period. <a href="./references#CD004161-bbs2-0004" title="FleischhackerWW , GopalS , LaneR , Gassmann‐Mayer , LimP , HoughD , et al. A randomized trial of paliperidone palmitate and risperidone long acting injectable in schizophrenia. International Journal of Neuropsychopharmacology2012;15:107‐18. ">Fleischhacker 2011</a> also featured significantly more severe adverse events in the paliperidone palmitate group. </p> <p>Differences in study design other than the length of follow‐up are unlikely to account for the excess severe adverse events as all three studies shall very similar methodology, with the exception that <a href="./references#CD004161-bbs2-0004" title="FleischhackerWW , GopalS , LaneR , Gassmann‐Mayer , LimP , HoughD , et al. A randomized trial of paliperidone palmitate and risperidone long acting injectable in schizophrenia. International Journal of Neuropsychopharmacology2012;15:107‐18. ">Fleischhacker 2011</a> &amp; <a href="./references#CD004161-bbs2-0010" title="PandinaG , LaneR , Gassmann‐MayerC , HoughD , RemmerieB , SimpsonG . A randomised double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Proceedings of the 27th International College of Neuropsychopharmacology Congress; 2010 June 6‐10; Hong Kong. 2010. PandinaG , LaneR , GopalS , Gassman‐MayerC , HoughD , RemmerieB , et al. A randomized double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Biological Psychiatry2010;67(9):77‐8. PandinaG , LaneR , GopalS , Gassmann‐MayerC , HoughD , RemmerieB , et al. A double‐blind study of paliperidone palmitate and risperidone long‐acting injectable in adults with schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:218‐26. ">Pandina 2011</a> are double‐blind studies, while <a href="./references#CD004161-bbs2-0008" title="LiH , RuiQ , NingX , XuH , GuN . A comparative study of paliperidone palmitate and risperidone long‐acting injectable therapy in schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:1002‐8. ">Li 2011</a> is open‐label. This finding is important because most people who are prescribed antipsychotics for schizophrenia are presumably expecting to take them for more than 13 weeks, so the short‐term studies might not present an accurate representation of the risk. </p> <p><a href="./references#CD004161-bbs2-0004" title="FleischhackerWW , GopalS , LaneR , Gassmann‐Mayer , LimP , HoughD , et al. A randomized trial of paliperidone palmitate and risperidone long acting injectable in schizophrenia. International Journal of Neuropsychopharmacology2012;15:107‐18. ">Fleischhacker 2011</a> also raises the possibility that while the two drugs may be similar in the short term, over time, the risk of serious adverse effects may be greater for PP; more long‐term studies of depot risperidone and paliperidone palmitate are needed to assess this. </p> <section id="CD004161-sec-0290"> <h6 class="title">8.4.1 Adverse events related to movement disorder, weight gain, prolactin levels and glucose metabolism </h6> <p><a href="./references#CD004161-bbs2-0007" title="KeksN , InghamM , KhanA , KarcherK . Long‐acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open‐label study. British Journal of Psychiatry2007;191:131‐9. KeksN , KhanA , AugustynsI , RabinowitzJ , InghamM . Non‐inferiority efficacy trial of risperidone long‐acting injection (RLAI) vs. olanzapine tablets (OLA). Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006. ">Keks 2007</a> has very strange analysis sets </p> </section> </section> <section id="CD004161-sec-0291"> <h5 class="title">8.5 Economic costs of treatment</h5> <p>Cost or cost‐effectiveness outcomes are not included in any of the three studies comparing depot risperidone versus paliperidone palmitate. </p> </section> </section> <section id="CD004161-sec-0292"> <h4 class="title">9. Risperidone depot versus typical depot antipsychotics</h4> <section id="CD004161-sec-0293"> <h5 class="title">9.1 Relapse</h5> <p><a href="./references#CD004161-bbs2-0003" title="CovellNH , McEvoyJP , SchoolerNR , StroupTS , JacksonCT , RojasIA , et al. Effectiveness of switching from long‐acting injectable fluphenazine or haloperidol decanoate to long‐acting injectable risperidone microspheres: an open‐label, randomized control trial. Journal of Clinical Psychiatry2012;73(5):669‐75. ">Covell 2012</a> did not directly assess rates of relapse for this comparison, but if we use rates of hospitalisation as a proxy for this outcome there was no difference between risperidone depot and typical depots (n = 62, <a href="./references#CD004161-bbs2-0003" title="CovellNH , McEvoyJP , SchoolerNR , StroupTS , JacksonCT , RojasIA , et al. Effectiveness of switching from long‐acting injectable fluphenazine or haloperidol decanoate to long‐acting injectable risperidone microspheres: an open‐label, randomized control trial. Journal of Clinical Psychiatry2012;73(5):669‐75. ">Covell 2012</a>, <a href="./references#CD004161-fig-0089" title="">Analysis 9.3</a>). </p> </section> <section id="CD004161-sec-0294"> <h5 class="title">9.2 Clinically significant improvement in mental state</h5> <p>The single study making this comparison (<a href="./references#CD004161-bbs2-0003" title="CovellNH , McEvoyJP , SchoolerNR , StroupTS , JacksonCT , RojasIA , et al. Effectiveness of switching from long‐acting injectable fluphenazine or haloperidol decanoate to long‐acting injectable risperidone microspheres: an open‐label, randomized control trial. Journal of Clinical Psychiatry2012;73(5):669‐75. ">Covell 2012</a>) did not provide details of the number of participants making a clinically significant improvement while on the study drugs, instead providing average PANNS total scores for each treatment arm at short‐, medium‐ and long‐term (for this study) follow‐up. These data showed no difference between the two groups at any point, but it is not possible to say anything about how many participants experienced a significant change in their mental state. As the study population were all initially being treated with typical depot antipsychotics, it is unlikely that much by way of clinically significant change took place. </p> </section> <section id="CD004161-sec-0295"> <h5 class="title">9.3 Leaving the study early for any reason</h5> <p>Participants randomised to receive depot risperidone were more likely to leave the study, both before commencement of their assigned treatment (RR 7.50 95 CI 1.00 to 56.44) and by six months (RR 3.05 95% CI 1.12 to 8.31, <a href="./references#CD004161-fig-0088" title="">Analysis 9.2</a>). As the researchers themselves noted, this can probably be explained by the study design; being randomised to risperidone depot came with a requirement to switch their medication, whereas those in the typical depot group were allowed to stay on the antipsychotics they had already been taking. It is understandable that some people would not feel comfortable switching and would therefore leave the study early, but it is not possible to differentiate these individuals from those who left for other reasons. </p> </section> <section id="CD004161-sec-0296"> <h5 class="title">9.4 Serious adverse effects</h5> <p>Data relating to serious adverse effects are not available for <a href="./references#CD004161-bbs2-0003" title="CovellNH , McEvoyJP , SchoolerNR , StroupTS , JacksonCT , RojasIA , et al. Effectiveness of switching from long‐acting injectable fluphenazine or haloperidol decanoate to long‐acting injectable risperidone microspheres: an open‐label, randomized control trial. Journal of Clinical Psychiatry2012;73(5):669‐75. ">Covell 2012</a>. The adverse effects data that were collected are skewed, and in accordance with our methodology, cannot be included in the analysis. </p> </section> <section id="CD004161-sec-0297"> <h5 class="title">9.5 Economic costs of treatment</h5> <p>There are no studies addressing the economic costs associated with risperidone depot compared to typical depot antipsychotics. </p> </section> </section> </section> <section id="CD004161-sec-0298"> <h3 class="title" id="CD004161-sec-0298">Overall completeness and applicability of evidence</h3> <p>Naturalistic protocols more closely resemble real‐life clinical practice, but very high attrition in some of these makes the results less useful. </p> <p>The applicability of the evidence in this review to real‐life practice may be somewhat hindered by the nature of the participants recruited to the included studies, more specifically the question of whether or not they really reflect the types of patients in the real world who would most benefit from taking depot antipsychotics over oral preparations. </p> <p>Depot antipsychotics are intended for people that do not want, or are unable, to take daily oral drugs. If an individual has enough stability and insight in their day to day life to adhere to an oral regimen, then they probably would not gain any greater freedom from their symptoms through a depot. In the real world, depots are prescribed for patients for whom the severity of their illness prevents this level of stability and control, and who may benefit from having their medication delivered consistently in a manner that is "out of their hands", so to speak. The people recruited to most, if not all, of these studies did not appear to be that ill, with baseline PANSS total scores consistently in the 60 to 80 range and recruitment criteria that excluded those with substance abuse problems, a history of violent or suicidal behaviour or comorbid psychiatric problems. The results can only really speak for the effects of risperidone depot on patients for whom receiving their medication as bi‐weekly injections or daily oral preparations may make very little difference to the amount of drug delivered to their system. </p> </section> <section id="CD004161-sec-0299"> <h3 class="title" id="CD004161-sec-0299">Quality of the evidence</h3> <p><a href="./references#CD004161-bbs2-0006" title="Anonymous . Injectible, long‐acting risperidone effective. Journal of Pharmacy Technology2001;4:157. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4‐8th May, Stockholm, Sweden)2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey)2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum; 2002 Jun 23‐27; Montreal, Canada)2002;5(Suppl 1):S188. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;53(3 Suppl.1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta (TM), a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cliag UK Ltd2002. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5‐9, 2002, Barcelona‐Spain2002;12(Supplement 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160(6):1125‐32. ">Kane 2002*</a> features a very high level of attrition from the study, almost 70% in the placebo group and just over 50% in the active treatment group. The consequence of this is that the authors conclusion, that depot risperidone is significantly more efficacious than placebo for improving the symptoms of schizophrenia, is based mainly on assumptions. Using the evidence from this study alone, there is nothing to support the idea that depot risperidone is any better than placebo. Yet despite the problems with this study, which was included in the previously published version of this review (<a href="./references#CD004161-bbs2-0101" title="HosalliP , DavisJM . Depot risperidone for schizophrenia. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD004161; PUBMED: 14584007] ">Hosalli 2003</a>), a decade later it is still the only randomised controlled trial that compares depot risperidone versus placebo. While the other results in this review demonstrate that depot risperidone is very likely as effective as other antipsychotics, it is worrying that these trials all took place in an environment where the superiority of depot risperidone was taken as read. </p> <p>Adverse event reporting was inconsistent amongst the included studies; specifically there was no evidence that the criteria used to define "serious adverse events/effects" were the same from study to study. This makes it difficult to compare these outcomes between studies to produce generalisable results. </p> <p>Open‐label study designs are associated with a high risk of performance bias; whereby the participants' knowledge of which intervention they are receiving affects their response to it. Most of the studies in this review utilised this design, resulting in widespread risk of bias that may downgrade the quality of the evidence. </p> </section> <section id="CD004161-sec-0300"> <h3 class="title" id="CD004161-sec-0300">Potential biases in the review process</h3> <p>The review protocol and process of study selection were strictly adhered to throughout the entire review process, and the process for searching for studies was thorough and data were extracted independently. We contacted authors of included studies to obtain details of ongoing or unpublished studies, but there remains a possibility that other unpublished trials of the intervention exist for which the review authors do not currently have access. </p> </section> <section id="CD004161-sec-0301"> <h3 class="title" id="CD004161-sec-0301">Agreements and disagreements with other studies or reviews</h3> <p>To the authors' knowledge, this is the first systematic review to comprehensively meta‐analyse RCTs relating to risperidone depot for schizophrenia. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004161-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram: 2010 and 2012, 2015 updated search" data-id="CD004161-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram: 2010 and 2012, 2015 updated search</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/full#CD004161-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD004161-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/full#CD004161-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD004161-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/full#CD004161-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 1 Mental state: 1. Change (exacerbation) in specific symptoms." data-id="CD004161-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 1 Mental state: 1. Change (exacerbation) in specific symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 2 Leaving the study early: 1. Any reason (by time period)." data-id="CD004161-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 2 Leaving the study early: 1. Any reason (by time period). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 3 Leaving the study early: 2. Any reason (by doses)." data-id="CD004161-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 3 Leaving the study early: 2. Any reason (by doses). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 4 Leaving the study early: 3. Because of insufficient response (by doses)." data-id="CD004161-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 4 Leaving the study early: 3. Because of insufficient response (by doses). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 5 Adverse events: 1. General: a. Death." data-id="CD004161-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 5 Adverse events: 1. General: a. Death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 6 Adverse events: 1. General: b. Severe adverse event (by doses)." data-id="CD004161-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 6 Adverse events: 1. General: b. Severe adverse event (by doses). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 7 Adverse events: 1. General: c. Adverse event necessitating withdrawal from study (by doses)." data-id="CD004161-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 7 Adverse events: 1. General: c. Adverse event necessitating withdrawal from study (by doses). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 8 Adverse events: 2. Specific: a. Cardiovascular." data-id="CD004161-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 8 Adverse events: 2. Specific: a. Cardiovascular. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 9 Adverse events: 2. Specific: b. Gastrointestinal." data-id="CD004161-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 9 Adverse events: 2. Specific: b. Gastrointestinal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 10 Adverse events: 2. Specific: c. Movement disorders: a. Extrapyramidal disorder ‐ spontaneously reported (by doses)." data-id="CD004161-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 10 Adverse events: 2. Specific: c. Movement disorders: a. Extrapyramidal disorder ‐ spontaneously reported (by doses). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 11 Adverse events: 2. Specific: d. Movement disorders: b. Hyperkinesia (by doses)." data-id="CD004161-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 11 Adverse events: 2. Specific: d. Movement disorders: b. Hyperkinesia (by doses). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 12 Adverse events: 2. Specific: e. Movement disorders: c. Hypertonia (by doses)." data-id="CD004161-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 12 Adverse events: 2. Specific: e. Movement disorders: c. Hypertonia (by doses). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 13 Adverse events: 2. Specific: f. Pain." data-id="CD004161-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 13 Adverse events: 2. Specific: f. Pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 14 Adverse events: 2. Specific: g. Salivation." data-id="CD004161-fig-0017" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 14 Adverse events: 2. Specific: g. Salivation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 15 Adverse events: 2. Specific: h. Sleep disturbances." data-id="CD004161-fig-0018" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 15 Adverse events: 2. Specific: h. Sleep disturbances. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 16 Adverse events: 2. Specific: i. Weight gain." data-id="CD004161-fig-0019" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 16 Adverse events: 2. Specific: i. Weight gain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 17 Adverse events: 2. Specific: j. Others." data-id="CD004161-fig-0020" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 RISPERIDONE DEPOT vs PLACEBO, Outcome 17 Adverse events: 2. Specific: j. Others. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 1 Global state: 1. Relapse (any reason)." data-id="CD004161-fig-0021" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 1 Global state: 1. Relapse (any reason). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 2 Global state: 2. Needing use of benzodiazepine or sedative drugs." data-id="CD004161-fig-0022" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 2 Global state: 2. Needing use of benzodiazepine or sedative drugs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 3 Service utilisation: 1. Hospitalisation." data-id="CD004161-fig-0023" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 3 Service utilisation: 1. Hospitalisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0024"> <p> <div class="table" id="CD004161-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>long term</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rosenheck 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone depot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>187</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rosenheck 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>182</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 4 Service utilisation: 2. Outpatient care ‐ number of outpatient visits (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0024">Navigate to figure in review</a></div> </div> <div class="figure" id="CD004161-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 5 Not receiving allocated study medication." data-id="CD004161-fig-0025" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 5 Not receiving allocated study medication. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 6 Leaving the study early: 1. Any reason." data-id="CD004161-fig-0026" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 6 Leaving the study early: 1. Any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 7 Leaving the study early: 2. Specific." data-id="CD004161-fig-0027" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 7 Leaving the study early: 2. Specific. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 8 Adverse events: 1. General: a. Death." data-id="CD004161-fig-0028" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 8 Adverse events: 1. General: a. Death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 9 Adverse events: 2. Specific." data-id="CD004161-fig-0029" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 9 Adverse events: 2. Specific. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 10 Adverse events: Nervous system disorders (inc. EPS)." data-id="CD004161-fig-0030" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS, Outcome 10 Adverse events: Nervous system disorders (inc. EPS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 1 Global state: 1. Moderate to severely ill at end of study period (CGI rating)." data-id="CD004161-fig-0031" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 1 Global state: 1. Moderate to severely ill at end of study period (CGI rating). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 2 Global state: 2. Mean change from baseline (CGI‐S, high score = worse)." data-id="CD004161-fig-0032" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 2 Global state: 2. Mean change from baseline (CGI‐S, high score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 3 Global state: 3. Mean (SD) GAF score change to endpoint." data-id="CD004161-fig-0033" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 3 Global state: 3. Mean (SD) GAF score change to endpoint. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 4 Global state: 4. Needing use of benzodiazepine or sedative drugs." data-id="CD004161-fig-0034" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 4 Global state: 4. Needing use of benzodiazepine or sedative drugs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 5 Mental state: 1. Average change/endpoint scores (PANSS, high score = worse)." data-id="CD004161-fig-0035" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 5 Mental state: 1. Average change/endpoint scores (PANSS, high score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 6 Leaving the study early: 1. Any reason." data-id="CD004161-fig-0036" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 6 Leaving the study early: 1. Any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 7 Leaving the study early: 2. Specific." data-id="CD004161-fig-0037" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 7 Leaving the study early: 2. Specific. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 8 Quality of life: Mean (SD) SF‐36 score change/endpoint (high score = better)." data-id="CD004161-fig-0038" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 8 Quality of life: Mean (SD) SF‐36 score change/endpoint (high score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 9 Adverse events: 1. General." data-id="CD004161-fig-0039" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 9 Adverse events: 1. General.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 10 Adverse events: 1. General: UKU average change score (high = worse)." data-id="CD004161-fig-0040" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 10 Adverse events: 1. General: UKU average change score (high = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 11 Adverse events: 2. Specific." data-id="CD004161-fig-0041" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 11 Adverse events: 2. Specific. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 12 Adverse events: 2. Specific: Mean (SD) weight increase in kg." data-id="CD004161-fig-0042" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 12 Adverse events: 2. Specific: Mean (SD) weight increase in kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 13 Adverse events: 3. Movement disorder." data-id="CD004161-fig-0043" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 13 Adverse events: 3. Movement disorder. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 14 Adverse events: Mean (SD) change in movement disorder rating scales." data-id="CD004161-fig-0044" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 RISPERIDONE DEPOT vs ORAL RISPERIDONE, Outcome 14 Adverse events: Mean (SD) change in movement disorder rating scales. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 RISPERIDONE DEPOT vs ORAL QUETIAPINE, Outcome 1 Leaving the study early: 1. Any reason." data-id="CD004161-fig-0045" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 RISPERIDONE DEPOT vs ORAL QUETIAPINE, Outcome 1 Leaving the study early: 1. Any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 RISPERIDONE DEPOT vs ORAL QUETIAPINE, Outcome 2 Leaving the study early: 2. Specific." data-id="CD004161-fig-0046" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 RISPERIDONE DEPOT vs ORAL QUETIAPINE, Outcome 2 Leaving the study early: 2. Specific. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 RISPERIDONE DEPOT vs ORAL QUETIAPINE, Outcome 3 Adverse events: 1. General." data-id="CD004161-fig-0047" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 RISPERIDONE DEPOT vs ORAL QUETIAPINE, Outcome 3 Adverse events: 1. General.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 RISPERIDONE DEPOT vs ORAL QUETIAPINE, Outcome 4 Adverse events: 2. Specifc." data-id="CD004161-fig-0048" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 RISPERIDONE DEPOT vs ORAL QUETIAPINE, Outcome 4 Adverse events: 2. Specifc.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 RISPERIDONE DEPOT vs ORAL QUETIAPINE, Outcome 5 Adverse events: 2. Specific: Mean (SD) weight increase in kg." data-id="CD004161-fig-0049" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 RISPERIDONE DEPOT vs ORAL QUETIAPINE, Outcome 5 Adverse events: 2. Specific: Mean (SD) weight increase in kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 RISPERIDONE DEPOT vs ORAL QUETIAPINE, Outcome 6 Adverse events: 3. Movement disorder." data-id="CD004161-fig-0050" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 RISPERIDONE DEPOT vs ORAL QUETIAPINE, Outcome 6 Adverse events: 3. Movement disorder. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 1 Global state: 1. Relapse (any reason)." data-id="CD004161-fig-0051" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 1 Global state: 1. Relapse (any reason). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 2 Global state: 3. Mean time in remission (days)." data-id="CD004161-fig-0052" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 2 Global state: 3. Mean time in remission (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 3 Mental state: 1. Average change scores (PANSS, high score = worse)." data-id="CD004161-fig-0053" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 3 Mental state: 1. Average change scores (PANSS, high score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 4 Leaving the study early: 1. Any reason." data-id="CD004161-fig-0054" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 4 Leaving the study early: 1. Any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 5 Leaving the study early: 2. Specific." data-id="CD004161-fig-0055" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 5 Leaving the study early: 2. Specific. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 6 Adverse events: 1. General." data-id="CD004161-fig-0056" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 6 Adverse events: 1. General. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 7 Adverse events: 2. Specific." data-id="CD004161-fig-0057" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 7 Adverse events: 2. Specific. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 8 Adverse events: 2. Specific 12. Mean (SD) weight increase in kg." data-id="CD004161-fig-0058" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 8 Adverse events: 2. Specific 12. Mean (SD) weight increase in kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-005-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-005-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 9 Adverse events: 3. Movement disorder." data-id="CD004161-fig-0059" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-005-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE, Outcome 9 Adverse events: 3. Movement disorder. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-005-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 RISPERIDONE DEPOT vs ORAL OLANZAPINE, Outcome 1 Mental state: 1. Average change scores (PANNS, high score = worse)." data-id="CD004161-fig-0060" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 RISPERIDONE DEPOT vs ORAL OLANZAPINE, Outcome 1 Mental state: 1. Average change scores (PANNS, high score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 RISPERIDONE DEPOT vs ORAL OLANZAPINE, Outcome 2 Leaving the study early: 1. Any reason." data-id="CD004161-fig-0061" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 RISPERIDONE DEPOT vs ORAL OLANZAPINE, Outcome 2 Leaving the study early: 1. Any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 RISPERIDONE DEPOT vs ORAL OLANZAPINE, Outcome 3 Leaving the study early: 2. Specific." data-id="CD004161-fig-0062" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 RISPERIDONE DEPOT vs ORAL OLANZAPINE, Outcome 3 Leaving the study early: 2. Specific. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 RISPERIDONE DEPOT vs ORAL OLANZAPINE, Outcome 4 Adverse events: 1. General." data-id="CD004161-fig-0063" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 RISPERIDONE DEPOT vs ORAL OLANZAPINE, Outcome 4 Adverse events: 1. General.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 RISPERIDONE DEPOT vs ORAL OLANZAPINE, Outcome 5 Adverse events: 2. Specific." data-id="CD004161-fig-0064" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 RISPERIDONE DEPOT vs ORAL OLANZAPINE, Outcome 5 Adverse events: 2. Specific.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 RISPERIDONE DEPOT vs ORAL OLANZAPINE, Outcome 6 Adverse events: 3. Movement disorder." data-id="CD004161-fig-0065" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 RISPERIDONE DEPOT vs ORAL OLANZAPINE, Outcome 6 Adverse events: 3. Movement disorder. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES), Outcome 1 Global state: 1. Relapse (any reason)." data-id="CD004161-fig-0066" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES), Outcome 1 Global state: 1. Relapse (any reason). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES), Outcome 2 Mental state: 1. Average change scores (PANSS, high score = worse) 1. total." data-id="CD004161-fig-0067" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES), Outcome 2 Mental state: 1. Average change scores (PANSS, high score = worse) 1. total. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES), Outcome 3 Leaving the study early: 1. Any reason." data-id="CD004161-fig-0068" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES), Outcome 3 Leaving the study early: 1. Any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES), Outcome 4 Adverse events: 1. Death." data-id="CD004161-fig-0069" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES), Outcome 4 Adverse events: 1. Death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES), Outcome 5 Adverse events: 1. General: a. any." data-id="CD004161-fig-0070" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES), Outcome 5 Adverse events: 1. General: a. any. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-007-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-007-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES), Outcome 6 Adverse events: 1. General: b. serious." data-id="CD004161-fig-0071" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-007-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES), Outcome 6 Adverse events: 1. General: b. serious. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-007-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-007-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-007-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES), Outcome 7 Adverse events: 2. Movement disorder: a. any extra pyramidal symptoms." data-id="CD004161-fig-0072" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-007-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7 RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES), Outcome 7 Adverse events: 2. Movement disorder: a. any extra pyramidal symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-007-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 1 Global State: 1. CGI‐S mean change from baseline (high score = worse)." data-id="CD004161-fig-0073" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 1 Global State: 1. CGI‐S mean change from baseline (high score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 2 Global state: 2. Schedule for Deficit Syndrome (SDS) scale (mean change from baseline, high score = worse)." data-id="CD004161-fig-0074" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 2 Global state: 2. Schedule for Deficit Syndrome (SDS) scale (mean change from baseline, high score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 3 Mental state: 1. PANSS scores (high score = worse) ‐ medium term." data-id="CD004161-fig-0075" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 3 Mental state: 1. PANSS scores (high score = worse) ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 4 Mental state: 2. Improved by 30% in total PANSS score (ITT data)." data-id="CD004161-fig-0076" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 4 Mental state: 2. Improved by 30% in total PANSS score (ITT data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 5 General functioning: Personal and Social Performance (PSP) scale (high score = better)." data-id="CD004161-fig-0077" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 5 General functioning: Personal and Social Performance (PSP) scale (high score = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 6 Leaving the study early: 1. Any reason." data-id="CD004161-fig-0078" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 6 Leaving the study early: 1. Any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-008-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-008-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 7 Adverse events: 1. General." data-id="CD004161-fig-0079" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 7 Adverse events: 1. General. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-008-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-008-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 8 Adverse events: 2. Specific." data-id="CD004161-fig-0080" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 8 Adverse events: 2. Specific. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-008-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-008-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 9 Adverse events: 3. Prolactin related." data-id="CD004161-fig-0081" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.9</div> <div class="figure-caption"> <p>Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 9 Adverse events: 3. Prolactin related. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-008-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-008-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 10 Adverse events: 4. Movement disorder." data-id="CD004161-fig-0082" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.10</div> <div class="figure-caption"> <p>Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 10 Adverse events: 4. Movement disorder. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-008-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-008-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 11 Adverse events: 5. Body weight (mean increase)." data-id="CD004161-fig-0083" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.11</div> <div class="figure-caption"> <p>Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 11 Adverse events: 5. Body weight (mean increase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-008-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-008-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 12 Adverse events: 6. Mean prolactin level increase (ng/mL)." data-id="CD004161-fig-0084" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.12</div> <div class="figure-caption"> <p>Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 12 Adverse events: 6. Mean prolactin level increase (ng/mL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-008-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-008-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 13 Adverse events: 7. Glucose related." data-id="CD004161-fig-0085" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.13</div> <div class="figure-caption"> <p>Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 13 Adverse events: 7. Glucose related. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-008-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-008-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 14 Adverse events: 8. Injection site pain (mean (sd) Visual Analogue Scale score (0‐100mm))." data-id="CD004161-fig-0086" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.14</div> <div class="figure-caption"> <p>Comparison 8 RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE), Outcome 14 Adverse events: 8. Injection site pain (mean (sd) Visual Analogue Scale score (0‐100mm)). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-008-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS, Outcome 1 Mental state: 1. Total endpoint scores (PANNS, high score = worse)." data-id="CD004161-fig-0087" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS, Outcome 1 Mental state: 1. Total endpoint scores (PANNS, high score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS, Outcome 2 Leaving the study early." data-id="CD004161-fig-0088" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS, Outcome 2 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-009-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS, Outcome 3 Hospitalisation by 6 months." data-id="CD004161-fig-0089" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS, Outcome 3 Hospitalisation by 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004161-fig-0090"> <p> <div class="table" id="CD004161-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Change in BMI ‐ short term (skew)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Covell 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone depot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Covell 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Typical depot antipsychotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Change in BMI ‐ medium term (skew)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Covell 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone depot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Covell 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Typical depot antipsychotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Change in BMI ‐ long term (skew)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Covell 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone depot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Covell 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Typical depot antipsychotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Prolactin endpoint levels (ng/mL) ‐ short term (skew)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Covell 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone depot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Covell 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Typical depot antipsychotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Prolactin endpoint levels (ng/mL) ‐ medium term (skew)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Covell 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone depot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Covell 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Typical depot antipsychotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Prolactin endpoint levels (ng/mL) ‐ long term (skew)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Covell 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone depot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Covell 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Typical depot antipsychotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9 RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS, Outcome 4 Adverse events: 1. Continuous outcomes (skew). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0090">Navigate to figure in review</a></div> </div> <div class="figure" id="CD004161-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/urn:x-wiley:14651858:media:CD004161:CD004161-CMP-009-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_t/tCD004161-CMP-009-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS, Outcome 5 Adverse events: 2. Sexual experiencesm, total endpoint (ASEX, high score = worse)." data-id="CD004161-fig-0091" src="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-009-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9 RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS, Outcome 5 Adverse events: 2. Sexual experiencesm, total endpoint (ASEX, high score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/media/CDSR/CD004161/image_n/nCD004161-CMP-009-05.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD004161-tbl-0009"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Suggested design of study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised, fully explicit description of methods of randomisation and allocation concealment.<br/> Blinding: single, tested.<br/> Setting: community rather than hospital.<br/> Duration: 12 weeks treatment, and then follow‐up to at least 52 weeks. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: schizophrenia (ICD/DSM/CCMD).<br/> N = 300.*<br/> Age: adults.<br/> Sex: both. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Depot risperidone. N = 150.</p> <p>2. Standard care. N = 150.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>General: time to all‐cause treatment failure marked by its discontinuation, relapse, general impression of clinician (CGI), career/other, compliance with treatment., healthy days,<br/> Mental state: BPRS and PANSS.<br/> Global state: CGI (Clinical Global Impression).<br/> Quality of life. QOL (Quality of Life Questionnaire).<br/> Family burden: FBQ (Family Burden Questionnaire).<br/> Social functioning: return to everyday living for 80% of time.*<br/> Adverse events: any adverse event recorded.<br/> Economic outcomes. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>* Powered to be able to identify a difference of ˜ 20% between groups for primary outcome with adequate degree of certainty. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>BPRS: Brief Psychiatric Rating Scale<br/> CGI: Clinical Global Impression<br/> PANSS: Positive and Negative Syndrome Scale </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Suggested design of study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/full#CD004161-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004161-tbl-0010"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Excluded studies and suggestions for relevant reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Excluded study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Existing review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Suggested future review titles</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004161-bbs2-0014" title="BouchardRH , MeretteC , PourcherE , DemersMF , VilleneuveJ , Roy GagnonMH , et al. The Quebec Schizophrenia Study Group. Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. Journal of Clinical Psychopharmacology2000;20(3):295‐304. [MEDLINE: 20289861] ">Bouchard 2000</a>; <a href="./references#CD004161-bbs2-0019" title="GallhoferB . Cognitive dysfunction in schizophrenia: comparison of treatment with a novel atypical antipsychotic agent versus conventional neuroleptic drugs. 8th Congress of the European College of Neuropsychopharmacology; 1995 Sep 30 ‐ Oct 4; Venice, Italy. 1995. ">Gallhofer 1995</a>; <a href="./references#CD004161-bbs2-0022" title='KogeorgosJ , KanellosP , MichalakeasA , IoannidisJ . Sulpiride and risperidone vs. "classical neuroleptics" in schizophrenia: a follow‐up study. 8th Congress of the European College of Neuropsychopharmacology; 1995 Sep 30 ‐ Oct 4; Venice, Italy. 1995. '>Kogeorgos 1995</a>; </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral risperidone vs conventional antipsychotic drugs (haloperidol, fluphenazine, chlorpromazine, trifluoperazine), not depot risperidone. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risperidone vs typical antipsychotic medication for schizophrenia (<a href="./references#CD004161-bbs2-0071" title="HunterR , KennedyE , SongF , GadonL , IrvingCB . Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD000440] ">Hunter 2003</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risperidone vs haloperidol, risperidone vs fluphenazine, risperidone vs chlorpromazine, risperidone vs trifluoperazine. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004161-bbs2-0026" title="LittrellKH . Patients switched from depot antipsychotics to oral risperidone or olanzapine: an open‐label randomized trial. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington, USA. 1999. [MEDLINE: 95283955] ">Littrell 1999</a>; <a href="./references#CD004161-bbs2-0033" title="RitchieC , AmesD , ChiuE , O'ConnorD , HallK , HassettA . Schizophrenia cohort study of olanzapine v risperidone in the elderly (score): analysis of conversion period. International Psychogeriatrics (Abstracts of the 9th Congress of the International Psychogeriatric Association, &quot;Challenges for the New Millennium: Professional, Cultural and Regional Diversity&quot;; 1999 Aug 15‐20; Vancouver, Canada)1999;11(Suppl 1):157‐8. ">Ritchie 1999</a>; <a href="./references#CD004161-bbs2-0034" title="RobinsonG , WheelerA , ByrdJ , VisserS . Longer‐term effects of switching from typical to atypical antipsychotics in patients with stable schizophrenia. Journal of the European College of Neuropsychopharmacology2000;10(Suppl 3):S291. ">Robinson 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral risperidone vs atypical antipsychotics (olanzapine), not depot risperidone.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risperidone vs olanzapine for schizophrenia (<a href="./references#CD004161-bbs2-0073" title="JayaramMB , HosalliP , StroupTS . Risperidone versus olanzapine for schizophrenia. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD005237.pub2] ">Jayaram 2006</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004161-bbs2-0029" title="MacFaddenW , BossieCA , TurkozI , HaskinsJT . Risperidone long acting therapy in stable patients with recently diagnosed schizophrenia. International Clinical Psychopharmacology2010;25(2):75‐82. MacfaddenW , BossieC , TurkozI , DiekampB , IbachB , HaskinsJT . Effect of long acting injectable risperidone on clinical outcomes in recently diagnosed stable schizophrenia patients. Proceedings of the XXVI Collegium Internationale Neuro Psychopharmacologicum congress; 2008 Jul 13‐17; Munich, Germany. 2008. MacfaddenW , BossieC , TurkozI , DorsonP , HaskinsT . Effect of long acting injectable risperidone on clinical outcomes in stable schizophrenia patients with early illness. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA2008. ">Macfadden 2008</a>; <a href="./references#CD004161-bbs2-0036" title="SimpsonGM , MahmoudRA , LasserRA , KujawaM , BossieCA , TurkozI , et al. A 1‐year double‐blind study of 2 doses of long‐acting risperidone in stable patients with schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry2006;67:1194‐203. ">Simpson 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose comparison (25 mg vs 50 mg of risperidone depot).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risperidone dose for schizophrenia (<a href="./references#CD004161-bbs2-0081" title="LiC , XiaJ , WangJ . Risperidone dose for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007474.pub2] ">Li 2009</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This could also generate further comparisons for this current review.</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Excluded studies and suggestions for relevant reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/full#CD004161-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004161-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">RISPERIDONE DEPOT compared with PLACEBO for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>RISPERIDONE DEPOT compared with PLACEBO for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> RISPERIDONE DEPOT<br/> <b>Comparison:</b> PLACEBO </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> PLACEBO</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> RISPERIDONE DEPOT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: Relapse ‐ long term</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: clinically significant improvement in mental state ‐ long term</b><sup>1</sup> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study reported PANSS responder rate, but unusable due to high attrition.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leaving the study early: Any reason ‐ all doses risperidone depot ‐ short term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>694 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>513 per 1000</b> <br/> (437 to 611) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.74</b> <br/> (0.63 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: General: Severe adverse event ‐ any dose risperidone depot ‐ short term</b> <br/> Spontaneous reporting by study participants </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>235 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>138 per 1000</b> <br/> (89 to 218) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.59</b> <br/> (0.38 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: Specific: Weight gain ‐ all doses of depot risperidone ‐ short term</b> <br/> Spontaneous reporting by study participants </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b> <br/> (10 to 187) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.11</b> <br/> (0.48 to 9.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Not reported: only included study (<a href="./references#CD004161-bbs2-0006" title="Anonymous . Injectible, long‐acting risperidone effective. Journal of Pharmacy Technology2001;4:157. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4‐8th May, Stockholm, Sweden)2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey)2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum; 2002 Jun 23‐27; Montreal, Canada)2002;5(Suppl 1):S188. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;53(3 Suppl.1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta (TM), a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cliag UK Ltd2002. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5‐9, 2002, Barcelona‐Spain2002;12(Supplement 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160(6):1125‐32. ">Kane 2002*</a>) reported PANSS responder rate, but these data were unusable due to high levels of attrition.<br/> <sup>2</sup> Risk of bias: 'very serious' ‐ high attrition in one included study (<a href="./references#CD004161-bbs2-0006" title="Anonymous . Injectible, long‐acting risperidone effective. Journal of Pharmacy Technology2001;4:157. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4‐8th May, Stockholm, Sweden)2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey)2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum; 2002 Jun 23‐27; Montreal, Canada)2002;5(Suppl 1):S188. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;53(3 Suppl.1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta (TM), a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cliag UK Ltd2002. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5‐9, 2002, Barcelona‐Spain2002;12(Supplement 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160(6):1125‐32. ">Kane 2002*</a>) of greater than 50% overall. Research supported by Johnson and Johnson/ Janssen, producers of depot risperidone.<br/> <sup>3</sup> Imprecision: 'serious' ‐ only one small study reported data for this comparison.<br/> <sup>4</sup> Control risk: mean baseline presented for one individual study.<br/> <sup>5</sup> Imprecision: 'serious' ‐ adverse events were reported spontaneously by participants, rather than systematically assessed by the researchers. This could effect the precision of the results as there is only one study (<a href="./references#CD004161-bbs2-0006" title="Anonymous . Injectible, long‐acting risperidone effective. Journal of Pharmacy Technology2001;4:157. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4‐8th May, Stockholm, Sweden)2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey)2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum; 2002 Jun 23‐27; Montreal, Canada)2002;5(Suppl 1):S188. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;53(3 Suppl.1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta (TM), a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cliag UK Ltd2002. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5‐9, 2002, Barcelona‐Spain2002;12(Supplement 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160(6):1125‐32. ">Kane 2002*</a>) addressing this comparison.<br/> <sup>6</sup> Imprecision: 'serious'‐ the method of measuring weight gain and threshold for reporting it were not described. This could effect the precision of the results as there is only one study (<a href="./references#CD004161-bbs2-0006" title="Anonymous . Injectible, long‐acting risperidone effective. Journal of Pharmacy Technology2001;4:157. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone formulation. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4‐8th May, Stockholm, Sweden)2002;17(Suppl 1):S193. KaneJ , EerdekensM , KeithS , LesemM , KarcherK , LindenmayerJP . Long‐acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13‐17; Istanbul, Turkey)2001;11(3):291. KaneJ , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta, the long‐acting injection risperidone formulation. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro‐Psychopharmacologicum; 2002 Jun 23‐27; Montreal, Canada)2002;5(Suppl 1):S188. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJ‐P . Efficacy and safety of a novel long‐acting risperidone microspheres formulation. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)2002;53(3 Suppl.1):174. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Efficacy and safety of risperdal consta (TM), a long‐acting injection risperidone formulation RIS‐USA‐121. Promotional slides on file from Janssen‐Cliag UK Ltd2002. KaneJM , EerdekensM , KeithSJ , LesemM , KarcherK , LindenmayerJP . Long‐acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5‐9, 2002, Barcelona‐Spain2002;12(Supplement 3):S325. KaneJM , EerdekensM , LindenmayerJP , KeithSJ , LesemM , KarcherK . Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. American Journal of Psychiatry2003;160(6):1125‐32. ">Kane 2002*</a>) addressing this comparison. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">RISPERIDONE DEPOT compared with PLACEBO for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/full#CD004161-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004161-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">RISPERIDONE DEPOT compared with GENERAL ORAL ANTIPSYCHOTICS for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>RISPERIDONE DEPOT compared with GENERAL ORAL ANTIPSYCHOTICS for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> RISPERIDONE DEPOT<br/> <b>Comparison:</b> GENERAL ORAL ANTIPSYCHOTICS </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> GENERAL ORAL ANTIPSYCHOTICS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> RISPERIDONE DEPOT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Global state: Relapse (any reason) ‐ long term</b> <br/> Number of participants relapsing in each treatment arm. </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.13</b> <br/> (0.84 to 5.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>63<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Criteria for relapse were derived from <a href="./references#CD004161-bbs2-0054" title="CsernanskyJG , MahmoodR , BrennerR , Risperidone‐USA‐79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine2002;346:16‐22. ">Csernansky 2002</a>.&lt;BR/&gt; </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>161 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>343 per 1000</b> <br/> (135 to 874) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: clinically significant improvement in mental state ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes relating to mental state were unusable due to high study attrition.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early: Any reason ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.24</b> <br/> (0.98 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>467<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>322 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>399 per 1000</b> <br/> (315 to 505) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>387 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>480 per 1000</b> <br/> (379 to 608) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: General: Severe adverse event ‐ any dose risperidone depot ‐ short term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Severe adverse events" were not explicitly reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse events: Specific ‐ prolactin‐related ‐ long term</b> <br/> It is unclear how adverse events were reported </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 10.27</b> <br/> (0.59 to 180.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>85<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b><sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>103 per 1000</b> <br/> (6 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b><sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> <br/> (59 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b><sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> <br/> (118 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events: Specific ‐ weight increase ‐ long term</b> <br/> It is unclear how adverse events were reported </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.33</b> <br/> (0.56 to 3.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>85<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b> <br/> (96 to 541) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b> <br/> (96 to 542) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events: Nervous system disorders (inc. EPS) ‐ long term</b> <br/> It is unclear how adverse events were reported </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.34</b> <br/> (1.13 to 1.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>369<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b> <br/> (96 to 541) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b> <br/> (96 to 542) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Assumed risk: mean baseline presented for one individual study.<br/> <sup>2</sup> Risk of bias: 'very serious' ‐ a high level of attrition (&gt; 50%), the open‐label nature of this study and the fact that it was supported by the manufacturers of depot risperidone result in a very serious risk of bias.<br/> <sup>3</sup> Imprecision: 'serious' ‐ the sample size for this outcome was small (n = 63).<br/> <sup>4</sup> Assumed risk: median control group risk from the studies.<br/> <sup>5</sup> Assumed risk: control risk relates to 'low' (0%).<br/> <sup>6</sup> Serious risk of imprecision due to the small sample size of this study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">RISPERIDONE DEPOT compared with GENERAL ORAL ANTIPSYCHOTICS for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/full#CD004161-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004161-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">RISPERIDONE DEPOT compared with ORAL RISPERIDONE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>RISPERIDONE DEPOT compared with ORAL RISPERIDONE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> RISPERIDONE DEPOT<br/> <b>Comparison:</b> ORAL RISPERIDONE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ORAL RISPERIDONE</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> RISPERIDONE DEPOT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: Relapse ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes relating to relapse were not available for this comparison.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: average PANSS total score at endpoint (non‐ITT data)</b> <br/> PANSS total scores (30 to 210) Higher scores are worse. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: average PANSS total score at endpoint (non‐ITT data) in the intervention groups was<br/> <b>1.05 higher</b> <br/> (0.77 lower to 2.88 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>591<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early: Any reason ‐ short term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.28</b> <br/> (0.92 to 1.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>690<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>145 per 1000</b><sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>185 per 1000</b> <br/> (133 to 259) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b><sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> <br/> (72 to 140) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: General: Severe adverse event ‐ any dose risperidone depot ‐ short term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Severe adverse events" were not explicitly reported by these studies.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events: Movement disorder ‐ any extra pyramidal symptoms ‐ short term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.05</b> <br/> (0.59 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>640<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>65 per 1000</b><sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>69 per 1000</b> <br/> (39 to 123) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>65 per 1000</b><sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b> <br/> (38 to 122) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: Specific: Mean (SD) weight increase in kg ‐ short term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean adverse events: specific: mean (SD) weight increase in kg ‐ short term in the control groups was<br/> <b>0.2 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean adverse events: specific: mean (SD) weight increase in kg ‐ short term in the intervention groups was<br/> <b>0.2 higher</b> <br/> (0.35 lower to 0.75 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>640<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: Specific ‐ prolactin‐related</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.5</b> <br/> (0.15 to 1.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>640<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b><sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b> <br/> (4 to 41) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: 'serious' ‐ both studies received funding support from the manufacturers of risperidone depot<br/> <sup>2</sup> Assumed risk: median control group risk from the studies.<br/> <sup>3</sup> Assumed risk: mean baseline presented for one individual study.<br/> <sup>4</sup> Risk of bias: 'serious' ‐ this research was supported by the manufacturers of risperidone depot. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">RISPERIDONE DEPOT compared with ORAL RISPERIDONE for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/full#CD004161-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004161-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">RISPERIDONE DEPOT compared with ORAL QUETIAPINE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>RISPERIDONE DEPOT compared with ORAL QUETIAPINE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> RISPERIDONE DEPOT<br/> <b>Comparison:</b> ORAL QUETIAPINE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ORAL QUETIAPINE</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> RISPERIDONE DEPOT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: Relapse ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Criteria for relapse were derived from <a href="./references#CD004161-bbs2-0054" title="CsernanskyJG , MahmoodR , BrennerR , Risperidone‐USA‐79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine2002;346:16‐22. ">Csernansky 2002</a>. &lt;BR/&gt; Outcomes relating to relapse were reported, but were unusable due to study attrition. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: clinically significant improvement in mental state ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes relating to mental state were unusable due to high study attrition.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Leaving the study early: Any reason ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.84</b> <br/> (0.74 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>666<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>644 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>541 per 1000</b> <br/> (477 to 612) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: General ‐ serious</b> <br/> Recorded at each follow‐up visit. </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.84</b> <br/> (0.62 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>666<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>229 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>192 per 1000</b> <br/> (142 to 259) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: Movement disorder ‐ any extra pyramidal symptom</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.83</b> <br/> (1.07 to 3.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>666<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>102 per 1000</b> <br/> (60 to 176) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: Specific: Mean (SD) weight increase in kg ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean adverse events: specific: mean (SD) weight increase in kg ‐ long term in the intervention groups was<br/> <b>1.25 higher</b> <br/> (0.25 to 2.25 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>666<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events: Specific ‐ prolactin‐related</b> <br/> Reported by participants at follow‐up visits </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.07</b> <br/> (1.13 to 8.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>666<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b> <br/> (17 to 124) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b> <br/> (17 to 125) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Assumed risk: mean baseline risk used for one included study.<br/> <sup>2</sup> Risk of bias: 'serious' ‐ this study was supported by the manufacturers of risperidone depot.<br/> <sup>3</sup> Risk of bias: 'serious' ‐ this study was open‐label in nature.<br/> <sup>4</sup> Risk of bias: 'very serious' ‐ study attrition was high (&gt; 50%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">RISPERIDONE DEPOT compared with ORAL QUETIAPINE for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/full#CD004161-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004161-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">RISPERIDONE DEPOT compared with ORAL ARIPIPRAZOLE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>RISPERIDONE DEPOT compared with ORAL ARIPIPRAZOLE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> RISPERIDONE DEPOT<br/> <b>Comparison:</b> ORAL ARIPIPRAZOLE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ORAL ARIPIPRAZOLE</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> RISPERIDONE DEPOT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Global state: Relapse (any reason) ‐ long term</b> <br/> Assessed by 5 blinded raters in accordance with study criteria (see comment). </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.05</b> <br/> (0.83 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>349<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Criteria for relapse were derived from <a href="./references#CD004161-bbs2-0054" title="CsernanskyJG , MahmoodR , BrennerR , Risperidone‐USA‐79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine2002;346:16‐22. ">Csernansky 2002</a>. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>436 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>458 per 1000</b> <br/> (362 to 580) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: Average change scores‐ long term</b> <br/> PANSS total score (30 to 210), higher scores are worse. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: average change scores‐ long term in the intervention groups was<br/> <b>0.1 lower</b> <br/> (3.15 lower to 2.95 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>349<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early: Any reason ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.83</b> <br/> (0.53 to 1.3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>723<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>387 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>321 per 1000</b> <br/> (205 to 503) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>531 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>441 per 1000</b> <br/> (281 to 690) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events: General ‐ serious</b> <br/> Unclear how these events were reported </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.96</b> <br/> (0.66 to 1.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>729<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>190 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>182 per 1000</b> <br/> (125 to 264) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>177 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>170 per 1000</b> <br/> (117 to 246) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events: Movement disorder ‐ any extra pyramidal symptoms</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.19</b> <br/> (0.91 to 1.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>729<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>285 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>339 per 1000</b> <br/> (259 to 442) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>196 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>233 per 1000</b> <br/> (178 to 304) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: Specific ‐ weight increase</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.57</b> <br/> (0.38 to 6.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>374<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>69 per 1000</b> <br/> (17 to 284) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events: Specific ‐ prolactin‐related</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 9.91</b> <br/> (2.78 to 35.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>729<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>90 per 1000</b> <br/> (25 to 319) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b> <br/> (17 to 212) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Assumed risk: mean baseline risk presented for one individual study.<br/> <sup>2</sup> Risk of bias: 'very serious' ‐ a number of the study authors were employed by the manufacturers of risperidone depot at the time of the study.<br/> <sup>3</sup> Risk of bias: 'serious' ‐ serious risk of bias due to the open nature label of the study.<br/> <sup>4</sup> Assumed risk: median control group risk from the studies.<br/> <sup>5</sup> Risk of bias: 'very serious' ‐ serious risk of bias as both studies were open‐label and supported by the manufacturers of risperidone depot.<br/> <sup>6</sup> Imprecision: 'serious' ‐ possibly serious risk of imprecision in <a href="./references#CD004161-bbs2-0005" title="GaebelW , BergmansP , DeArceR , RouillonF , CordesJ , ErikssonL , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable versus quetiapine:Randomized, long‐term, open‐label, clinical trial results (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1020. GaebelW , SchreinerA , BergmansP , DeArceR , RouillonF , CordesJ , et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: Results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology2010;35(12):2367‐77. MedoriR , WapenaarR , deArceR , RouillonF , GaebelW , CordesJ , et al. Relapse prevention and effectiveness in schizophrenia of risperidone long‐acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , SchreinerA . Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1023. SchreinerA , RouillonF , ErikssonL , BurbaB , RabochJ , KaprinisG , et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:382. SchreinerA , deArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:381. SmeraldiE , CavallaroR , Folnegovic SmalcV , BidzanL , CeylanE , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (constatre). Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal2009;24:S1021. SmeraldiE , CavallaroR , SmalcVF , BidzanL , CeylanME , SchreinerA , et al. Long‐term remission in schizophrenia and schizoaffective disorder: results from the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry2009:389. deArce CordónR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , SchreinerA . Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical NeuroscienceMarch 2010;262:139‐49. ">Gaebel 2010*</a> as the aripiprazole arm of this study was very small (n = 45) compared to the risperidone depot (n = 329) arm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">RISPERIDONE DEPOT compared with ORAL ARIPIPRAZOLE for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/full#CD004161-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004161-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">RISPERIDONE DEPOT compared with ORAL OLANZAPINE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>RISPERIDONE DEPOT compared with ORAL OLANZAPINE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> RISPERIDONE DEPOT<br/> <b>Comparison:</b> ORAL OLANZAPINE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ORAL OLANZAPINE</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> RISPERIDONE DEPOT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: Relapse ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes relating to relapse were not reported for this comparison.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: Average change scores ‐ long term</b> <br/> PANSS total score (30‐210), high scores are worse. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: average change scores ‐ long term in the intervention groups was<br/> <b>0.1 higher</b> <br/> (3.96 lower to 4.16 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>361<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early: Any reason ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.32</b> <br/> (1.1 to 1.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>618<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>377 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>497 per 1000</b> <br/> (414 to 595) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>377 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>498 per 1000</b> <br/> (415 to 596) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: General ‐ serious</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.1</b> <br/> (0.8 to 1.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>547<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>210 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>231 per 1000</b> <br/> (168 to 317) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: Movement disorder ‐ any extra pyramidal symptoms</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.67</b> <br/> (1.19 to 2.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>547<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b> <br/> (179 to 354) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events: Specific ‐ weight increase</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.56</b> <br/> (0.42 to 0.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>547<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>360 per 1000</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>202 per 1000</b> <br/> (151 to 270) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: 'very serious' ‐ serious risk of bias due to study attrition in excess of 50%.<br/> <sup>2</sup> Risk of bias: 'serious' ‐ serious risk of bias as this study was supported by the manufacturers of risperidone depot, and some of the authors are employed by the same.<br/> <sup>3</sup> Risk of bias: 'serious' ‐ serious risk of bias due to the open‐label nature of the study.<br/> <sup>4</sup> Assumed risk: mean baseline risk from one included study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">RISPERIDONE DEPOT compared with ORAL OLANZAPINE for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/full#CD004161-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004161-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">RISPERIDONE DEPOT compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>RISPERIDONE DEPOT compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> RISPERIDONE DEPOT<br/> <b>Comparison:</b> ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> RISPERIDONE DEPOT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: Relapse ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes relating to relapse were not reported for this comparison.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mental state: PANSS responders (ITT data) ‐ medium term</b> <br/> PANSS responders‐ participants achieving a &gt;30% improvement in total score </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.01</b> <br/> (0.83 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1326<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>585 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>591 per 1000</b> <br/> (486 to 720) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>619 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>625 per 1000</b> <br/> (514 to 761) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early: lack of efficacy ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.60</b> <br/> (0.45 to 0.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>749<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>361 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>307 per 1000</b> <br/> (275 to 340) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>280 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>238 per 1000</b> <br/> (213 to 263) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events: Movement disorder requiring the use of anti‐EPS medication ‐ medium term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.46</b> <br/> (1.18 to 1.8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1666<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2,3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>122 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>178 per 1000</b> <br/> (144 to 220) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>182 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>266 per 1000</b> <br/> (215 to 328) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: Body weight (mean increase) ‐ medium/long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean adverse events: body weight (mean increase) ‐ medium/long term in the intervention groups was<br/> <b>0.18 higher</b> <br/> (0.36 lower to 0.72 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2350<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events: Any prolactin‐related ‐ medium term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.02</b> <br/> (0.61 to 1.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1666<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b> <br/> (20 to 55) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b> <br/> (29 to 82) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: Any glucose‐related ‐ medium/long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> <br/> (9 to 36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.79</b> <br/> (0.89 to 3.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2413<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Assumed risk: median control group risk from the studies.<br/> <sup>2</sup> Risk of bias: 'serious' ‐ <a href="./references#CD004161-bbs2-0008" title="LiH , RuiQ , NingX , XuH , GuN . A comparative study of paliperidone palmitate and risperidone long‐acting injectable therapy in schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:1002‐8. ">Li 2011</a> was open‐label and supported by the manufacturer of risperidone depot.<br/> <sup>3</sup> Risk of bias: 'serious' ‐ <a href="./references#CD004161-bbs2-0010" title="PandinaG , LaneR , Gassmann‐MayerC , HoughD , RemmerieB , SimpsonG . A randomised double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Proceedings of the 27th International College of Neuropsychopharmacology Congress; 2010 June 6‐10; Hong Kong. 2010. PandinaG , LaneR , GopalS , Gassman‐MayerC , HoughD , RemmerieB , et al. A randomized double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia. Biological Psychiatry2010;67(9):77‐8. PandinaG , LaneR , GopalS , Gassmann‐MayerC , HoughD , RemmerieB , et al. A double‐blind study of paliperidone palmitate and risperidone long‐acting injectable in adults with schizophrenia. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35:218‐26. ">Pandina 2011</a> was supported by the manufacturer of risperidone depot.<br/> <sup>4</sup> Risk of bias: 'serious' ‐ as the attrition rate of <a href="./references#CD004161-bbs2-0004" title="FleischhackerWW , GopalS , LaneR , Gassmann‐Mayer , LimP , HoughD , et al. A randomized trial of paliperidone palmitate and risperidone long acting injectable in schizophrenia. International Journal of Neuropsychopharmacology2012;15:107‐18. ">Fleischhacker 2011</a> was in excess of 50%, and the study was supported by the manufacturer of risperidone depot.<br/> <sup>5</sup> Possible imprecision: the rate of movement disorder requiring anti‐EPS medication may not be a reflection of the true rate of movement disorders. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">RISPERIDONE DEPOT compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/full#CD004161-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004161-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">RISPERIDONE DEPOT compared with TYPICAL DEPOT ANTIPSYCHOTICS for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>RISPERIDONE DEPOT compared with TYPICAL DEPOT ANTIPSYCHOTICS for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> RISPERIDONE DEPOT<br/> <b>Comparison:</b> TYPICAL DEPOT ANTIPSYCHOTICS </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> TYPICAL DEPOT ANTIPSYCHOTICS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> RISPERIDONE DEPOT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: Relapse ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes relating to relapse were not reported for this comparison.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: Total average scores (PANSS, high score = worse) ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: total average scores (PANSS, high score = worse) ‐ long term in the intervention groups was<br/> <b>1.8 higher</b> <br/> (10.04 lower to 13.64 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early for any reason ‐ long term</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.05</b> <br/> (1.12 to 8.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>62<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b><sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>407 per 1000</b> <br/> (149 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b><sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>406 per 1000</b> <br/> (149 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: General: Severe adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Severe adverse events" were not explicitly reported for this comparison.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: related to movement disorder, weight gain, prolactin levels and glucose metabolism ‐ medium/long term</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcomes relating to specific adverse events were not reported in such as way as to be useable. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: 'serious' ‐ due to the open‐label nature of this study.<br/> <sup>2</sup> Imprecision: 'serious' ‐ due to the small size of the single study.<br/> <sup>3</sup> Assumed risk: median control group risk from the studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">RISPERIDONE DEPOT compared with TYPICAL DEPOT ANTIPSYCHOTICS for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/full#CD004161-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004161-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">RISPERIDONE DEPOT vs PLACEBO</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mental state: 1. Change (exacerbation) in specific symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 anxiety ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.32, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 agitation ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.39, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 hallucinations ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.47, 3.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 nervousness ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.12, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 psychosis ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.33, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Leaving the study early: 1. Any reason (by time period) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 very early on (&lt;1 injection)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.55, 3.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 by 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.63, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Leaving the study early: 2. Any reason (by doses) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 all doses risperidone depot ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.63, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 25mg risperidone depot ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.59, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 50mg risperidone depot ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.59, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 75mg risperidone depot ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.60, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Leaving the study early: 3. Because of insufficient response (by doses) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 all three doses ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.36, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 25mg depot risperidone group ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.45, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 50mg depot risperidone group ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.27, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 75mg depot risperidone group ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.21, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events: 1. General: a. Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.00, 2.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events: 1. General: b. Severe adverse event (by doses) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 any dose risperidone depot ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.38, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 25mg risperidone depot ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.30, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 50mg risperidone depot ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.32, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 75mg risperidone depot ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.36, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events: 1. General: c. Adverse event necessitating withdrawal from study (by doses) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 any dose risperidone depot ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.54, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 25mg risperidone depot ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.42, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 50mg risperidone depot ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.45, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 75mg risperidone depot ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.56, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse events: 2. Specific: a. Cardiovascular <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 dizziness ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.62, 3.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 tachycardia ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.11, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse events: 2. Specific: b. Gastrointestinal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 constipation ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.17 [0.84, 45.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 diarrhoea ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.23, 3.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 nausea ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.39, 2.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 vomiting ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.23, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse events: 2. Specific: c. Movement disorders: a. Extrapyramidal disorder ‐ spontaneously reported (by doses) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 all doses of depot risperidone ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.38 [0.73, 7.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 25mg risperidone group ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.30, 5.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 50mg risperidone group ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.54 [0.69, 9.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 75mg risperidone group ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.27 [0.93, 11.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse events: 2. Specific: d. Movement disorders: b. Hyperkinesia (by doses) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 all doses of risperidone ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.60, 4.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 25mg risperidone group ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.09, 2.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 50mg risperidone group ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.14 [0.68, 6.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 75mg of risperidone group ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [0.79, 7.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse events: 2. Specific: e. Movement disorders: c. Hypertonia (by doses) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 all doses of depot risperidone ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.47, 3.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 25mg risperidone ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.22, 2.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 50mg risperidone ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.28, 3.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 75mg risperidone ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [0.70, 5.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse events: 2. Specific: f. Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 headache ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.88, 2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 pain ‐ unspecified ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.48, 4.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse events: 2. Specific: g. Salivation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 decreased ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [0.37, 22.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 increased ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [0.37, 22.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse events: 2. Specific: h. Sleep disturbances <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 insomnia ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.60, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 somnolence ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.27 [0.69, 7.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse events: 2. Specific: i. Weight gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 all doses of depot risperidone ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.11 [0.48, 9.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 25mg risperidone ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.47 [0.49, 12.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 50mg risperidone ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [0.36, 10.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 75mg risperidone ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [0.37, 10.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse events: 2. Specific: j. Others <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 coughing ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.32, 2.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 fatigue ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.82 [0.53, 147.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 injury ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.13, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4 rhinitis ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.47, 2.17]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">RISPERIDONE DEPOT vs PLACEBO</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004161-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: 1. Relapse (any reason) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.13 [0.84, 5.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 2. Needing use of benzodiazepine or sedative drugs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.68, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Service utilisation: 1. Hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.68, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Service utilisation: 2. Outpatient care ‐ number of outpatient visits (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Not receiving allocated study medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.06, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Leaving the study early: 1. Any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>467</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.98, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>467</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.98, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Leaving the study early: 2. Specific <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 insufficient response ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.15, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 withdrawn consent ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.86, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse events: 1. General: a. Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.14, 7.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse events: 2. Specific <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 anxiety ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.42, 4.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 diabetes mellitus ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.73, 3.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 dizziness ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.53, 4.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 fatigue/somnolence ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [0.78, 5.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 gastrointestinal ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.95, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6 general disorders and administration site conditions ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [1.02, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7 headache ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.80 [1.12, 7.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.8 insomnia ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.77, 3.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.9 nausea/ vomiting ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [0.50, 6.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.10 prolactin related ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.27 [0.59, 180.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.11 weight increase ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.56, 3.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse events: Nervous system disorders (inc. EPS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [1.13, 1.58]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004161-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">RISPERIDONE DEPOT vs ORAL RISPERIDONE</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: 1. Moderate to severely ill at end of study period (CGI rating) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.92, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 2. Mean change from baseline (CGI‐S, high score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.25, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: 3. Mean (SD) GAF score change to endpoint <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.8 [‐5.66, 4.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global state: 4. Needing use of benzodiazepine or sedative drugs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.74, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.74, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: 1. Average change/endpoint scores (PANSS, high score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 mean total (non ITT data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐2.91, 2.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 average change: 1. total (non ITT data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [‐0.77, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 average change: 2. positive (non‐ITT data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [‐0.69, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 average change: 3. negative (non ITT data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.76, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 average change: 4. disorganised thoughts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.45, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 average change: 5. hostility/excitement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.18, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 average change: 6. anxiety/depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.45, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Leaving the study early: 1. Any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.92, 1.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.92, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Leaving the study early: 2. Specific <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 adverse events ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.62, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 insufficient response ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.63, 3.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 withdrawn consent ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.65, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Quality of life: Mean (SD) SF‐36 score change/endpoint (high score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Physical component summary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.4 [‐2.64, 5.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Mental component summary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐5.06, 4.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Role physical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [‐20.71, 22.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Role emotional</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.60 [‐34.13, 12.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Vitality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.6 [‐10.24, 7.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 General health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.60 [‐13.14, 7.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7 Mental health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.8 [‐5.20, 16.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.8 Bodily pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.70 [‐9.89, 17.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.9 Physical function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.6 [‐14.25, 5.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.10 Social function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.5 [3.98, 33.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse events: 1. General <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 any ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.91, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 death ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse events: 1. General: UKU average change score (high = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.99 [‐3.59, ‐0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse events: 2. Specific <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.84, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 psychosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.58, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 prolactin related</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.15, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 impotence/ejaculation failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 dysmenorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.06, 16.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.6 hyperprolactinaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.7 galactorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.14, 7.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.8 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.66, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.9 insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.66, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.10 sexual dysfunction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 5.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse events: 2. Specific: Mean (SD) weight increase in kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.2 [‐0.35, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse events: 3. Movement disorder <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 any extra pyramidal symptoms ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.59, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 participants requiring anti‐cholinergic drugs ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.66, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 tardive dyskinesia ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.06 [0.49, 167.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse events: Mean (SD) change in movement disorder rating scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 AIMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [‐1.23, 3.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 BARS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [‐0.65, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 SAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.55 [‐3.71, 2.61]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">RISPERIDONE DEPOT vs ORAL RISPERIDONE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004161-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">RISPERIDONE DEPOT vs ORAL QUETIAPINE</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Leaving the study early: 1. Any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.74, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Leaving the study early: 2. Specific <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 due to relapse ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.40, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events: 1. General <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 any</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.89, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.62, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.26, 9.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events: 2. Specifc <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 psychiatric symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.84, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 prolactin related</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.07 [1.13, 8.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 hyperprolactinaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.81 [3.53, 21.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 serious psychiatric symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.58, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 weight increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.63, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.64, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 fatigue/somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.07, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events: 2. Specific: Mean (SD) weight increase in kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.25, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events: 3. Movement disorder <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 any extra pyramidal symptom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [1.07, 3.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.12 [1.13, 23.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 tardive dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.04, 3.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 dystonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.05, 5.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 parkinsonism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.56 [1.01, 6.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 hyperkinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [0.70, 3.96]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">RISPERIDONE DEPOT vs ORAL QUETIAPINE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004161-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: 1. Relapse (any reason) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.83, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 3. Mean time in remission (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.80 [‐43.59, 77.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state: 1. Average change scores (PANSS, high score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐3.15, 2.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Leaving the study early: 1. Any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.53, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.53, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Leaving the study early: 2. Specific <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.05, 3.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 insufficient response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.29, 5.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 withdrawn consent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.67, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 due to relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.36, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 loss to follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [0.83, 3.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events: 1. General <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 any</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.87, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.66, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.13, 7.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events: 2. Specific <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.75, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.85, 2.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 psychosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.69, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 psychiatric symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.60, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 serious psychiatric symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.27, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.63, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7 prolactin related</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.91 [2.78, 35.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8 hyperprolactinaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.13 [0.76, 193.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.9 weight increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.38, 6.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.10 nausea/vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.64, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.11 gastrointestinal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.14, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.12 decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [1.00, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.13 diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.31, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.14 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.46, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.15 insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.65, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.16 upper resp. tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.16, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.17 pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.69, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.18 nasopharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.58, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.19 dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [1.00, 3.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.20 glucose related</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.58, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse events: 2. Specific 12. Mean (SD) weight increase in kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [‐0.42, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse events: 3. Movement disorder <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 any extra pyramidal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.91, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.65, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.55, 1.76]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004161-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">RISPERIDONE DEPOT vs ORAL OLANZAPINE</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mental state: 1. Average change scores (PANNS, high score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 total ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>377</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [‐2.25, 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 total ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐3.96, 4.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 positive symptoms ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐1.61, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 negative symptoms ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐1.28, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 disorganised thoughts ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐1.34, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 hostility/excitement ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.60, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 anxiety/depression ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.46, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Leaving the study early: 1. Any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.10, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Leaving the study early: 2. Specific <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.28, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 insufficient response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.49, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 withdrawn consent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.54 [1.56, 4.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 due to weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.03, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events: 1. General <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.80, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.06, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events: 2. Specific <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [1.06, 3.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.58, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.99, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 psychosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.87, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 impotence/ejaculation failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.17, 8.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 galactorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.04 [0.59, 15.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 serious psychiatric symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.64, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8 serious anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.48, 4.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9 suicide attempt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.56, 3.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.10 serious injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [0.49, 8.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.11 weight increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.42, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.12 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.81, 3.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.13 insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.59 [2.61, 8.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.14 fatigue/somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.35, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.15 nasopharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.61, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.16 diabetes mellitus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.08, 19.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.17 hyperglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.25, 3.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.18 hypoglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.02, 9.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events: 3. Movement disorder <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 any extra pyramidal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.19, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [1.04, 5.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 tardive dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.17, 8.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 hypertonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.56, 3.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 dystonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.07 [0.29, 125.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 hyperkinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [1.01, 4.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 requiring antiparkinson drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [1.02, 1.56]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">RISPERIDONE DEPOT vs ORAL OLANZAPINE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004161-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: 1. Relapse (any reason) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 vs aripiprazole ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.83, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 vs general oral antipsychotics ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.13 [0.84, 5.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mental state: 1. Average change scores (PANSS, high score = worse) 1. total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 vs oral risperidone (non ITT data) ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [‐0.77, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 vs olanzapine ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>377</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [‐2.25, 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 vs olanzapine ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐3.96, 4.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 vs aripiprazole ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐3.15, 2.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Leaving the study early: 1. Any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 vs aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.53, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 vs quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.74, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 vs oral risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.92, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 vs any new generation antipsychotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.55, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 vs olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.10, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 vs any oral antipsychotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.93, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events: 1. Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 vs olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.06, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 vs oral risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 vs any oral antipsychotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.14, 7.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 vs aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.13, 7.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 vs quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.26, 9.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events: 1. General: a. any <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 vs aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.87, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 vs oral risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.91, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 vs quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.89, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events: 1. General: b. serious <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 vs quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.62, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 vs aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.66, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 vs olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.80, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events: 2. Movement disorder: a. any extra pyramidal symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 vs aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.91, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 vs quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [1.07, 3.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 vs olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.19, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 vs oral risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.59, 1.88]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">RISPERIDONE DEPOT vs ALL ORAL ANTIPSYCHOTICS (PRIMARY OUTCOMES)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004161-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global State: 1. CGI‐S mean change from baseline (high score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.26, 0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.26, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 2. Schedule for Deficit Syndrome (SDS) scale (mean change from baseline, high score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>913</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.29, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state: 1. PANSS scores (high score = worse) ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 total mean change to endpoint (ITT and per protocol data)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [‐2.79, 5.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 positive symptoms score change to endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [‐1.39, 2.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 negative symptoms score change to endpoint (ITT data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.47, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 disorganised thoughts score change to endpoint (ITT data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.55, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 uncontrolled hostility/excitement score change to endpoint (ITT data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.50, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 anxiety/depression score change to endpoint (ITT data)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.67, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: 2. Improved by 30% in total PANSS score (ITT data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.83, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 General functioning: Personal and Social Performance (PSP) scale (high score = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [‐0.69, 1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 mean endpoint ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [‐0.69, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Leaving the study early: 1. Any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Lack of efficacy ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.29, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Lack of efficacy ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>749</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.45, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Adverse events ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.28, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Adverse events ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>749</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.53, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Patient choice/withdrawn consent ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.22, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Patient choice/withdrawn consent ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>749</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.83, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 Lost to follow‐up ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.93, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8 Lost to follow‐up ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>749</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.39, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.9 Pregnancy ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.03, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.10 Pregnancy ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>749</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.06, 16.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.11 Death ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>749</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.12 Other ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.45, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.13 Other ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>749</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.67, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.14 Any reason ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.51, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.15 Any reason ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>749</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.75, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events: 1. General <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 overall rate ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.33, 4.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 overall rate ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.58, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 worsening of schizophrenia ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.40, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 worsening of psychiatric disorders ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.22, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 death ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.14, 6.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 death ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>749</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse events: 2. Specific <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 overall rate ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.86, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 overall rate ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.95, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 insomnia ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.49, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 insomnia ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.71, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 psychotic disorder ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.59, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 worsening of schizophrenia ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.49, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7 anxiety ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.26, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.8 anxiety ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.01, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.9 headache ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.78, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.10 constipation ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.79 [1.42, 10.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.11 injection site pain ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.07, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.12 somnolence ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.21, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.13 weight gain (proportion of participants with &gt;7% increase) ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.72, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.14 tachycardia ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.26, 4.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.15 tachycardia ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.11, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse events: 3. Prolactin related <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 amenorrhoea ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>784</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.24, 13.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 galactorrhoea ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.02, 8.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 hyperprolactinaemia ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.13 [0.60, 43.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 erectile dysfunction ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.18, 3.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 increase in serum prolactin ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.35, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6 amenorrhoea‐galactorrhoea syndrome ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.3 [0.14, 80.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7 any prolactin related ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.61, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.8 proportion of male participants with abnormally high prolactin ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [1.32, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.9 proportion of female participants with abnormally high prolactin ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.95, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse events: 4. Movement disorder <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 akathisia ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.98, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 tremor ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.07, 2.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 tardive dyskinesia ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.06, 15.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 requiring use of anti‐EPS medication ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.18, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 hyperkinesia ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [1.00, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6 neuroleptic malignant syndrome ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse events: 5. Body weight (mean increase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐0.36, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.38, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>684</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.13, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse events: 6. Mean prolactin level increase (ng/mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 female participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>807</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.40 [‐12.65, 5.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 male participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.43 [‐5.88, 5.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse events: 7. Glucose related <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 increased blood glucose ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.44, 5.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 hyperglycaemia ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.31, 6.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 diabetes mellitus ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.12 [0.46, 36.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 glycosuria ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5 ketonuria ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.6 urine ketone body present ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.7 hypoglycaemia ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.09 [0.13, 75.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.8 any glucose related ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [0.52, 5.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.9 any glucose related ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.77, 4.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse events: 8. Injection site pain (mean (sd) Visual Analogue Scale score (0‐100mm)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [‐0.24, 3.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 at endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐1.07, 1.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004161-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mental state: 1. Total endpoint scores (PANNS, high score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [‐8.12, 9.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐9.02, 8.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [‐10.04, 13.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 before beginning assigned treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.50 [1.00, 56.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 by 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [1.12, 8.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 due to increased psychiatric symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.81 [0.31, 25.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 due to EPS effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.01, 7.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 due to weight gain and hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.82 [0.12, 66.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 due to participant preference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.06, 14.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Hospitalisation by 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.11, 3.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events: 1. Continuous outcomes (skew) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Change in BMI ‐ short term (skew)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Change in BMI ‐ medium term (skew)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Change in BMI ‐ long term (skew)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Prolactin endpoint levels (ng/mL) ‐ short term (skew)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Prolactin endpoint levels (ng/mL) ‐ medium term (skew)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Prolactin endpoint levels (ng/mL) ‐ long term (skew)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events: 2. Sexual experiencesm, total endpoint (ASEX, high score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [‐1.26, 4.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [‐2.30, 4.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐4.08, 3.88]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004161.pub2/references#CD004161-tbl-0019">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004161.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD004161-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD004161-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004161-note-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD004161-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD004161-note-0002">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004161\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004161\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004161\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004161\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004161\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004161\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004161\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004161\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004161\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004161\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004161\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004161\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004161\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004161\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004161\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004161\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004161\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004161\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004161.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004161.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004161.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004161.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004161.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714758212"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004161.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714758216"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004161.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7677f89e937d',t:'MTc0MDcxNDc1OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 